[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"fda-warning-letters-search:[\"Stradis Medical, LLC dba Stradis Healthcare\",\"\",\"\",\"\",\"\",1]":3,"fda-latest-sync-dates":270},{"warningLetters":4,"total":269},[5,31,54,76,95,115,127,148,165,182,201,220,233,245],{"id":6,"raw":7,"subject":12,"body_html":14,"body_text":15,"firm_name":16,"letter_id":17,"created_at":18,"fei_number":19,"letter_url":20,"updated_at":21,"action_type":22,"case_status":23,"posted_date":24,"marcs_cms_no":25,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":27,"body_fetched_at":28,"delivery_method":29,"recipient_title":19,"reference_number":19,"action_taken_date":30,"medical_device_id":19,"response_letter_date":19},62,[8,9,10,11,12,13,13,13],"\u003Ctime datetime=\"2026-06-30T04:00:00Z\">06\u002F30\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-05-20T04:00:00Z\">05\u002F20\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002F3b-medical-inc-dba-reach-health-inc-725108-05202026\">3B Medical, Inc. dba Reach Health, Inc.\u003C\u002Fa>","Center for Devices and Radiological Health","CGMP\u002FQSR\u002FMedical Devices\u002FAdulterated","","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>William H. Shoop\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>CEO\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>3B Medical, Inc. dba Reach Health, Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>5475 Rings Road\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Dublin\u003C\u002Fspan>, \u003Cspan>OH\u003C\u002Fspan> \u003Cspan>43017\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:(b)(4)\"> (b)(4)\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003Cbr>\u003Cstrong>CMS # 725108\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>May 20, 2026\u003C\u002Fp>\u003Cp>Dear Mr. Shoop:\u003C\u002Fp>\u003Cp>During an inspection of your firm located in Dublin, OH from December 1, 2025 through December 10, 2025, an investigator from the United States Food and Drug Administration (FDA) determined that your firm manufactures iCodeConnect, a cloud-based software device, intended for use in conjunction with Continuous Positive Airway Pressure (CPAP) and Auto-Adjusting Positive Airway Pressure (Auto-CPAP or APAP) ventilator devices, in treating obstructive sleep apnea (OSA) in adults. Your firm also imports and provides complaint handling for APAP and Bilevel Positive Airway Pressure (BPAP) ventilator devices from BMC Medical Co., Ltd. (Beijing, China) to include, but not limited to, Luna G3 APAP (LG3600), G3X APAP (G4600), Luna G3 BPAP (LG3700), Luna G3 30VT (LG3800), and Luna G2 APAP (LG2A02). Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Quality System Regulation Violations\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>This inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, \u003Cu>Code of Federal Regulations\u003C\u002Fu> (CFR), Part 820.\u003C\u002Fp>\u003Cp>We received a response from Rebecca Legare, Quality Systems and Compliance Director, dated January 2, 2026, and February 13, 2026, and from Shalini Yadav, Senior Manager of Regulatory Affairs on March 27, 2026, concerning our investigator’s observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, that was issued to your firm. We address this response below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\u003C\u002Fp>\u003Cp>1. Failure to establish and maintain procedures for receiving, reviewing, and evaluating complaints by a formally designated unit to ensure that all complaints are processed in a uniform and timely manner and complaints are evaluated to determine whether the complaint represents an event which is required to be reported to FDA under part 803 or 804 of this chapter, Medical Device Reporting (MDR), as required by 21 CFR 820.198(a), 820.198(a)(1), and 820.198(a)(3).\u003C\u002Fp>\u003Cp>Specifically:\u003C\u002Fp>\u003Cp>A. Your firm failed to implement section 9.1.1 of your “Customer Complaints” procedure (SP.QA.0011; Rev. G-I; Effective: 8\u002F27\u002F24, 12\u002F5\u002F24, 6\u002F27\u002F25) which requires you to “***\u003Cem>determine if there is a complaint based on the definition of a complaint above and Complaint Decision Tree\u003C\u002Fem>***,” as required by 21 CFR 820.198(a). For example:\u003C\u002Fp>\u003Cp>1. Seven (7) out of eleven (11) complaint records reviewed were cancelled although they met the definition of a complaint defined in your procedure as “\u003Cem>Any written, electronic, or verbal communication that alleges deficiencies related to the identity, quality, durability, reliability, safety, effectiveness, or performance of a device following release for distribution\u003C\u002Fem>.” Examples include:\u003C\u002Fp>\u003Cp> \u003Cu>CN-028565\u003C\u002Fu> (9\u002F5\u002F25) for Luna G3 APAP states “***\u003Cem>used it Wednesday and Thursday nights. It collected data that shows in the machine display. But, using the React Health Plus app on my iPhone, when I try to upload the data by scanning the iCode QR+ code, the app appears to scan successfully, but the data does not show in the app\u003C\u002Fem>***.” The documented justification for cancelling the complaint was “***\u003Cem>The device was not returned. Tech Support provided information to the customer about data transmission, and the customer later confirmed that data was being displayed. The ticket was canceled. No issue was confirmed\u003C\u002Fem>***.” However, this incident meets the definition of a complaint due to alleged concern with performance regardless of whether it was determined to be a use error.\u003C\u002Fp>\u003Cp> \u003Cu>CN-030142\u003C\u002Fu> (10\u002F3\u002F25) for Luna 2 Auto states “***\u003Cem>Pt dropped machine and it stopped working\u003C\u002Fem>***.” The documented justification for cancelling the complaint was “***\u003Cem>This issue is not a complaint because the patient dropped the device\u003C\u002Fem>.***” However, this incident meets the definition of a complaint due to alleged concern with durability, regardless of whether it was determined to be a use error.\u003C\u002Fp>\u003Cp>From August 28, 2024 to November 21, 2025, your firm cancelled \u003Cstrong>(b)(4)\u003C\u002Fstrong> complaints despite allegations for pressure delivery issues (fluctuations, pulsating, surging, etc.), shutdowns, and electronic and software failures (data transmission, modem connectivity, error codes, etc.) with your Luna G3 APAP\u002FBPAP devices; abnormal pressure readings, low oxygen output, and persistent red-light alarms for your Stratus oxygen concentrators; abnormal smells from your Phoenix 5L oxygen concentrators; and durability issues with your Rio masks.\u003C\u002Fp>\u003Cp>2. Thirteen (13) out of fifteen (15) inquiries reviewed met the definition of a complaint defined in your procedure. Examples include:\u003C\u002Fp>\u003Cp> \u003Cu>INQ-26292\u003C\u002Fu> (8\u002F18\u002F25) for Luna G3 APAP states “***\u003Cem>Pt turned machine over on nightstand, causing water to flow back into machine. Machine pressure now fluctuates heavily and constantly\u003C\u002Fem>***.” The documented justification for not logging this incident as a complaint was “***\u003Cem>Because the patient turned the device over on the nightstand, this is considered patient damage, not a complaint\u003C\u002Fem>***.” However, this incident meets the definition of a complaint due to alleged concern with performance regardless of whether it was determined to be a use error.\u003C\u002Fp>\u003Cp> \u003Cu>INQ-23277\u003C\u002Fu> (6\u002F23\u002F25) for Luna 2 Auto states “***\u003Cem>Button on machine is broken\u003C\u002Fem>***.” The documented justification for not logging this incident as a complaint was “***\u003Cem>The device was not confirmed to be received from React Health with a broken button. Since the device is out of warranty, it has been used, and the damage is considered to be customer induced. Therefore, this is not a complaint\u003C\u002Fem>***.” However, this incident meets the definition of a complaint due to alleged concern with durability regardless of whether it was determined to be a use error or out of warranty.\u003C\u002Fp>\u003Cp>Your firm has received over \u003Cstrong>(b)(4)\u003C\u002Fstrong> records from August 26, 2024, to December 23, 2025, that you classified as inquiries and found that several should have been categorized as complaints because they contained allegations similar to 1(A)(1) for your Luna G3 APAP\u002FBPAP ventilator devices, Stratus and Phoenix oxygen concentrators, and Rio masks. For example, on August 1, 2025, you received an allegation that \"***\u003Cem>CPAP suddenly started to pulsating in pressure after ramp up\u003C\u002Fem>***” (INQ-25644) that was logged as an inquiry instead of a complaint.\u003C\u002Fp>\u003Cp>B. Your firm’s “Customer Complaints” procedure (SP.QA.0011; Rev. G-I; Effective: 8\u002F27\u002F24, 12\u002F5\u002F24, 6\u002F27\u002F25) and “Incident Reporting Procedure” (SP.QA.0013; Rev. G-I; Effective: 8\u002F27\u002F24, 12\u002F5\u002F24, 6\u002F27\u002F25) do not ensure that additional information is requested to evaluate the need for medical device reportability when the alleged issue has the potential to result in a serious injury, as required by 21 CFR 820.198(a)(3). For example, in three (3) out of eleven (11) complaints reviewed, there was no documentation of follow-up questions asked of complainants to determine whether the incidents were reportable although complainants reported incidents of choking and shortness of breath.\u003C\u002Fp>\u003Cp> \u003Cu>CN-011887\u003C\u002Fu> (1\u002F31\u002F25) for Luna G3 APAP states “***\u003Cem>that the machine shuts off in the middle of the night***chokes her out and she is afraid to use it\u003C\u002Fem>***.” There is no additional documentation in the complaint record about whether medical complications occurred, including the nature of the complication, and\u002For if medical or surgical intervention was required to preclude permanent impairment of a body function\u002Fstructure. No medical device report (MDR) was filed.\u003C\u002Fp>\u003Cp> \u003Cu>CN-026089\u003C\u002Fu> (7\u002F24\u002F25) for Luna G3 APAP states “***\u003Cem>that in the middle of therapy the device will suddenly send burst of hard rapid airflow that wakes him and makes him short of breath\u003C\u002Fem>***.” There is no additional documentation in the complaint record about whether medical complications occurred, including the nature of the complication, and\u002For if medical or surgical intervention was required to preclude permanent impairment of a body function\u002Fstructure. No MDR was filed.\u003C\u002Fp>\u003Cp> \u003Cu>CN-014116\u003C\u002Fu> (2\u002F21\u002F25) for Luna G3 APAP states that the “***\u003Cem>device not auto adjusting, pt woke up short of air, device not tracking\u003C\u002Fem>***.” There is no additional documentation in the complaint record about whether medical complications occurred, including the nature of the complication, and\u002For if medical or surgical intervention was required to preclude permanent impairment of a body function\u002Fstructure. No MDR was filed.\u003C\u002Fp>\u003Cp>C. Your firm failed to implement section 9.1.2 of your “Customer Complaints” procedure (SP.QA.0011; Rev. G-I; Effective: 8\u002F27\u002F24, 12\u002F5\u002F24, 6\u002F27\u002F25) which states that “***\u003Cem>Complaints shall be processed in a uniform and in a timely manner\u003C\u002Fem>***,” as required by 21 CFR 820.198(a)(1). For example, your June 18, 2025 Quality Data Review documents that as of May 2025, there were backlogs of over \u003Cstrong>(b)(4)\u003C\u002Fstrong> complaints for your Stratus oxygen concentrator devices and over \u003Cstrong>(b)(4)\u003C\u002Fstrong> complaints for your Luna ventilator devices. In addition, review of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> complaints received between August 27, 2024 and December 2, 2025 revealed that over \u003Cstrong>(b)(4)\u003C\u002Fstrong> complaints were in the workflow status of “open”, “pending approval”, “evaluation in process”, or “investigation in process” for at least \u003Cstrong>(b)(4)\u003C\u002Fstrong> or more.\u003C\u002Fp>\u003Cp>We reviewed your firm’s responses and conclude that they are not adequate. Under CAPA 2504, your firm reviewed FDA-483 observation 1 with your complaint team; re-launched complaint awareness training; updated SP.QA.0011 with an end-to-end complaint investigation workflow to ensure collection of medical and patient outcome information in cases of potential or suspected patient harm; developed a complaint intake tool; provided training on identification of potential patient harm to complaint handling employees; and initiated a retrospective review project of all cancelled complaints and inquiries with a target date of November 1, 2026; and developed an intake ticketing system that defines complaint sources. However, neither the updated SP.QA.0011 or “Customer Contact Form” provide assurance that additional follow-up questions are requested of complainants in cases where sufficient information is not provided (but there is a possibility of patient harm) in order to determine whether the complaint represents an MDR reportable event. Furthermore, no actions were identified to address the backlog of open complaints noted in the 1(C) above or to assess whether staffing levels are adequate. The inspection found that \u003Cstrong>(b)(4)\u003C\u002Fstrong> employees, \u003Cstrong>(b)(4)\u003C\u002Fstrong> of whom were temporary, were tasked with the responsibility of processing over \u003Cstrong>(b)(4)\u003C\u002Fstrong> complaints received during the 15-month period prior to the inspection. Please provide a response on how you plan to address the above deficiencies. In addition, please continue to provide updates on the progress of your corrections and\u002For corrective actions, including any supporting evidence.\u003C\u002Fp>\u003Cp>2. Failure to establish and maintain procedures for implementing corrective and preventive action, as required by 21 CFR 820.100(a).\u003C\u002Fp>\u003Cp>Specifically, your firm failed to implement section 10.4 of your “Corrective and Preventive Action (CAPA) Procedure” (SP.QA.0012; Rev. D; Effective: 7\u002F12\u002F23) which requires that the containment phase “***\u003Cstrong>(b)(4)\u003C\u002Fstrong>.” For example, you initiated CAPA 2408, dated November 25, 2024, due to the shipment of expired Ultra Soft 12 Food Oxygen Cannulae (Part # 02U2012; Lot # \u003Cstrong>(b)(4)\u003C\u002Fstrong>; Exp: 4\u002F2022) from your warehouse to a customer on October 28, 2024. However, the containment activities only included \u003Cstrong>(b)(4)\u003C\u002Fstrong> out of \u003Cstrong>(b)(4)\u003C\u002Fstrong> possible warehouses that could receive product. Your firm did not consider the other \u003Cstrong>(b)(4)\u003C\u002Fstrong> warehouses to ensure that they were also unable to ship products that are past expiration date.\u003C\u002Fp>\u003Cp>Moreover, although section 10.4 of SP.QA.0012 states a “***\u003Cem>recall, correction, or removal requires CAPA initiation\u003C\u002Fem>***” and your Manager of Quality Systems and Compliance stated that CAPA 2408 was opened in part to control the field action initiated on November 27, 2024, there is no mention of this field action (RES 95918) in this CAPA record.\u003C\u002Fp>\u003Cp>We reviewed your firm’s responses and conclude that they are not adequate. Under CAPA 2505, your firm ran a full inventory report for all expiry-dated products across all warehouses; performed a gap assessment on all active Supplier Quality Agreements (SQAs); updated the CAPA 2408 record to document containment verification and include linkage to the field action; and conducted a for-cause supplier audit at the \u003Cstrong>(b)(4)\u003C\u002Fstrong> as a follow-up to the Expired Cannula Recall (RES 95918). By May 15, 2026, your firm also plans to add expiration controls to ensure expired products cannot be released or shipped; a requirement for routine inventory checks at all warehouses, including third-party logistics \u003Cstrong>(b)(4)\u003C\u002Fstrong> partners; and mandatory review of these results at Management Review meetings. However, there was no action identified to conduct a risk assessment on whether a field action is needed for product released from the additional warehouses which were not accounted for in CAPA 2408 and subsequent field action under RES 95918. This includes the \u003Cstrong>(b)(4)\u003C\u002Fstrong> distribution centers operated by \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Please provide a response on how you plan to address the above deficiencies. In addition, please continue to provide updates on the progress of your corrections and\u002For corrective actions, including any supporting evidence.\u003C\u002Fp>\u003Cp>3. Failure to establish and maintain adequate procedures for implementing corrective and preventive action, including requirements for analyzing processes, work operations, concessions, quality audit, reports, quality records, service records, complaints, returned product, and other sources of quality data to identify existing and potential causes of nonconforming product, or other quality problems. Appropriate statistical methodology shall be employed where necessary to detect recurring quality problems, as required by 21 CFR 820.100(a)(1).\u003C\u002Fp>\u003Cp>Specifically, the “Matrix, Quality Data Metrics” form (SP.QA.0035.F1; Rev. D; Effective: 10\u002F29\u002F24) used by your firm to trend quality data is inadequate because it does not ensure that reported complaints are analyzed in a manner which detects all potential sources of nonconforming product and other quality problems, as required by 21 CFR 820.100(a)(1). Your Quality Data Review (QDR) dated June 18, 2025 identified \"Pressure Fluctuation\u002F Pulsating\" as the most frequently reported issue in complaints received from June 2024 to May 2025 across all ventilator devices (G3X APAP, Luna G3 APAP, Luna G3 BPAP, and Luna G3 30VT, and Luna G2 APAP) but no additional analysis was performed to uncover other potential issues that may warrant evaluation for the need for corrective actions. For example, when this same analysis was applied to complaint data from August 27, 2024, to December 2, 2025 for the G3X APAP and Luna G3 APAP devices individually, the highest reported issues differed, with “Damaged\u002FBroken” and “Error Code Message” reported as the most frequently reported allegations, respectively. Your CAPA Log from December 2022 to December 2025 shows that no CAPA has been initiated for damaged or broken G3X APAP devices or error codes associated with Luna G3 APAP devices.\u003C\u002Fp>\u003Cp>We reviewed your firm’s responses and conclude that they are not adequate. Under CAPA 2505, your firm re-ran complaint trending QDR for December 2024 through May 2025 (6-month review) to depict data by Luna model; re-evaluated \"Pressure Fluctuation\" Dec 2024 through May 2025 (6-month review) trend that triggered review for potential CAPA or SCAR; and added “investigated issue (root cause)” charts to QDR. However, no supporting evidence was provided to allow review of the adequacy of the revised analysis method applied to the December 2024 to May 2025 complaint data, including the outcome of the assessment for the need for CAPAs as well as the added corrective action in CAPA 2505 to revise SP.QA.0015 and SP.QA.0035 to require ongoing complaint trending by 510(k) model, failure mode, and root cause. Please provide a response on how you plan to address the above deficiencies. In addition, please continue to provide updates on the progress of your corrections and\u002For corrective actions, including any supporting evidence.\u003C\u002Fp>\u003Cp>4. Failure to establish and maintain procedures for validating the device design, including risk analysis, as required by 21 CFR 820.30(g).\u003C\u002Fp>\u003Cp>Specifically, your firm failed to implement section 9.10 of your “Risk Management Process” procedure (SP.QA.0025; Rev. C; Effective: 3\u002F27\u002F23) which states that “***\u003Cem>Prior to, or commensurate with, the release for commercial distribution of the medical device***The risk management report shall\u003C\u002Fem> \u003Cem>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fem>***.” For example, upon acquisition of the iCodeConnect software on May 8, 2025, your firm accepted an outdated version 1.1 of the Risk Management Report (YF-CSP1-3-02; Effective: 8\u002F13\u002F16) instead of version 4.0 listed in Appendix A of the “Software Copyright Transfer Contract”. Consequently, this 2016 version of the Risk Management Report fails to include an assessment of the risk acceptability of post-production design changes to the iCodeConnect software which transpired between 2018 and 2025 such as (but not limited to) the release of a refactored version in July 2024 and added ability for use with the following ventilator devices:\u003C\u002Fp>\u003Cp> Luna G2 APAP in October 2018\u003Cbr> Luna G3 APAP in January 2022\u003Cbr> Luna G3 25A Bilevel in January 2022\u003Cbr> Luna G3 30VT BiPap in February 2023\u003Cbr> G3 X APAP in July 2025\u003C\u002Fp>\u003Cp>The adequacy of your firm’s responses cannot be determined at this time. Under CAPA 2508, your firm froze software development and design changes for the iCodeConnect software; performed a regulatory assessment for the intent of a health hazard evaluation; created an iCodeConnect quality plan to establish a comprehensive Design History File (DHF), including the risk management file in the QMS; performed training for personnel supporting regulated stand-alone software, DHF requirements, and document control expectations under 21 CFR 820 and ISO 13485; updated the Design Controls procedures to clarify the process that will be used for developing &amp; maintaining regulated software; created an architecture document that describes the scope of iCodeConnect; and performed a Regulatory Assessment of the iCodeConnect software. By May 15, 2026, your firm plans to establish a new, complete and compliant DHF based on the results of the Regulatory Assessment of the iCodeConnect and update and formalize the risk management file for the current version 3.0 of the iCodeConnect. Please continue to provide updates on the progress of your corrections and\u002For corrective actions, including any supporting evidence.\u003C\u002Fp>\u003Cp>5. Failure to establish and maintain procedures to ensure that all personnel are trained to adequately perform their assigned responsibilities, as required by 21 CFR 820.25(b).\u003C\u002Fp>\u003Cp>Specifically, your firm failed to implement section 8 of the “Training and Competency Procedure” (SP.HR.004; Rev. C; Effective: 6\u002F28\u002F24) which includes the requirement to “Evaluate Training Effectiveness” after conducting assigned training in the process flow chart. For example, the training record forms (FO.HR.0004) for \u003Cstrong>(b)(4)\u003C\u002Fstrong> out of \u003Cstrong>(b)(4)\u003C\u002Fstrong> employees who conduct complaint handling and incident reporting revealed that no “Effectiveness Check(s)” were conducted after receiving training on the “Customer Complaint Procedure” (SP.QA.0011) or Electronic Medical Device Reporting (eMDR) Procedure (SP.QA.0013).\u003C\u002Fp>\u003Cp>The adequacy of your firm’s responses cannot be determined at this time. Under CAPA 2509, your firm performed a training gap assessment, verified training completeness, and conducted training effectiveness checks for the \u003Cstrong>(b)(4)\u003C\u002Fstrong> identified employees; updated SP.HR.004 to establish role-based training needs identification, training effectiveness verification methods, and management governance controls; and implemented standardized training tools (e.g., training needs assessment criteria, instructions for use of training effectiveness templates, and monitoring mechanisms) followed with training. Please continue to provide updates on the progress of your corrections and\u002For corrective actions, including any supporting evidence.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Unapproved Device Violations\u003C\u002Fu>\u003C\u002Fstrong>\u003Cbr>Our inspection revealed that the APAP devices that your firm distributes as Luna G3 APAP and Luna G3X APAP are adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption under section 520(g) of the Act, 21 U.S.C. § 360j(g). The devices are also misbranded under section 502(o) of the Act, 21 U.S.C. § 352(o), because your firm introduced or delivered for introduction into interstate commerce for commercial distribution these devices with significant changes or modifications without submitting a new premarket notification to FDA, as required by section 510(k) of the Act, 21 U.S.C. § 360(k), and 21 CFR 807.81(a)(3). For a device requiring premarket approval, the notification required by section 510(k) is deemed satisfied when a PMA is pending before the agency. [21 CFR 807.81(b)]. The kind of information that your firm needs to submit in order to obtain approval or clearance for the device is described on the Internet at http:\u002F\u002Fwww.fda.gov\u002FMedicalDevices\u002FDeviceRegulationandGuidance\u002FHowtoMarketYourDevice\u002Fdefault.htm. The FDA will evaluate the information that your firm submits and decide whether the product may be legally marketed.\u003C\u002Fp>\u003Cp>According to our records, the most recent FDA clearance for the APAP devices was granted on September 8, 2016, under 510(k) number K153387. The cleared intended use for these APAP devices, branded as Luna® CPAP and Auto CPAP System, was \"for single-patient use by prescription in the home or hospital\u002Finstitutional environment on adult patients.\" However, the user manuals obtained during the inspection, authored by your firm, and available for public download from your firm's website (https:\u002F\u002Fwww.reacthealth.com\u002Fsleep\u002Fpap-devices) as of May 19, 2026, indicate that the APAP devices are intended \"for single-patient re-use in the home environment or for multi-patient re-use in the hospital\u002Finstitutional environment.\" This constitutes a major change or modification to the intended use of these devices for which they lack clearance or approval. This major change or modification to the intended use could significantly affect the safety and effectiveness of these devices because multi-patient use introduces risks of cross-contamination and transmission of infectious pathogens between patients, including respiratory viruses and bacteria, that are not present in single-patient use. These risks are new and not addressed by the cleared device's labeling or existing reprocessing instructions, as the device was not evaluated or cleared for the decontamination protocols necessary to ensure patient safety between uses.\u003C\u002Fp>\u003Cp>FDA’s regulations at 21 CFR 807.81(a)(3)(i) provide that submission of a 510(k) is required for “a change or modification in the device that could significantly affect the safety or effectiveness of the device, e.g., a significant change or modification in design, material, chemical composition, energy source, or manufacturing process.” FDA requests that your firm cease any activities that result in the misbranding or adulteration of these devices.\u003C\u002Fp>\u003Cp>For further explanation on the need for a new premarket notification, or \"510(k),\" for changes to the intended use or design affecting safety and effectiveness, consult the guidance document \"\u003Cem>Deciding When to Submit a 510(k) for a Change to an Existing Device — Guidance for Industry and Food and Drug Administration Staff (fda.gov)\u003C\u002Fem>.\" The “\u003Cem>Requests for Feedback and Meetings for Medical Device Submissions: The Q-Submission Program Guidance for Industry and Food and Drug Administration Staff\u003C\u002Fem>,” is also recommended for obtaining FDA feedback on the 510(k) submission for the modified Luna G3 APAP devices.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Corrections and Removals Violations\u003C\u002Fu>\u003C\u002Fstrong>\u003Cbr>Our inspection also revealed that your firm’s Rio II Nasal Pillows devices are misbranded under section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information respecting the device that is required by or under section 519 of the Act, 21 U.S.C. § 360i, and 21 CFR Part 806 – Medical Devices; Reports of Corrections and Removals. Significant violations include, but are not limited to, the following:\u003C\u002Fp>\u003Cp>1. Failure to submit a Report required by 21 CFR 806.10 to FDA, within 10 working days of initiating the correction or removal. For example: your Rio II Nasal Pillows devices were packaged in boxes that incorrectly all had one part number on the front and all size checkboxes filled in. The box labels for all sizes incorrectly had the same UDI number, regardless of size. An incorrect sized mask can result in high leaks (when using larger size) or inability to use the mask (when incorrectly using small size). When this happens, the therapy is not provided to the patients with obstructive sleep apnea, which presents a risk to health. You notified Durable Medical Equipment (DME) companies beginning June 22, 2023, to remedy the violation or reduce the risk to health posed by the device. This action is a medical device correction or removal initiated to reduce the risk to health posed by the device or to remedy a violation of the Act caused by the device which may present a risk to health, for which you are required to submit a Report of Correction or Removal to FDA. As of December 10, 2025, you did not submit a Medical Device Report of Correction or Removal to FDA for this action.\u003C\u002Fp>\u003Cp>We reviewed your firm’s responses and conclude that they are not adequate. Your responses do not address Reports of Correction or Removal, and your firm has not submitted a Report of Correction or Removal to FDA for the incorrectly labeled Rio II Nasal Pillows as of May 19, 2026.\u003C\u002Fp>\u003Cp>Your firm should take prompt action to address any violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\u003C\u002Fp>\u003Cp>Other federal agencies may take your compliance with the FD&amp;C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed. Should FDA determine that your devices or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted.\u003C\u002Fp>\u003Cp>On February 2, 2024, the FDA issued a \u003Cu>final rule\u003C\u002Fu> amending the device current good manufacturing practice (CGMP) requirements of the Quality System (QS) Regulation under 21 CFR 820 to align more closely with the international consensus standard for Quality Management Systems for medical devices used by many other regulatory authorities around the world. The revised part 820, referred to as the Quality Management System Regulation (QMSR), became effective on February 2, 2026. Your most recent inspection from December 1, 2025 to December 10, 2025 was conducted pursuant to the QS Regulation, which was in effect at the time of the inspection. However, any corrective actions you propose, or implement must be pursuant to the QMSR requirements in effect as of February 2, 2026. For more information on the QMSR please refer to our frequently asked questions webpage:\u003Cbr>https:\u002F\u002Fwww.fda.gov\u002Fmedical-devices\u002Fquality-system-qs-regulationmedical-device-current-good-manufacturing-practices-cgmp\u002Fquality-management-system-regulation-final-rule-amending-quality-system-regulation-frequently-asked.\u003C\u002Fp>\u003Cp>Please notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration as part of your response.\u003C\u002Fp>\u003Cp>Your firm’s response should be sent via email to Gina Brackett, Establishment Assessment Team 1 Assistant Director at CDRHEnforcement@fda.hhs.gov. Please include in the subject line, “CMS Case 725108” when replying. If you have any questions about the contents of this letter, please contact: Sargum Morgan, Compliance Officer at sargum.morgan@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Barbara A. Marsden\u003Cbr>Director\u003Cbr>Office of Regulatory Programs\u003Cbr>Office of Product Evaluation and Quality\u003Cbr>Center for Devices and Radiological Health\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nProduct:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nWilliam H. Shoop\n\nRecipient Title\n\nCEO\n\n3B Medical, Inc. dba Reach Health, Inc.\n\n5475 Rings Road\n\nDublin, OH 43017\n\nUnited States\n\n(b)(4)\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nWARNING LETTER\nCMS # 725108\nMay 20, 2026\nDear Mr. Shoop:\nDuring an inspection of your firm located in Dublin, OH from December 1, 2025 through December 10, 2025, an investigator from the United States Food and Drug Administration (FDA) determined that your firm manufactures iCodeConnect, a cloud-based software device, intended for use in conjunction with Continuous Positive Airway Pressure (CPAP) and Auto-Adjusting Positive Airway Pressure (Auto-CPAP or APAP) ventilator devices, in treating obstructive sleep apnea (OSA) in adults. Your firm also imports and provides complaint handling for APAP and Bilevel Positive Airway Pressure (BPAP) ventilator devices from BMC Medical Co., Ltd. (Beijing, China) to include, but not limited to, Luna G3 APAP (LG3600), G3X APAP (G4600), Luna G3 BPAP (LG3700), Luna G3 30VT (LG3800), and Luna G2 APAP (LG2A02). Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\nQuality System Regulation Violations\nThis inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820.\nWe received a response from Rebecca Legare, Quality Systems and Compliance Director, dated January 2, 2026, and February 13, 2026, and from Shalini Yadav, Senior Manager of Regulatory Affairs on March 27, 2026, concerning our investigator’s observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, that was issued to your firm. We address this response below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\n1. Failure to establish and maintain procedures for receiving, reviewing, and evaluating complaints by a formally designated unit to ensure that all complaints are processed in a uniform and timely manner and complaints are evaluated to determine whether the complaint represents an event which is required to be reported to FDA under part 803 or 804 of this chapter, Medical Device Reporting (MDR), as required by 21 CFR 820.198(a), 820.198(a)(1), and 820.198(a)(3).\nSpecifically:\nA. Your firm failed to implement section 9.1.1 of your “Customer Complaints” procedure (SP.QA.0011; Rev. G-I; Effective: 8\u002F27\u002F24, 12\u002F5\u002F24, 6\u002F27\u002F25) which requires you to “***determine if there is a complaint based on the definition of a complaint above and Complaint Decision Tree***,” as required by 21 CFR 820.198(a). For example:\n1. Seven (7) out of eleven (11) complaint records reviewed were cancelled although they met the definition of a complaint defined in your procedure as “Any written, electronic, or verbal communication that alleges deficiencies related to the identity, quality, durability, reliability, safety, effectiveness, or performance of a device following release for distribution.” Examples include:\n CN-028565 (9\u002F5\u002F25) for Luna G3 APAP states “***used it Wednesday and Thursday nights. It collected data that shows in the machine display. But, using the React Health Plus app on my iPhone, when I try to upload the data by scanning the iCode QR+ code, the app appears to scan successfully, but the data does not show in the app***.” The documented justification for cancelling the complaint was “***The device was not returned. Tech Support provided information to the customer about data transmission, and the customer later confirmed that data was being displayed. The ticket was canceled. No issue was confirmed***.” However, this incident meets the definition of a complaint due to alleged concern with performance regardless of whether it was determined to be a use error.\n CN-030142 (10\u002F3\u002F25) for Luna 2 Auto states “***Pt dropped machine and it stopped working***.” The documented justification for cancelling the complaint was “***This issue is not a complaint because the patient dropped the device.***” However, this incident meets the definition of a complaint due to alleged concern with durability, regardless of whether it was determined to be a use error.\nFrom August 28, 2024 to November 21, 2025, your firm cancelled (b)(4) complaints despite allegations for pressure delivery issues (fluctuations, pulsating, surging, etc.), shutdowns, and electronic and software failures (data transmission, modem connectivity, error codes, etc.) with your Luna G3 APAP\u002FBPAP devices; abnormal pressure readings, low oxygen output, and persistent red-light alarms for your Stratus oxygen concentrators; abnormal smells from your Phoenix 5L oxygen concentrators; and durability issues with your Rio masks.\n2. Thirteen (13) out of fifteen (15) inquiries reviewed met the definition of a complaint defined in your procedure. Examples include:\n INQ-26292 (8\u002F18\u002F25) for Luna G3 APAP states “***Pt turned machine over on nightstand, causing water to flow back into machine. Machine pressure now fluctuates heavily and constantly***.” The documented justification for not logging this incident as a complaint was “***Because the patient turned the device over on the nightstand, this is considered patient damage, not a complaint***.” However, this incident meets the definition of a complaint due to alleged concern with performance regardless of whether it was determined to be a use error.\n INQ-23277 (6\u002F23\u002F25) for Luna 2 Auto states “***Button on machine is broken***.” The documented justification for not logging this incident as a complaint was “***The device was not confirmed to be received from React Health with a broken button. Since the device is out of warranty, it has been used, and the damage is considered to be customer induced. Therefore, this is not a complaint***.” However, this incident meets the definition of a complaint due to alleged concern with durability regardless of whether it was determined to be a use error or out of warranty.\nYour firm has received over (b)(4) records from August 26, 2024, to December 23, 2025, that you classified as inquiries and found that several should have been categorized as complaints because they contained allegations similar to 1(A)(1) for your Luna G3 APAP\u002FBPAP ventilator devices, Stratus and Phoenix oxygen concentrators, and Rio masks. For example, on August 1, 2025, you received an allegation that \"***CPAP suddenly started to pulsating in pressure after ramp up***” (INQ-25644) that was logged as an inquiry instead of a complaint.\nB. Your firm’s “Customer Complaints” procedure (SP.QA.0011; Rev. G-I; Effective: 8\u002F27\u002F24, 12\u002F5\u002F24, 6\u002F27\u002F25) and “Incident Reporting Procedure” (SP.QA.0013; Rev. G-I; Effective: 8\u002F27\u002F24, 12\u002F5\u002F24, 6\u002F27\u002F25) do not ensure that additional information is requested to evaluate the need for medical device reportability when the alleged issue has the potential to result in a serious injury, as required by 21 CFR 820.198(a)(3). For example, in three (3) out of eleven (11) complaints reviewed, there was no documentation of follow-up questions asked of complainants to determine whether the incidents were reportable although complainants reported incidents of choking and shortness of breath.\n CN-011887 (1\u002F31\u002F25) for Luna G3 APAP states “***that the machine shuts off in the middle of the night***chokes her out and she is afraid to use it***.” There is no additional documentation in the complaint record about whether medical complications occurred, including the nature of the complication, and\u002For if medical or surgical intervention was required to preclude permanent impairment of a body function\u002Fstructure. No medical device report (MDR) was filed.\n CN-026089 (7\u002F24\u002F25) for Luna G3 APAP states “***that in the middle of therapy the device will suddenly send burst of hard rapid airflow that wakes him and makes him short of breath***.” There is no additional documentation in the complaint record about whether medical complications occurred, including the nature of the complication, and\u002For if medical or surgical intervention was required to preclude permanent impairment of a body function\u002Fstructure. No MDR was filed.\n CN-014116 (2\u002F21\u002F25) for Luna G3 APAP states that the “***device not auto adjusting, pt woke up short of air, device not tracking***.” There is no additional documentation in the complaint record about whether medical complications occurred, including the nature of the complication, and\u002For if medical or surgical intervention was required to preclude permanent impairment of a body function\u002Fstructure. No MDR was filed.\nC. Your firm failed to implement section 9.1.2 of your “Customer Complaints” procedure (SP.QA.0011; Rev. G-I; Effective: 8\u002F27\u002F24, 12\u002F5\u002F24, 6\u002F27\u002F25) which states that “***Complaints shall be processed in a uniform and in a timely manner***,” as required by 21 CFR 820.198(a)(1). For example, your June 18, 2025 Quality Data Review documents that as of May 2025, there were backlogs of over (b)(4) complaints for your Stratus oxygen concentrator devices and over (b)(4) complaints for your Luna ventilator devices. In addition, review of the (b)(4) complaints received between August 27, 2024 and December 2, 2025 revealed that over (b)(4) complaints were in the workflow status of “open”, “pending approval”, “evaluation in process”, or “investigation in process” for at least (b)(4) or more.\nWe reviewed your firm’s responses and conclude that they are not adequate. Under CAPA 2504, your firm reviewed FDA-483 observation 1 with your complaint team; re-launched complaint awareness training; updated SP.QA.0011 with an end-to-end complaint investigation workflow to ensure collection of medical and patient outcome information in cases of potential or suspected patient harm; developed a complaint intake tool; provided training on identification of potential patient harm to complaint handling employees; and initiated a retrospective review project of all cancelled complaints and inquiries with a target date of November 1, 2026; and developed an intake ticketing system that defines complaint sources. However, neither the updated SP.QA.0011 or “Customer Contact Form” provide assurance that additional follow-up questions are requested of complainants in cases where sufficient information is not provided (but there is a possibility of patient harm) in order to determine whether the complaint represents an MDR reportable event. Furthermore, no actions were identified to address the backlog of open complaints noted in the 1(C) above or to assess whether staffing levels are adequate. The inspection found that (b)(4) employees, (b)(4) of whom were temporary, were tasked with the responsibility of processing over (b)(4) complaints received during the 15-month period prior to the inspection. Please provide a response on how you plan to address the above deficiencies. In addition, please continue to provide updates on the progress of your corrections and\u002For corrective actions, including any supporting evidence.\n2. Failure to establish and maintain procedures for implementing corrective and preventive action, as required by 21 CFR 820.100(a).\nSpecifically, your firm failed to implement section 10.4 of your “Corrective and Preventive Action (CAPA) Procedure” (SP.QA.0012; Rev. D; Effective: 7\u002F12\u002F23) which requires that the containment phase “***(b)(4).” For example, you initiated CAPA 2408, dated November 25, 2024, due to the shipment of expired Ultra Soft 12 Food Oxygen Cannulae (Part # 02U2012; Lot # (b)(4); Exp: 4\u002F2022) from your warehouse to a customer on October 28, 2024. However, the containment activities only included (b)(4) out of (b)(4) possible warehouses that could receive product. Your firm did not consider the other (b)(4) warehouses to ensure that they were also unable to ship products that are past expiration date.\nMoreover, although section 10.4 of SP.QA.0012 states a “***recall, correction, or removal requires CAPA initiation***” and your Manager of Quality Systems and Compliance stated that CAPA 2408 was opened in part to control the field action initiated on November 27, 2024, there is no mention of this field action (RES 95918) in this CAPA record.\nWe reviewed your firm’s responses and conclude that they are not adequate. Under CAPA 2505, your firm ran a full inventory report for all expiry-dated products across all warehouses; performed a gap assessment on all active Supplier Quality Agreements (SQAs); updated the CAPA 2408 record to document containment verification and include linkage to the field action; and conducted a for-cause supplier audit at the (b)(4) as a follow-up to the Expired Cannula Recall (RES 95918). By May 15, 2026, your firm also plans to add expiration controls to ensure expired products cannot be released or shipped; a requirement for routine inventory checks at all warehouses, including third-party logistics (b)(4) partners; and mandatory review of these results at Management Review meetings. However, there was no action identified to conduct a risk assessment on whether a field action is needed for product released from the additional warehouses which were not accounted for in CAPA 2408 and subsequent field action under RES 95918. This includes the (b)(4) distribution centers operated by (b)(4). Please provide a response on how you plan to address the above deficiencies. In addition, please continue to provide updates on the progress of your corrections and\u002For corrective actions, including any supporting evidence.\n3. Failure to establish and maintain adequate procedures for implementing corrective and preventive action, including requirements for analyzing processes, work operations, concessions, quality audit, reports, quality records, service records, complaints, returned product, and other sources of quality data to identify existing and potential causes of nonconforming product, or other quality problems. Appropriate statistical methodology shall be employed where necessary to detect recurring quality problems, as required by 21 CFR 820.100(a)(1).\nSpecifically, the “Matrix, Quality Data Metrics” form (SP.QA.0035.F1; Rev. D; Effective: 10\u002F29\u002F24) used by your firm to trend quality data is inadequate because it does not ensure that reported complaints are analyzed in a manner which detects all potential sources of nonconforming product and other quality problems, as required by 21 CFR 820.100(a)(1). Your Quality Data Review (QDR) dated June 18, 2025 identified \"Pressure Fluctuation\u002F Pulsating\" as the most frequently reported issue in complaints received from June 2024 to May 2025 across all ventilator devices (G3X APAP, Luna G3 APAP, Luna G3 BPAP, and Luna G3 30VT, and Luna G2 APAP) but no additional analysis was performed to uncover other potential issues that may warrant evaluation for the need for corrective actions. For example, when this same analysis was applied to complaint data from August 27, 2024, to December 2, 2025 for the G3X APAP and Luna G3 APAP devices individually, the highest reported issues differed, with “Damaged\u002FBroken” and “Error Code Message” reported as the most frequently reported allegations, respectively. Your CAPA Log from December 2022 to December 2025 shows that no CAPA has been initiated for damaged or broken G3X APAP devices or error codes associated with Luna G3 APAP devices.\nWe reviewed your firm’s responses and conclude that they are not adequate. Under CAPA 2505, your firm re-ran complaint trending QDR for December 2024 through May 2025 (6-month review) to depict data by Luna model; re-evaluated \"Pressure Fluctuation\" Dec 2024 through May 2025 (6-month review) trend that triggered review for potential CAPA or SCAR; and added “investigated issue (root cause)” charts to QDR. However, no supporting evidence was provided to allow review of the adequacy of the revised analysis method applied to the December 2024 to May 2025 complaint data, including the outcome of the assessment for the need for CAPAs as well as the added corrective action in CAPA 2505 to revise SP.QA.0015 and SP.QA.0035 to require ongoing complaint trending by 510(k) model, failure mode, and root cause. Please provide a response on how you plan to address the above deficiencies. In addition, please continue to provide updates on the progress of your corrections and\u002For corrective actions, including any supporting evidence.\n4. Failure to establish and maintain procedures for validating the device design, including risk analysis, as required by 21 CFR 820.30(g).\nSpecifically, your firm failed to implement section 9.10 of your “Risk Management Process” procedure (SP.QA.0025; Rev. C; Effective: 3\u002F27\u002F23) which states that “***Prior to, or commensurate with, the release for commercial distribution of the medical device***The risk management report shall (b)(4)***.” For example, upon acquisition of the iCodeConnect software on May 8, 2025, your firm accepted an outdated version 1.1 of the Risk Management Report (YF-CSP1-3-02; Effective: 8\u002F13\u002F16) instead of version 4.0 listed in Appendix A of the “Software Copyright Transfer Contract”. Consequently, this 2016 version of the Risk Management Report fails to include an assessment of the risk acceptability of post-production design changes to the iCodeConnect software which transpired between 2018 and 2025 such as (but not limited to) the release of a refactored version in July 2024 and added ability for use with the following ventilator devices:\n Luna G2 APAP in October 2018\n Luna G3 APAP in January 2022\n Luna G3 25A Bilevel in January 2022\n Luna G3 30VT BiPap in February 2023\n G3 X APAP in July 2025\nThe adequacy of your firm’s responses cannot be determined at this time. Under CAPA 2508, your firm froze software development and design changes for the iCodeConnect software; performed a regulatory assessment for the intent of a health hazard evaluation; created an iCodeConnect quality plan to establish a comprehensive Design History File (DHF), including the risk management file in the QMS; performed training for personnel supporting regulated stand-alone software, DHF requirements, and document control expectations under 21 CFR 820 and ISO 13485; updated the Design Controls procedures to clarify the process that will be used for developing & maintaining regulated software; created an architecture document that describes the scope of iCodeConnect; and performed a Regulatory Assessment of the iCodeConnect software. By May 15, 2026, your firm plans to establish a new, complete and compliant DHF based on the results of the Regulatory Assessment of the iCodeConnect and update and formalize the risk management file for the current version 3.0 of the iCodeConnect. Please continue to provide updates on the progress of your corrections and\u002For corrective actions, including any supporting evidence.\n5. Failure to establish and maintain procedures to ensure that all personnel are trained to adequately perform their assigned responsibilities, as required by 21 CFR 820.25(b).\nSpecifically, your firm failed to implement section 8 of the “Training and Competency Procedure” (SP.HR.004; Rev. C; Effective: 6\u002F28\u002F24) which includes the requirement to “Evaluate Training Effectiveness” after conducting assigned training in the process flow chart. For example, the training record forms (FO.HR.0004) for (b)(4) out of (b)(4) employees who conduct complaint handling and incident reporting revealed that no “Effectiveness Check(s)” were conducted after receiving training on the “Customer Complaint Procedure” (SP.QA.0011) or Electronic Medical Device Reporting (eMDR) Procedure (SP.QA.0013).\nThe adequacy of your firm’s responses cannot be determined at this time. Under CAPA 2509, your firm performed a training gap assessment, verified training completeness, and conducted training effectiveness checks for the (b)(4) identified employees; updated SP.HR.004 to establish role-based training needs identification, training effectiveness verification methods, and management governance controls; and implemented standardized training tools (e.g., training needs assessment criteria, instructions for use of training effectiveness templates, and monitoring mechanisms) followed with training. Please continue to provide updates on the progress of your corrections and\u002For corrective actions, including any supporting evidence.\nUnapproved Device Violations\nOur inspection revealed that the APAP devices that your firm distributes as Luna G3 APAP and Luna G3X APAP are adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption under section 520(g) of the Act, 21 U.S.C. § 360j(g). The devices are also misbranded under section 502(o) of the Act, 21 U.S.C. § 352(o), because your firm introduced or delivered for introduction into interstate commerce for commercial distribution these devices with significant changes or modifications without submitting a new premarket notification to FDA, as required by section 510(k) of the Act, 21 U.S.C. § 360(k), and 21 CFR 807.81(a)(3). For a device requiring premarket approval, the notification required by section 510(k) is deemed satisfied when a PMA is pending before the agency. [21 CFR 807.81(b)]. The kind of information that your firm needs to submit in order to obtain approval or clearance for the device is described on the Internet at http:\u002F\u002Fwww.fda.gov\u002FMedicalDevices\u002FDeviceRegulationandGuidance\u002FHowtoMarketYourDevice\u002Fdefault.htm. The FDA will evaluate the information that your firm submits and decide whether the product may be legally marketed.\nAccording to our records, the most recent FDA clearance for the APAP devices was granted on September 8, 2016, under 510(k) number K153387. The cleared intended use for these APAP devices, branded as Luna® CPAP and Auto CPAP System, was \"for single-patient use by prescription in the home or hospital\u002Finstitutional environment on adult patients.\" However, the user manuals obtained during the inspection, authored by your firm, and available for public download from your firm's website (https:\u002F\u002Fwww.reacthealth.com\u002Fsleep\u002Fpap-devices) as of May 19, 2026, indicate that the APAP devices are intended \"for single-patient re-use in the home environment or for multi-patient re-use in the hospital\u002Finstitutional environment.\" This constitutes a major change or modification to the intended use of these devices for which they lack clearance or approval. This major change or modification to the intended use could significantly affect the safety and effectiveness of these devices because multi-patient use introduces risks of cross-contamination and transmission of infectious pathogens between patients, including respiratory viruses and bacteria, that are not present in single-patient use. These risks are new and not addressed by the cleared device's labeling or existing reprocessing instructions, as the device was not evaluated or cleared for the decontamination protocols necessary to ensure patient safety between uses.\nFDA’s regulations at 21 CFR 807.81(a)(3)(i) provide that submission of a 510(k) is required for “a change or modification in the device that could significantly affect the safety or effectiveness of the device, e.g., a significant change or modification in design, material, chemical composition, energy source, or manufacturing process.” FDA requests that your firm cease any activities that result in the misbranding or adulteration of these devices.\nFor further explanation on the need for a new premarket notification, or \"510(k),\" for changes to the intended use or design affecting safety and effectiveness, consult the guidance document \"Deciding When to Submit a 510(k) for a Change to an Existing Device — Guidance for Industry and Food and Drug Administration Staff (fda.gov).\" The “Requests for Feedback and Meetings for Medical Device Submissions: The Q-Submission Program Guidance for Industry and Food and Drug Administration Staff,” is also recommended for obtaining FDA feedback on the 510(k) submission for the modified Luna G3 APAP devices.\nCorrections and Removals Violations\nOur inspection also revealed that your firm’s Rio II Nasal Pillows devices are misbranded under section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information respecting the device that is required by or under section 519 of the Act, 21 U.S.C. § 360i, and 21 CFR Part 806 – Medical Devices; Reports of Corrections and Removals. Significant violations include, but are not limited to, the following:\n1. Failure to submit a Report required by 21 CFR 806.10 to FDA, within 10 working days of initiating the correction or removal. For example: your Rio II Nasal Pillows devices were packaged in boxes that incorrectly all had one part number on the front and all size checkboxes filled in. The box labels for all sizes incorrectly had the same UDI number, regardless of size. An incorrect sized mask can result in high leaks (when using larger size) or inability to use the mask (when incorrectly using small size). When this happens, the therapy is not provided to the patients with obstructive sleep apnea, which presents a risk to health. You notified Durable Medical Equipment (DME) companies beginning June 22, 2023, to remedy the violation or reduce the risk to health posed by the device. This action is a medical device correction or removal initiated to reduce the risk to health posed by the device or to remedy a violation of the Act caused by the device which may present a risk to health, for which you are required to submit a Report of Correction or Removal to FDA. As of December 10, 2025, you did not submit a Medical Device Report of Correction or Removal to FDA for this action.\nWe reviewed your firm’s responses and conclude that they are not adequate. Your responses do not address Reports of Correction or Removal, and your firm has not submitted a Report of Correction or Removal to FDA for the incorrectly labeled Rio II Nasal Pillows as of May 19, 2026.\nYour firm should take prompt action to address any violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\nOther federal agencies may take your compliance with the FD&C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed. Should FDA determine that your devices or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted.\nOn February 2, 2024, the FDA issued a final rule amending the device current good manufacturing practice (CGMP) requirements of the Quality System (QS) Regulation under 21 CFR 820 to align more closely with the international consensus standard for Quality Management Systems for medical devices used by many other regulatory authorities around the world. The revised part 820, referred to as the Quality Management System Regulation (QMSR), became effective on February 2, 2026. Your most recent inspection from December 1, 2025 to December 10, 2025 was conducted pursuant to the QS Regulation, which was in effect at the time of the inspection. However, any corrective actions you propose, or implement must be pursuant to the QMSR requirements in effect as of February 2, 2026. For more information on the QMSR please refer to our frequently asked questions webpage:\nhttps:\u002F\u002Fwww.fda.gov\u002Fmedical-devices\u002Fquality-system-qs-regulationmedical-device-current-good-manufacturing-practices-cgmp\u002Fquality-management-system-regulation-final-rule-amending-quality-system-regulation-frequently-asked.\nPlease notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration as part of your response.\nYour firm’s response should be sent via email to Gina Brackett, Establishment Assessment Team 1 Assistant Director at CDRHEnforcement@fda.hhs.gov. Please include in the subject line, “CMS Case 725108” when replying. If you have any questions about the contents of this letter, please contact: Sargum Morgan, Compliance Officer at sargum.morgan@fda.hhs.gov.\nFinally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\nSincerely,\n\u002FS\u002F\nBarbara A. Marsden\nDirector\nOffice of Regulatory Programs\nOffice of Product Evaluation and Quality\nCenter for Devices and Radiological Health","3B Medical, Inc. dba Reach Health, Inc.","3b-medical-inc-dba-reach-health-inc-725108-05202026","2026-08-18T06:42:28.498414+00:00",null,"https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002F3b-medical-inc-dba-reach-health-inc-725108-05202026","2026-10-26T08:07:47.656925+00:00","Warning Letter","Issued","2026-06-30","725108","Medical Devices","William H. Shoop","2026-08-19T04:32:04.542+00:00","VIA Electronic Mail","2026-05-20",{"id":32,"raw":33,"subject":38,"body_html":39,"body_text":40,"firm_name":41,"letter_id":42,"created_at":43,"fei_number":19,"letter_url":44,"updated_at":45,"action_type":22,"case_status":23,"posted_date":46,"marcs_cms_no":47,"product_type":48,"closeout_date":19,"issuing_office":37,"recipient_name":49,"body_fetched_at":50,"delivery_method":51,"recipient_title":19,"reference_number":52,"action_taken_date":53,"medical_device_id":19,"response_letter_date":19},1066,[34,35,36,37,38,13,13,13],"\u003Ctime datetime=\"2025-02-11T05:00:00Z\">02\u002F11\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-01-30T05:00:00Z\">01\u002F30\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fstrukmyer-llc-dba-strukmyer-medical-692686-01302025\">Strukmyer LLC dba Strukmyer Medical \u003C\u002Fa>","Center for Drug Evaluation and Research (CDER)","CGMP\u002FFinished Pharmaceuticals\u002FAdulterated","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Electronic Mail Return Confirmation Requested\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>320-25-37\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Sudheer Kancherla\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Chief Executive Officer\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Strukmyer LLC dba Strukmyer Medical \u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>1801 Big Town Blvd. Ste. 100\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Mesquite\u003C\u002Fspan>, \u003Cspan>TX\u003C\u002Fspan> \u003Cspan>75149-1011\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter\u003C\u002Fstrong> 320-25-37\u003C\u002Fp>\u003Cp>January 30, 2025\u003C\u002Fp>\u003Cp>Dear Mr. Kancherla:\u003C\u002Fp>\u003Cp>The U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility, Strukmyer LLC dba Strukmyer Medical, FEI 3000205837, at 1801 Big Town Blvd. Ste. 100, Mesquite, TX, from July 8 to August 1, 2024.\u003C\u002Fp>\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\u003C\u002Fp>\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\u003Cp>We reviewed your August 22, 2024 response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\u003C\u002Fp>\u003Cp>\u003Cstrong>1. Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>On over 60 occasions, your firm isolated objectionable microorganisms (e.g., \u003Cem>Burkholderia, Pseudomonas, Staphylococcus, Bacillus\u003C\u002Fem>, and \u003Cem>Aspergillus\u003C\u002Fem> species) from your \u003Cstrong>(b)(4)\u003C\u002Fstrong> water system used as a component to manufacture over-the-counter (OTC) drug products intended for use in wounds and on burns between November 1, 2022 and July 10, 2024. For example, Pseudomonas and Burkholderia were recovered from samples of your \u003Cstrong>(b)(4)\u003C\u002Fstrong> water system on August 15 and August 21, 2023, respectively, and water from this system was used to manufacture \u003Cstrong>(b)(4)\u003C\u002Fstrong> batches \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong> on August 21, 2023. You failed to adequately investigate and implement corrective actions to determine root causes and prevent recurrence of these contamination incidents. We note that this drug product was previously the subject of a recall in 2020 for microbial contamination with \u003Cem>Burkholderia cepacia\u003C\u002Fem>.\u003C\u002Fp>\u003Cp>In your response, you state that you updated your \u003Cstrong>(b)(4)\u003C\u002Fstrong> water monitoring procedures to include specifications for the absence of objectionable organisms. You also state that you conducted an investigation into the implicated \u003Cstrong>(b)(4)\u003C\u002Fstrong> lots and incidents of \u003Cem>Burkholderia\u003C\u002Fem> and \u003Cem>Pseudomonas\u003C\u002Fem> isolates in your water system and concluded there is no product impact because subsequent water samples collected at the time the water was used to manufacture the drug product were tested and results were observed to be within limits. Further, you state that your finished drug products met your microbial specifications.\u003C\u002Fp>\u003Cp>Your response is inadequate. Your investigation did not adequately identify the root cause of the contamination of your \u003Cstrong>(b)(4)\u003C\u002Fstrong> water system with objectionable microorganisms and failed to consider the impact to your distributed drug products that were manufactured with \u003Cstrong>(b)(4)\u003C\u002Fstrong> water contaminated with objectionable microorganisms. Microbial contamination is not typically uniformly distributed, especially in a deficient system, and thus samples may not be representative of the type or level of contamination that may exist in other individual units of a batch.\u003C\u002Fp>\u003Cp>Inadequate investigations can lead to unidentified root causes, ineffective corrective actions and preventive actions (CAPA), and recurring problems that compromise the ability to manufacture safe and effective drug products. Frequent microbiological excursions suggest that your purified water system may not be in an adequate state of control.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A comprehensive, independent assessment of the design and control of your firm’s manufacturing operations, with a detailed and thorough review of all microbiological hazards.\u003C\u002Fli>\u003Cli>A detailed risk assessment addressing the hazards posed by distributing drug products with potentially objectionable contamination. Specify actions you will take in response to the risk assessment, such as customer notifications and product recalls.\u003C\u002Fli>\u003Cli>Complete investigations into all batches with potential objectionable microbial contamination or an out-of-specification (OOS) microbiological result (whether or not later invalidated). The investigations should detail your findings regarding the root causes of the contamination.\u003C\u002Fli>\u003Cli>Appropriate microbiological batch release specifications (i.e., total counts, identification of bioburden to detect objectionable microbes) for each of your drug products.\u003C\u002Fli>\u003Cli>All chemical and microbial test methods used to analyze each of your drug products.\u003C\u002Fli>\u003Cli>A summary of results from testing retain samples of all drug product batches within expiry. You should test all appropriate quality attributes including, but not limited to, identity and strength of active ingredients and microbiological quality (total counts and identification of bioburden to detect any objectionable microbes) of each batch. If testing yields an OOS result, indicate the corrective actions you will take, including notifying customers and initiating recalls.\u003C\u002Fli>\u003Cli>A comprehensive, independent assessment of your overall system for investigating deviations, discrepancies, complaints, OOS results, and failures. Provide a detailed action plan to remediate this system. Your action plan should include, but not be limited to, significant improvements in investigation competencies, scope determination, root cause evaluation, CAPA effectiveness, quality unit oversight, and written procedures. Address how your firm will ensure all phases of investigations are appropriately conducted.\u003C\u002Fli>\u003Cli>An independent assessment and remediation plan for your CAPA program. Provide a report that evaluates whether the program includes effective root cause analysis, ensures CAPA effectiveness, analyzes investigations trends, improves the CAPA program when needed, implements final quality unit decisions, and is fully supported by executive management.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>2. Your firm failed to test samples of each component for identity and conformity with all appropriate written specifications for purity, strength, and quality. Your firm also failed to validate and establish the reliability of your component supplier’s test analyses at appropriate intervals (21 CFR 211.84(d)(1) and 211.84(d)(2)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>You failed to perform adequate incoming testing of each component lot used in the manufacture of your OTC drug products, such as Therabreath Mild Mint Toothpaste intended for use in children. You also relied on your suppliers’ certificate of analysis (COA) without establishing the reliability of your component suppliers’ test analyses at appropriate intervals.\u003C\u002Fp>\u003Cp>\u003Cem>Glycerin\u003C\u002Fem>\u003C\u002Fp>\u003Cp>You failed to adequately test each shipment of each lot of glycerin for identity, a component at high-risk of diethylene glycol (DEG) or ethylene glycol (EG) contamination. Identity testing for glycerin and certain other high-risk drug components\u003Cem>\u003Cstrong>\u003Csup>1\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> includes a limit test in the United States Pharmacopeia (USP) to ensure the component meets the relevant safety limits for levels of DEG or EG. Because you did not perform identity testing on each shipment of each lot using the USP identification test that detects these hazardous impurities, you failed to assure the acceptability of these components for use in the manufacture of your drug products.\u003C\u002Fp>\u003Cp>The use of ingredients contaminated with DEG or EG has resulted in various lethal poisoning incidents in humans worldwide. See FDA’s guidance document \u003Cem>Testing of Glycerin, Propylene Glycol, Maltitol Solution, Hydrogenated Starch Hydrolysate, Sorbitol Solution, and Other High-Risk Drug Components for Diethylene Glycol and Ethylene Glycol\u003C\u002Fem> to help you meet the CGMP requirements when manufacturing drugs containing ingredients at high-risk for DEG or EG contamination at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F167974\u002Fdownload.\u003C\u002Fp>\u003Cp>In your response, you state that you would update the specifications for your glycerin component to include identity testing, including DEG and EG testing, at a \u003Cstrong>(b)(4)\u003C\u002Fstrong> testing frequency. Additionally, you state that you tested retain sample of one glycerin lot from each \u003Cstrong>(b)(4)\u003C\u002Fstrong> since May 2023 to verify the quality of previously manufactured batches. You also committed to performing DEG and EG testing on the first lot of glycerin received each \u003Cstrong>(b)(4)\u003C\u002Fstrong> to confirm the reliability of the testing results on the supplier’s COA.\u003C\u002Fp>\u003Cp>Your response is inadequate. CGMP requires that each shipment of each lot of a component undergo appropriate identity testing (which for glycerin, as noted above, includes a limit test for DEG and EG) before use in drug product manufacturing. Your response also did not include an evaluation of the quality of your drug products currently on the U.S market with inadequate component testing.\u003C\u002Fp>\u003Cp>Component testing is fundamental to quality. Without adequate testing, you do not have scientific evidence that your incoming components conform to appropriate specifications before us in the manufacture of drug products.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A description of how you will test each component lot for conformity with all appropriate specifications for identity, strength, quality, and purity. If you intend to accept any results from your supplier’s COA instead of testing each component lot for strength, quality, and purity, specify how you will robustly establish the reliability of your supplier’s results through initial validation as well as periodic revalidation. In addition, include a commitment to always conduct at least one specific identity test for each incoming component lot. In the case of glycerin, propylene glycol, and certain additional high-risk components we note that this includes the performance of parts A, B, and C of the USP monograph.\u003C\u002Fli>\u003Cli>The chemical quality control specifications you use to test each incoming lot of high-risk drug components to determine acceptability for use in manufacturing.\u003C\u002Fli>\u003Cli>A comprehensive, independent review of your material system to determine whether all suppliers of components, containers, and closures, are each qualified and the materials are assigned appropriate expiration or retest dates. The review should also determine whether incoming material controls are adequate to prevent use of unsuitable components, containers, and closures.\u003C\u002Fli>\u003Cli>A summary of your program for qualifying and overseeing contract facilities that test the drug products you manufacture.\u003C\u002Fli>\u003Cli>A summary of results obtained from testing all components to evaluate the reliability of the COA from each component manufacturer. Include your standard operating procedure (SOP) that describes this COA validation program.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>3. Your firm failed to clean, maintain, and, as appropriate for the nature of the drug, sanitize and\u002For sterilize equipment and utensils at appropriate intervals to prevent malfunctions or contamination that would alter the safety, identity, strength, quality, or purity of the drug product beyond the official or other established requirements (21 CFR 211.67(a)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>You failed to demonstrate your cleaning and disinfection practices are adequate to remove all contaminants from the equipment used to manufacture your topical OTC drug products. For example, your cleaning validation only tested for the absence of Gram-negative bacteria, but you have previously isolated fungi and gram-positive microorganisms from your water system.\u003C\u002Fp>\u003Cp>Inadequate removal of microbial organisms from manufacturing equipment during cleaning can result in contamination of your drug products, which can potentially cause patient harm depending on the organism.\u003C\u002Fp>\u003Cp>In your response, you committed to performing a new cleaning validation based on “worst-case” scenarios, including a toxicological and microbiological risk assessment of all raw materials using in manufacturing.\u003C\u002Fp>\u003Cp>Your response is inadequate in that the test methods appear to be incomplete.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>Your total microbial count limits to monitor whether this system is producing water suitable for the intended uses for each of your drug products.\u003C\u002Fli>\u003Cli>A summary of updated SOPs that ensure an appropriate program is in place for verification and validation of cleaning procedures for products, processes, and equipment.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>4. Your firm failed to establish an adequate quality control unit with the responsibility and authority to approve or reject all components, drug product containers, closures, in-process materials, packaging materials, labeling, and drug products (21 CFR 211.22(a)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your quality unit (QU) failed to ensure the chemical and microbial testing methods performed by your contract laboratory for finished drug product release testing and water system monitoring were not adequately validated or verified as appropriate.\u003C\u002Fp>\u003Cp>In your response, you state that you sent drug product and \u003Cstrong>(b)(4)\u003C\u002Fstrong> water samples to your contract laboratory to complete method verification for your chemical and microbial tests. You also updated your procedure to require that method validations and verifications be performed on required test methods.\u003C\u002Fp>\u003Cp>Your response is inadequate. It did not provide assurance that the analytical test methods used to test your components and finished drug products are suitable for the intended purpose. Further, you did not provide an evaluation of potential impact to drug products currently on the U.S. market.\u003C\u002Fp>\u003Cp>An adequate QU overseeing all elements of CGMP is necessary to consistently ensure drug product quality. Your firm’s quality systems are inadequate. See FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload for help in implementing quality systems and risk management approaches.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\u003Cbr>o A determination of whether procedures used by your firm to ensure you have an adequate contract testing facility are robust and appropriate.\u003Cbr>o Provisions for QU oversight throughout your laboratory operations to evaluate adherence to appropriate practices.\u003Cbr>o Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>CGMP Consultant Recommended\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Based upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to evaluate your operations and to assist your firm in meeting CGMP requirements. The qualified consultant should also perform a comprehensive six-system audit of your entire operation for CGMP compliance and evaluate the completion and efficacy of your CAPA before you pursue resolution of your firm’s compliance status with FDA.\u003C\u002Fp>\u003Cp>Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\u003C\u002Fp>\u003Cp>\u003Cstrong>Cosmetics Manufactured for Distribution in the United States\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>In addition, we note that some of the products you manufacture may be regulated as cosmetics, as defined in section 201(i) of the FD&amp;C Act. Any cosmetics you manufacture must comply with applicable statutory and regulatory requirements, including the FD&amp;C Act. A cosmetic is deemed adulterated under section 601(c) of the FD&amp;C Act [21 U.S.C. 361(c)] if it has been prepared, packed, or held under insanitary conditions whereby it may have become contaminated with filth or whereby it may have been rendered injurious to health.\u003C\u002Fp>\u003Cp>Some conditions that cause the drug products you manufacture to be adulterated may also cause any cosmetics you manufacture to be adulterated. We note that under section 301(a) of the FD&amp;C Act [21 U.S.C. 331(a)], it is a prohibited act to introduce or deliver for introduction into interstate commerce a cosmetic that is adulterated. Further, your facility may be subject to requirements under the Modernization of Cosmetics Regulations Act of 2022 (MoCRA). Information on MoCRA requirements may be found at https:\u002F\u002Fwww.fda.gov\u002Fcosmetics\u002Fcosmetics-laws-regulations\u002Fmodernization-cosmetics-regulation-act-2022-mocra.\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\u003Cp>Correct any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\u003C\u002Fp>\u003Cp>Failure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\u003C\u002Fp>\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\u003Cp>Send your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3000205837 and ATTN: Philip Kreiter.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Francis Godwin\u003Cbr>Director\u003Cbr>Office of Manufacturing Quality\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003C\u002Fp>\u003Cp>___________________\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> Components with higher risk of DEG or EG contamination compared to other drug components.\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Electronic Mail Return Confirmation Requested\n\nReference #:\n\n320-25-37\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMr. Sudheer Kancherla\n\nRecipient Title\n\nChief Executive Officer\n\nStrukmyer LLC dba Strukmyer Medical\n\n1801 Big Town Blvd. Ste. 100\n\nMesquite, TX 75149-1011\n\nUnited States\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWarning Letter 320-25-37\nJanuary 30, 2025\nDear Mr. Kancherla:\nThe U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility, Strukmyer LLC dba Strukmyer Medical, FEI 3000205837, at 1801 Big Town Blvd. Ste. 100, Mesquite, TX, from July 8 to August 1, 2024.\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\nWe reviewed your August 22, 2024 response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\n1. Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).\nOn over 60 occasions, your firm isolated objectionable microorganisms (e.g., Burkholderia, Pseudomonas, Staphylococcus, Bacillus, and Aspergillus species) from your (b)(4) water system used as a component to manufacture over-the-counter (OTC) drug products intended for use in wounds and on burns between November 1, 2022 and July 10, 2024. For example, Pseudomonas and Burkholderia were recovered from samples of your (b)(4) water system on August 15 and August 21, 2023, respectively, and water from this system was used to manufacture (b)(4) batches (b)(4) and (b)(4) on August 21, 2023. You failed to adequately investigate and implement corrective actions to determine root causes and prevent recurrence of these contamination incidents. We note that this drug product was previously the subject of a recall in 2020 for microbial contamination with Burkholderia cepacia.\nIn your response, you state that you updated your (b)(4) water monitoring procedures to include specifications for the absence of objectionable organisms. You also state that you conducted an investigation into the implicated (b)(4) lots and incidents of Burkholderia and Pseudomonas isolates in your water system and concluded there is no product impact because subsequent water samples collected at the time the water was used to manufacture the drug product were tested and results were observed to be within limits. Further, you state that your finished drug products met your microbial specifications.\nYour response is inadequate. Your investigation did not adequately identify the root cause of the contamination of your (b)(4) water system with objectionable microorganisms and failed to consider the impact to your distributed drug products that were manufactured with (b)(4) water contaminated with objectionable microorganisms. Microbial contamination is not typically uniformly distributed, especially in a deficient system, and thus samples may not be representative of the type or level of contamination that may exist in other individual units of a batch.\nInadequate investigations can lead to unidentified root causes, ineffective corrective actions and preventive actions (CAPA), and recurring problems that compromise the ability to manufacture safe and effective drug products. Frequent microbiological excursions suggest that your purified water system may not be in an adequate state of control.\nIn response to this letter, provide:\nA comprehensive, independent assessment of the design and control of your firm’s manufacturing operations, with a detailed and thorough review of all microbiological hazards.\nA detailed risk assessment addressing the hazards posed by distributing drug products with potentially objectionable contamination. Specify actions you will take in response to the risk assessment, such as customer notifications and product recalls.\nComplete investigations into all batches with potential objectionable microbial contamination or an out-of-specification (OOS) microbiological result (whether or not later invalidated). The investigations should detail your findings regarding the root causes of the contamination.\nAppropriate microbiological batch release specifications (i.e., total counts, identification of bioburden to detect objectionable microbes) for each of your drug products.\nAll chemical and microbial test methods used to analyze each of your drug products.\nA summary of results from testing retain samples of all drug product batches within expiry. You should test all appropriate quality attributes including, but not limited to, identity and strength of active ingredients and microbiological quality (total counts and identification of bioburden to detect any objectionable microbes) of each batch. If testing yields an OOS result, indicate the corrective actions you will take, including notifying customers and initiating recalls.\nA comprehensive, independent assessment of your overall system for investigating deviations, discrepancies, complaints, OOS results, and failures. Provide a detailed action plan to remediate this system. Your action plan should include, but not be limited to, significant improvements in investigation competencies, scope determination, root cause evaluation, CAPA effectiveness, quality unit oversight, and written procedures. Address how your firm will ensure all phases of investigations are appropriately conducted.\nAn independent assessment and remediation plan for your CAPA program. Provide a report that evaluates whether the program includes effective root cause analysis, ensures CAPA effectiveness, analyzes investigations trends, improves the CAPA program when needed, implements final quality unit decisions, and is fully supported by executive management.\n2. Your firm failed to test samples of each component for identity and conformity with all appropriate written specifications for purity, strength, and quality. Your firm also failed to validate and establish the reliability of your component supplier’s test analyses at appropriate intervals (21 CFR 211.84(d)(1) and 211.84(d)(2)).\nYou failed to perform adequate incoming testing of each component lot used in the manufacture of your OTC drug products, such as Therabreath Mild Mint Toothpaste intended for use in children. You also relied on your suppliers’ certificate of analysis (COA) without establishing the reliability of your component suppliers’ test analyses at appropriate intervals.\nGlycerin\nYou failed to adequately test each shipment of each lot of glycerin for identity, a component at high-risk of diethylene glycol (DEG) or ethylene glycol (EG) contamination. Identity testing for glycerin and certain other high-risk drug components1 includes a limit test in the United States Pharmacopeia (USP) to ensure the component meets the relevant safety limits for levels of DEG or EG. Because you did not perform identity testing on each shipment of each lot using the USP identification test that detects these hazardous impurities, you failed to assure the acceptability of these components for use in the manufacture of your drug products.\nThe use of ingredients contaminated with DEG or EG has resulted in various lethal poisoning incidents in humans worldwide. See FDA’s guidance document Testing of Glycerin, Propylene Glycol, Maltitol Solution, Hydrogenated Starch Hydrolysate, Sorbitol Solution, and Other High-Risk Drug Components for Diethylene Glycol and Ethylene Glycol to help you meet the CGMP requirements when manufacturing drugs containing ingredients at high-risk for DEG or EG contamination at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F167974\u002Fdownload.\nIn your response, you state that you would update the specifications for your glycerin component to include identity testing, including DEG and EG testing, at a (b)(4) testing frequency. Additionally, you state that you tested retain sample of one glycerin lot from each (b)(4) since May 2023 to verify the quality of previously manufactured batches. You also committed to performing DEG and EG testing on the first lot of glycerin received each (b)(4) to confirm the reliability of the testing results on the supplier’s COA.\nYour response is inadequate. CGMP requires that each shipment of each lot of a component undergo appropriate identity testing (which for glycerin, as noted above, includes a limit test for DEG and EG) before use in drug product manufacturing. Your response also did not include an evaluation of the quality of your drug products currently on the U.S market with inadequate component testing.\nComponent testing is fundamental to quality. Without adequate testing, you do not have scientific evidence that your incoming components conform to appropriate specifications before us in the manufacture of drug products.\nIn response to this letter, provide:\nA description of how you will test each component lot for conformity with all appropriate specifications for identity, strength, quality, and purity. If you intend to accept any results from your supplier’s COA instead of testing each component lot for strength, quality, and purity, specify how you will robustly establish the reliability of your supplier’s results through initial validation as well as periodic revalidation. In addition, include a commitment to always conduct at least one specific identity test for each incoming component lot. In the case of glycerin, propylene glycol, and certain additional high-risk components we note that this includes the performance of parts A, B, and C of the USP monograph.\nThe chemical quality control specifications you use to test each incoming lot of high-risk drug components to determine acceptability for use in manufacturing.\nA comprehensive, independent review of your material system to determine whether all suppliers of components, containers, and closures, are each qualified and the materials are assigned appropriate expiration or retest dates. The review should also determine whether incoming material controls are adequate to prevent use of unsuitable components, containers, and closures.\nA summary of your program for qualifying and overseeing contract facilities that test the drug products you manufacture.\nA summary of results obtained from testing all components to evaluate the reliability of the COA from each component manufacturer. Include your standard operating procedure (SOP) that describes this COA validation program.\n3. Your firm failed to clean, maintain, and, as appropriate for the nature of the drug, sanitize and\u002For sterilize equipment and utensils at appropriate intervals to prevent malfunctions or contamination that would alter the safety, identity, strength, quality, or purity of the drug product beyond the official or other established requirements (21 CFR 211.67(a)).\nYou failed to demonstrate your cleaning and disinfection practices are adequate to remove all contaminants from the equipment used to manufacture your topical OTC drug products. For example, your cleaning validation only tested for the absence of Gram-negative bacteria, but you have previously isolated fungi and gram-positive microorganisms from your water system.\nInadequate removal of microbial organisms from manufacturing equipment during cleaning can result in contamination of your drug products, which can potentially cause patient harm depending on the organism.\nIn your response, you committed to performing a new cleaning validation based on “worst-case” scenarios, including a toxicological and microbiological risk assessment of all raw materials using in manufacturing.\nYour response is inadequate in that the test methods appear to be incomplete.\nIn response to this letter, provide:\nYour total microbial count limits to monitor whether this system is producing water suitable for the intended uses for each of your drug products.\nA summary of updated SOPs that ensure an appropriate program is in place for verification and validation of cleaning procedures for products, processes, and equipment.\n4. Your firm failed to establish an adequate quality control unit with the responsibility and authority to approve or reject all components, drug product containers, closures, in-process materials, packaging materials, labeling, and drug products (21 CFR 211.22(a)).\nYour quality unit (QU) failed to ensure the chemical and microbial testing methods performed by your contract laboratory for finished drug product release testing and water system monitoring were not adequately validated or verified as appropriate.\nIn your response, you state that you sent drug product and (b)(4) water samples to your contract laboratory to complete method verification for your chemical and microbial tests. You also updated your procedure to require that method validations and verifications be performed on required test methods.\nYour response is inadequate. It did not provide assurance that the analytical test methods used to test your components and finished drug products are suitable for the intended purpose. Further, you did not provide an evaluation of potential impact to drug products currently on the U.S. market.\nAn adequate QU overseeing all elements of CGMP is necessary to consistently ensure drug product quality. Your firm’s quality systems are inadequate. See FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload for help in implementing quality systems and risk management approaches.\nIn response to this letter, provide:\nA comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\no A determination of whether procedures used by your firm to ensure you have an adequate contract testing facility are robust and appropriate.\no Provisions for QU oversight throughout your laboratory operations to evaluate adherence to appropriate practices.\no Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products.\nCGMP Consultant Recommended\nBased upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to evaluate your operations and to assist your firm in meeting CGMP requirements. The qualified consultant should also perform a comprehensive six-system audit of your entire operation for CGMP compliance and evaluate the completion and efficacy of your CAPA before you pursue resolution of your firm’s compliance status with FDA.\nYour use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\nCosmetics Manufactured for Distribution in the United States\nIn addition, we note that some of the products you manufacture may be regulated as cosmetics, as defined in section 201(i) of the FD&C Act. Any cosmetics you manufacture must comply with applicable statutory and regulatory requirements, including the FD&C Act. A cosmetic is deemed adulterated under section 601(c) of the FD&C Act [21 U.S.C. 361(c)] if it has been prepared, packed, or held under insanitary conditions whereby it may have become contaminated with filth or whereby it may have been rendered injurious to health.\nSome conditions that cause the drug products you manufacture to be adulterated may also cause any cosmetics you manufacture to be adulterated. We note that under section 301(a) of the FD&C Act [21 U.S.C. 331(a)], it is a prohibited act to introduce or deliver for introduction into interstate commerce a cosmetic that is adulterated. Further, your facility may be subject to requirements under the Modernization of Cosmetics Regulations Act of 2022 (MoCRA). Information on MoCRA requirements may be found at https:\u002F\u002Fwww.fda.gov\u002Fcosmetics\u002Fcosmetics-laws-regulations\u002Fmodernization-cosmetics-regulation-act-2022-mocra.\nConclusion\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\nCorrect any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\nFailure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\nSend your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3000205837 and ATTN: Philip Kreiter.\nSincerely,\n\u002FS\u002F\nFrancis Godwin\nDirector\nOffice of Manufacturing Quality\nOffice of Compliance\nCenter for Drug Evaluation and Research\n___________________\n1 Components with higher risk of DEG or EG contamination compared to other drug components.","Strukmyer LLC dba Strukmyer Medical","strukmyer-llc-dba-strukmyer-medical-692686-01302025","2026-08-18T06:42:28.856152+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fstrukmyer-llc-dba-strukmyer-medical-692686-01302025","2026-10-26T08:10:06.710761+00:00","2025-02-11","692686","Drugs","Mr. Sudheer Kancherla","2026-08-19T17:02:33.632+00:00","Via Electronic Mail Return Confirmation Requested","320-25-37","2025-01-30",{"id":55,"raw":56,"subject":60,"body_html":61,"body_text":62,"firm_name":63,"letter_id":64,"created_at":65,"fei_number":19,"letter_url":66,"updated_at":67,"action_type":22,"case_status":23,"posted_date":68,"marcs_cms_no":69,"product_type":70,"closeout_date":19,"issuing_office":37,"recipient_name":71,"body_fetched_at":72,"delivery_method":73,"recipient_title":19,"reference_number":74,"action_taken_date":75,"medical_device_id":19,"response_letter_date":19},22203,[57,58,59,37,60,13,13,13],"\u003Ctime datetime=\"2026-11-10T05:00:00Z\">11\u002F10\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-10-29T04:00:00Z\">10\u002F29\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Ftianjin-healthcare-medical-technology-co-ltd-736415-10292026\">Tianjin Healthcare Medical Technology Co., Ltd.\u003C\u002Fa>","Refusal to Provide Access to and Copying of Records","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA ELECTRONIC MAIL READ\u002FDELIVERY RECEIPT REQUESTED\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>320-27-15\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n                          \u003Cbr>Over-the-Counter Drugs\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Jianyu Zhao\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Firm Contact\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Tianjin Healthcare Medical Technology Co., Ltd.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>2-2066, No 88 HuanHe South Road\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Tianjin Free Trade Pilot Zone\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>KongGang Economic Zone\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Tianjin Shi\u003C\u002Fspan>, \u003Cspan>300000\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>China\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:(b)(6)\"> (b)(6)\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>October 29, 2026\u003Cbr>&nbsp;\u003C\u002Fp>\u003Cp>WARNING LETTER\u003Cbr>Reference number: 320-27-15\u003C\u002Fp>\u003Cp>To Jianyu Zhao:\u003C\u002Fp>\u003Cp>This warning letter advises you of a significant violation identified during a U.S. Food and Drug Administration (FDA) review of records from your facility and provides you the opportunity to address them. This is not intended to be an all-inclusive list of violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations. Failure to adequately address any violations may result in regulatory action without further notice.\u003C\u002Fp>\u003Cp>Your facility, Tianjin Healthcare Medical Technology Co., Ltd. (hereafter THM), FDA Establishment Identifier (FEI) # 3015495180 at 2-2066, No 88 HuanHe South Road, Tianjin Free Trade Pilot Zone, KongGang Economic Zone, Tianjin is registered with the FDA as a manufacturer of active pharmaceutical ingredients (APIs).\u003C\u002Fp>\u003Cp>A review of import records showed multiple shipments of APIs intended for pharmacy compounding into the U.S., which declared THM, as the drug manufacturer. The FDA sent requests for records and other information, pursuant to section 704(a)(4) of the Federal Food, Drug and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 374(a)(4), to the contact email address provided in your registration file. Your firm refused to provide the duly requested records.\u003C\u002Fp>\u003Cp>It is a prohibited act under section 301(e) of the FD&amp;C Act (21 U.S.C. 331(e)) to refuse to permit access to or copying of any record as required by section 704(a). Because your firm failed to respond to the section 704(a)(4) records requests and associated communication attempts, we have no indication of the level of quality assurance for drugs listed as manufactured at your facility.\u003C\u002Fp>\u003Cp>\u003Cstrong>Refusal to Provide Records\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>On June 17, 2026, the FDA sent an electronic records request to the contact email address provided in your registration file. You replied on June 24, 2026, that you would “discontinue the production of relevant \u003Cstrong>(b)(4)\u003C\u002Fstrong> products” for the U.S. market and refused to provide the requested documents. A follow up request was sent on June 25, 2026, informing you that APIs your firm manufactured were imported to the U.S. market and were still within expiry. Therefore, the requested records were still required. You responded that you would not provide the requested records.\u003C\u002Fp>\u003Cp>Simply ceasing commercial distribution or expressing an intent to stop production does not retroactively relieve you of your regulatory obligations.\u003C\u002Fp>\u003Cp>FDA placed all drugs and drug products offered for import into the U.S. from your firm on Import Alert 66-79 on August 25, 2026.\u003C\u002Fp>\u003Cp>If you no longer intend to manufacture or distribute drug products for the U.S. market, you must formally update your registration and drug listings to reflect this change in operations. Pursuant to 21 CFR 207.29(a)(3), an establishment must update its registration within 30 calendar days of ceasing operations.\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The violation cited in this letter is not intended to be an all-inclusive list of violations at your facility.\u003C\u002Fp>\u003Cp>Until FDA is able to confirm compliance with CGMP and other applicable requirements, we may withhold approval of any new applications or supplements listing your firm as a drug manufacturer. In addition, shipments of articles manufactured at THM, 2-2066, No 88 HuanHe South Road, Tianjin Free Trade Pilot Zone, KongGang Economic Zone, Tianjin into the U.S. that appear to be adulterated or misbranded are subject to being detained or refused admission pursuant to section 801(a)(3) of the FD&amp;C Act, 21 U.S.C. 381(a)(3).\u003C\u002Fp>\u003Cp>In response to this letter, you may submit a request to schedule an FDA inspection.\u003C\u002Fp>\u003Cp>Send your written response to CDER-OC-OMQ-Communications@fda.hhs.gov within fifteen (15) business days of receipt of this letter. Identify your written response with FEI 3015495180 and ATTN: Marva Taylor in the letter in the subject line of the email.\u003C\u002Fp>\u003Cp>If you have information that you believe demonstrates that your products are not in violation of the FD&amp;C Act and FDA regulations, include that information for our consideration.\u003C\u002Fp>\u003Cp>FDA posts warning letters to www.FDA.gov.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Francis Godwin\u003Cbr>Director\u003Cbr>Office of Manufacturing Quality\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003Cbr>U.S. Food and Drug Administration\u003C\u002Fp>\u003Cp>cc: U.S. agent\u003Cbr>\u003Cstrong>(b)(6)\u003C\u002Fstrong>\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA ELECTRONIC MAIL READ\u002FDELIVERY RECEIPT REQUESTED\n\nReference #:\n\n320-27-15\n\nProduct:\n\nDrugs\n\nOver-the-Counter Drugs\n\nRecipient:\n\nRecipient Name\n\nJianyu Zhao\n\nRecipient Title\n\nFirm Contact\n\nTianjin Healthcare Medical Technology Co., Ltd.\n\n2-2066, No 88 HuanHe South Road\n\nTianjin Free Trade Pilot Zone\n\nKongGang Economic Zone\n\nTianjin Shi, 300000\n\nChina\n\n(b)(6)\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nOctober 29, 2026\n\nWARNING LETTER\nReference number: 320-27-15\nTo Jianyu Zhao:\nThis warning letter advises you of a significant violation identified during a U.S. Food and Drug Administration (FDA) review of records from your facility and provides you the opportunity to address them. This is not intended to be an all-inclusive list of violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations. Failure to adequately address any violations may result in regulatory action without further notice.\nYour facility, Tianjin Healthcare Medical Technology Co., Ltd. (hereafter THM), FDA Establishment Identifier (FEI) # 3015495180 at 2-2066, No 88 HuanHe South Road, Tianjin Free Trade Pilot Zone, KongGang Economic Zone, Tianjin is registered with the FDA as a manufacturer of active pharmaceutical ingredients (APIs).\nA review of import records showed multiple shipments of APIs intended for pharmacy compounding into the U.S., which declared THM, as the drug manufacturer. The FDA sent requests for records and other information, pursuant to section 704(a)(4) of the Federal Food, Drug and Cosmetic Act (FD&C Act), 21 U.S.C. 374(a)(4), to the contact email address provided in your registration file. Your firm refused to provide the duly requested records.\nIt is a prohibited act under section 301(e) of the FD&C Act (21 U.S.C. 331(e)) to refuse to permit access to or copying of any record as required by section 704(a). Because your firm failed to respond to the section 704(a)(4) records requests and associated communication attempts, we have no indication of the level of quality assurance for drugs listed as manufactured at your facility.\nRefusal to Provide Records\nOn June 17, 2026, the FDA sent an electronic records request to the contact email address provided in your registration file. You replied on June 24, 2026, that you would “discontinue the production of relevant (b)(4) products” for the U.S. market and refused to provide the requested documents. A follow up request was sent on June 25, 2026, informing you that APIs your firm manufactured were imported to the U.S. market and were still within expiry. Therefore, the requested records were still required. You responded that you would not provide the requested records.\nSimply ceasing commercial distribution or expressing an intent to stop production does not retroactively relieve you of your regulatory obligations.\nFDA placed all drugs and drug products offered for import into the U.S. from your firm on Import Alert 66-79 on August 25, 2026.\nIf you no longer intend to manufacture or distribute drug products for the U.S. market, you must formally update your registration and drug listings to reflect this change in operations. Pursuant to 21 CFR 207.29(a)(3), an establishment must update its registration within 30 calendar days of ceasing operations.\nConclusion\nThe violation cited in this letter is not intended to be an all-inclusive list of violations at your facility.\nUntil FDA is able to confirm compliance with CGMP and other applicable requirements, we may withhold approval of any new applications or supplements listing your firm as a drug manufacturer. In addition, shipments of articles manufactured at THM, 2-2066, No 88 HuanHe South Road, Tianjin Free Trade Pilot Zone, KongGang Economic Zone, Tianjin into the U.S. that appear to be adulterated or misbranded are subject to being detained or refused admission pursuant to section 801(a)(3) of the FD&C Act, 21 U.S.C. 381(a)(3).\nIn response to this letter, you may submit a request to schedule an FDA inspection.\nSend your written response to CDER-OC-OMQ-Communications@fda.hhs.gov within fifteen (15) business days of receipt of this letter. Identify your written response with FEI 3015495180 and ATTN: Marva Taylor in the letter in the subject line of the email.\nIf you have information that you believe demonstrates that your products are not in violation of the FD&C Act and FDA regulations, include that information for our consideration.\nFDA posts warning letters to www.FDA.gov.\nSincerely,\n\u002FS\u002F\nFrancis Godwin\nDirector\nOffice of Manufacturing Quality\nOffice of Compliance\nCenter for Drug Evaluation and Research\nU.S. Food and Drug Administration\ncc: U.S. agent\n(b)(6)","Tianjin Healthcare Medical Technology Co., Ltd.","tianjin-healthcare-medical-technology-co-ltd-736415-10292026","2026-11-17T01:02:03.701861+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Ftianjin-healthcare-medical-technology-co-ltd-736415-10292026","2026-11-17T01:02:49.409207+00:00","2026-11-10","736415","Drugs Over-the-Counter Drugs","Jianyu Zhao","2026-11-17T01:02:49.249+00:00","VIA ELECTRONIC MAIL READ\u002FDELIVERY RECEIPT REQUESTED","320-27-15","2026-10-29",{"id":77,"raw":78,"subject":83,"body_html":84,"body_text":85,"firm_name":86,"letter_id":87,"created_at":18,"fei_number":19,"letter_url":88,"updated_at":89,"action_type":22,"case_status":23,"posted_date":90,"marcs_cms_no":91,"product_type":48,"closeout_date":19,"issuing_office":37,"recipient_name":92,"body_fetched_at":93,"delivery_method":73,"recipient_title":19,"reference_number":19,"action_taken_date":94,"medical_device_id":19,"response_letter_date":19},301,[79,80,81,37,82,13,13,13],"\u003Ctime datetime=\"2026-03-03T05:00:00Z\">03\u002F03\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-02-20T05:00:00Z\">02\u002F20\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fstrut-health-llc-dba-strut-721448-02202026\">Strut Health, LLC dba Strut\u003C\u002Fa>","False &amp; Misleading Claims\u002FMisbranded (Telehealth)","False & Misleading Claims\u002FMisbranded (Telehealth)","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA ELECTRONIC MAIL READ\u002FDELIVERY RECEIPT REQUESTED\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Simal Patel, MD\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Chief Executive Officer\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Strut Health, LLC dba Strut\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>701 Commerce St\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Dallas\u003C\u002Fspan>, \u003Cspan>TX\u003C\u002Fspan> \u003Cspan>75202\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:care@struthealth.com\"> care@struthealth.com \u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>February 20, 2026\u003C\u002Fp>\u003Cp>Dr. Patel:\u003C\u002Fp>\u003Cp>This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https:\u002F\u002Fwww.struthealth.com, in December 2025, and has observed that your website offers compounded drug products, including semaglutide and tirzepatide drug products.\u003Cem>\u003Cstrong>\u003Csup>1\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> As described below, your website’s false or misleading claims concerning compounded semaglutide and tirzepatide products under sections 502(a) and 502(bb) of the Federal Food, Drug, and Cosmetic Act (FDCA) [21 U.S.C. §§ 352(a) and 352(bb)], result in products being introduced or delivered for introduction into interstate commerce in violation of section 301(a) of the FDCA [21 U.S.C. § 331(a)].\u003C\u002Fp>\u003Cp>Under section 502(a) of the FDCA [21 U.S.C. § 352(a)] a drug is misbranded if its labeling is false or misleading in any particular. Furthermore, under section 502(bb) of the FDCA [21 U.S.C. § 352(bb)], a compounded drug is misbranded if its advertising or promotion is false or misleading in any particular.\u003C\u002Fp>\u003Cp>The compounded semaglutide and tirzepatide products displayed on your website identify “Strut” on the pictured label, suggesting Strut is the compounder of those drugs when in fact it is not.\u003Cem>\u003Cstrong>\u003Csup>2\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> Accordingly, the representations on your website that Strut is the compounder of these drug products are false or misleading, and the products are therefore misbranded under sections 502(a) and 502(bb) of the FDCA [21 U.S.C. §§ 352(a) and (bb)].\u003C\u002Fp>\u003Cp>Additionally, the following claims concerning compounded semaglutide and tirzepatide products appear on your website:\u003C\u002Fp>\u003Cul>\u003Cli>“Generic Zepbound, Mounjaro”\u003C\u002Fli>\u003Cli>“Semaglutide is the active ingredient in the brand medications.”\u003C\u002Fli>\u003Cli>“Tirzepatide is the active ingredient in the brand medications Zepbound® and Mounjaro®.”\u003C\u002Fli>\u003C\u002Ful>\u003Cp>Compounded drug products are not FDA-approved. Your claims imply that your products have been FDA-approved or otherwise evaluated for safety and effectiveness when they have not. As a result, these claims are false or misleading and your products are therefore misbranded under sections 502(a) and 502(bb) of the FDCA [21 U.S.C. §§ 352(a) and (bb)].\u003C\u002Fp>\u003Cp>The introduction or delivery for introduction into interstate commerce of these misbranded products is a prohibited act under section 301(a) of the FDCA [21 U.S.C. § 331(a)]. The representations and claims identified in this letter put you on notice of our concerns but do not represent an exhaustive list of violations.\u003C\u002Fp>\u003Cp>For the reasons discussed above, your compounded semaglutide and tirzepatide products are misbranded drugs under sections 502(a) and 502(bb) of the FDCA [21 U.S.C. §§ 352(a) and 352(bb)], introduced or delivered for introduction into interstate commerce in violation of section 301(a) of the FDCA [21 U.S.C. § 331(a)]. Please be advised, the receipt in interstate commerce of misbranded drugs, and the delivery or proffered delivery thereof, is also a violation of section 301(c) of the FDCA [21 U.S.C. § 331(c)].\u003C\u002Fp>\u003Cp>As previously stated, the violations cited in this letter are not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your operations comply with all requirements of federal law, including FDA regulations. For example, compounded drug products must meet the conditions in sections 503A or 503B of the FD&amp;C Act [21 U.S.C. §§ 353a or 353b] in order to be exempt from certain requirements under the Act, including the new drug approval requirements.\u003C\u002Fp>\u003Cp>You should take immediate action to address any violations. Failure to adequately address any violations may result in legal action without further notice, including, without limitation, seizure and injunction.\u003C\u002Fp>\u003Cp>Within fifteen (15) working days of receipt of this letter, please provide a written response to the Office of Compounding Quality and Compliance (OCQC) within the Center for Drug Evaluation and Research (CDER)’s Office of Compliance describing the specific steps you have taken to address any violations. Please include an explanation of each step being taken to prevent the recurrence of any violations, as well as copies of related documentation. Such steps may include:\u003C\u002Fp>\u003Cp>1) Identifying the entities that produce the compounded products offered on your website;\u003C\u002Fp>\u003Cp>2) Providing a representative sample of labeling for such products; and\u003C\u002Fp>\u003Cp>3) Addressing the basis for other website claims that could be construed as false or misleading or demonstrating that such claims have been modified or removed in light of FDCA §§ 502(a) and 502(bb)) [21 U.S.C. §§ 352(a) and (bb)].\u003C\u002Fp>\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. In your written response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot completely address this matter within fifteen (15) working days, state the reason for the delay and the time within which you will do so.\u003C\u002Fp>\u003Cp>If you are not located in the U.S., please note that products that appear to be misbranded may be detained or refused admission. We may advise the appropriate regulatory officials in the country from which you operate that your products referenced above appear to be misbranded products that cannot be legally sold to consumers in the U.S.\u003C\u002Fp>\u003Cp>All correspondence should include a subject line that clearly identifies the submission as a Response to Warning Letter. If you have questions regarding the contents of this letter, please contact compoundinginspections@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003Cbr>Matthew J. Lash\u003Cbr>Acting Director\u003Cbr>Office of Compounding Quality and Compliance\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003C\u002Fp>\u003Cp>__________________\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> The semaglutide and tirzepatide products offered on your website are drugs within the meaning of section 201(g) of the FDCA [21 U.S.C. § 321(g)] because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of diseases and\u002For because they are intended to affect the structure or any function of the body. Further, they are “new drugs” within the meaning of section 201(p) of the FDCA [21 U.S.C. § 321(p)] because they are not generally recognized as safe and effective for their labeled uses.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> See also 21 CFR § 201.1(h)(2) (“The appearance on a drug product label of a person’s name without qualification is a representation that the named person is the sole manufacturer of the product. That representation is false and misleading, and the drug product is misbranded under section 502(a) of the act, if the person is not the manufacturer of the product in accordance with this section.”); FDCA §503(b) [21 § U.S.C. 353(b)], FDCA §503B(a)(10)(A)(ii) [21 U.S.C. § 353b(a)(10)(A)(ii)]. We note that 21 CFR § 201.1(a) does not apply to drug products dispensed in accordance with section 503(b)(1) of the FDCA [21 USC § 353(b)(1)]. However, see 45 Fed. Reg. 25760, 25765 (Apr. 15, 1980) (“…if the label of a prescription drug product dispensed by a pharmacist does contain a representation as to the manufacturer, packer, or distributor, it must comply with all the provisions of § 201.1…”). In addition, the labels of your drug products as depicted on the website do not indicate that they are dispensed under section 503(b)(1) of the FDCA [21 USC § 353(b)(1)], nor do they appear to comply with the requirements of section 503(b)(2) [21 USC § 353(b)(2)].\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA ELECTRONIC MAIL READ\u002FDELIVERY RECEIPT REQUESTED\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nSimal Patel, MD\n\nRecipient Title\n\nChief Executive Officer\n\nStrut Health, LLC dba Strut\n\n701 Commerce St\n\nDallas, TX 75202\n\nUnited States\n\ncare@struthealth.com\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWARNING LETTER\nFebruary 20, 2026\nDr. Patel:\nThis letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https:\u002F\u002Fwww.struthealth.com, in December 2025, and has observed that your website offers compounded drug products, including semaglutide and tirzepatide drug products.1 As described below, your website’s false or misleading claims concerning compounded semaglutide and tirzepatide products under sections 502(a) and 502(bb) of the Federal Food, Drug, and Cosmetic Act (FDCA) [21 U.S.C. §§ 352(a) and 352(bb)], result in products being introduced or delivered for introduction into interstate commerce in violation of section 301(a) of the FDCA [21 U.S.C. § 331(a)].\nUnder section 502(a) of the FDCA [21 U.S.C. § 352(a)] a drug is misbranded if its labeling is false or misleading in any particular. Furthermore, under section 502(bb) of the FDCA [21 U.S.C. § 352(bb)], a compounded drug is misbranded if its advertising or promotion is false or misleading in any particular.\nThe compounded semaglutide and tirzepatide products displayed on your website identify “Strut” on the pictured label, suggesting Strut is the compounder of those drugs when in fact it is not.2 Accordingly, the representations on your website that Strut is the compounder of these drug products are false or misleading, and the products are therefore misbranded under sections 502(a) and 502(bb) of the FDCA [21 U.S.C. §§ 352(a) and (bb)].\nAdditionally, the following claims concerning compounded semaglutide and tirzepatide products appear on your website:\n“Generic Zepbound, Mounjaro”\n“Semaglutide is the active ingredient in the brand medications.”\n“Tirzepatide is the active ingredient in the brand medications Zepbound® and Mounjaro®.”\nCompounded drug products are not FDA-approved. Your claims imply that your products have been FDA-approved or otherwise evaluated for safety and effectiveness when they have not. As a result, these claims are false or misleading and your products are therefore misbranded under sections 502(a) and 502(bb) of the FDCA [21 U.S.C. §§ 352(a) and (bb)].\nThe introduction or delivery for introduction into interstate commerce of these misbranded products is a prohibited act under section 301(a) of the FDCA [21 U.S.C. § 331(a)]. The representations and claims identified in this letter put you on notice of our concerns but do not represent an exhaustive list of violations.\nFor the reasons discussed above, your compounded semaglutide and tirzepatide products are misbranded drugs under sections 502(a) and 502(bb) of the FDCA [21 U.S.C. §§ 352(a) and 352(bb)], introduced or delivered for introduction into interstate commerce in violation of section 301(a) of the FDCA [21 U.S.C. § 331(a)]. Please be advised, the receipt in interstate commerce of misbranded drugs, and the delivery or proffered delivery thereof, is also a violation of section 301(c) of the FDCA [21 U.S.C. § 331(c)].\nAs previously stated, the violations cited in this letter are not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your operations comply with all requirements of federal law, including FDA regulations. For example, compounded drug products must meet the conditions in sections 503A or 503B of the FD&C Act [21 U.S.C. §§ 353a or 353b] in order to be exempt from certain requirements under the Act, including the new drug approval requirements.\nYou should take immediate action to address any violations. Failure to adequately address any violations may result in legal action without further notice, including, without limitation, seizure and injunction.\nWithin fifteen (15) working days of receipt of this letter, please provide a written response to the Office of Compounding Quality and Compliance (OCQC) within the Center for Drug Evaluation and Research (CDER)’s Office of Compliance describing the specific steps you have taken to address any violations. Please include an explanation of each step being taken to prevent the recurrence of any violations, as well as copies of related documentation. Such steps may include:\n1) Identifying the entities that produce the compounded products offered on your website;\n2) Providing a representative sample of labeling for such products; and\n3) Addressing the basis for other website claims that could be construed as false or misleading or demonstrating that such claims have been modified or removed in light of FDCA §§ 502(a) and 502(bb)) [21 U.S.C. §§ 352(a) and (bb)].\nThis letter notifies you of our concerns and provides you an opportunity to address them. In your written response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot completely address this matter within fifteen (15) working days, state the reason for the delay and the time within which you will do so.\nIf you are not located in the U.S., please note that products that appear to be misbranded may be detained or refused admission. We may advise the appropriate regulatory officials in the country from which you operate that your products referenced above appear to be misbranded products that cannot be legally sold to consumers in the U.S.\nAll correspondence should include a subject line that clearly identifies the submission as a Response to Warning Letter. If you have questions regarding the contents of this letter, please contact compoundinginspections@fda.hhs.gov.\nSincerely,\n\u002FS\u002F\nMatthew J. Lash\nActing Director\nOffice of Compounding Quality and Compliance\nOffice of Compliance\nCenter for Drug Evaluation and Research\n__________________\n1 The semaglutide and tirzepatide products offered on your website are drugs within the meaning of section 201(g) of the FDCA [21 U.S.C. § 321(g)] because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of diseases and\u002For because they are intended to affect the structure or any function of the body. Further, they are “new drugs” within the meaning of section 201(p) of the FDCA [21 U.S.C. § 321(p)] because they are not generally recognized as safe and effective for their labeled uses.\n2 See also 21 CFR § 201.1(h)(2) (“The appearance on a drug product label of a person’s name without qualification is a representation that the named person is the sole manufacturer of the product. That representation is false and misleading, and the drug product is misbranded under section 502(a) of the act, if the person is not the manufacturer of the product in accordance with this section.”); FDCA §503(b) [21 § U.S.C. 353(b)], FDCA §503B(a)(10)(A)(ii) [21 U.S.C. § 353b(a)(10)(A)(ii)]. We note that 21 CFR § 201.1(a) does not apply to drug products dispensed in accordance with section 503(b)(1) of the FDCA [21 USC § 353(b)(1)]. However, see 45 Fed. Reg. 25760, 25765 (Apr. 15, 1980) (“…if the label of a prescription drug product dispensed by a pharmacist does contain a representation as to the manufacturer, packer, or distributor, it must comply with all the provisions of § 201.1…”). In addition, the labels of your drug products as depicted on the website do not indicate that they are dispensed under section 503(b)(1) of the FDCA [21 USC § 353(b)(1)], nor do they appear to comply with the requirements of section 503(b)(2) [21 USC § 353(b)(2)].","Strut Health, LLC dba Strut","strut-health-llc-dba-strut-721448-02202026","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fstrut-health-llc-dba-strut-721448-02202026","2026-10-26T08:10:06.759951+00:00","2026-03-03","721448","Simal Patel, MD","2026-08-19T04:56:00.436+00:00","2026-02-20",{"id":96,"raw":97,"subject":38,"body_html":102,"body_text":103,"firm_name":104,"letter_id":105,"created_at":43,"fei_number":19,"letter_url":106,"updated_at":107,"action_type":22,"case_status":23,"posted_date":108,"marcs_cms_no":109,"product_type":48,"closeout_date":19,"issuing_office":37,"recipient_name":110,"body_fetched_at":111,"delivery_method":112,"recipient_title":19,"reference_number":113,"action_taken_date":114,"medical_device_id":19,"response_letter_date":19},1223,[98,99,100,37,101,13,13,13],"\u003Ctime datetime=\"2024-10-08T13:20:00Z\">10\u002F08\u002F2024\u003C\u002Ftime>\n","\u003Ctime datetime=\"2024-09-24T04:00:00Z\">09\u002F24\u002F2024\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmmc-healthcare-ltd-684644-09242024\">MMC Healthcare Ltd.\u003C\u002Fa>","CGMP\u002FFinished Pharmaceuticals\u002FAdulterated\u003Cbr \u002F>\r\n","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Email\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>320-24-62\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Nageswara Rao Gupta Manepalli\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Managing Director\u002FCEO\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>MMC Healthcare Ltd.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>34-B Sidco Industrial Estate\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Thirumazhisai, Chennai\u003C\u002Fspan> \u003Cspan>600124\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Tamil Nadu\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>India\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:ceo@mmchealthcareltd.com\"> ceo@mmchealthcareltd.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter\u003C\u002Fstrong> 320-24-62\u003C\u002Fp>\n\n\u003Cp>September 24, 2024\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Manepalli:\u003C\u002Fp>\n\n\u003Cp>The U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility, MMC Healthcare Ltd., FEI 3014773352, at 34-B Sidco Industrial Estate, Thirumazhisai, Chennai, Tamil Nadu, from March 25 to 30, 2024.\u003C\u002Fp>\n\n\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\u003C\u002Fp>\n\n\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\n\n\u003Cp>We reviewed your April 18, 2024 response to our Form FDA 483 in detail.\u003C\u002Fp>\n\n\u003Cp>During our inspection, our investigator observed specific violations including, but not limited to, the following.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>1. Your firm failed to establish an adequate quality control unit with the responsibility and authority to approve or reject all components, drug product containers, closures, in-process materials, packaging materials, labeling, and drug products (21 CFR 211.22(a)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>During the inspection of your facility our Investigator observed that your 2021 \u003Cstrong>(b)(4)\u003C\u002Fstrong> Tablets “PROCESS VALIDATION” report had data added, backdated signatures, and replaced pages. Your Quality Assurance Manager, Quality Control Manager, Formulation Research &amp; Development Manager, and Production Manager admitted to participating in these practices.\u003C\u002Fp>\n\n\u003Cp>Review of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> Capsules \u003Cstrong>(b)(4)\u003C\u002Fstrong> mg “PROCESS VALIDATION” report collected during the inspection also found a backdated approval stamp and signatures.\u003C\u002Fp>\n\n\u003Cp>In your response, you state that “due to pressure and tensions the concerned team mentioned the back date instead of current date unintentionally.” Additionally, you provide evidence of training conducted with your validation team to prevent such issues from recurring.\u003C\u002Fp>\n\n\u003Cp>Your response is inadequate because you fail to fully review the extent of your practice of backdating CGMP documents. You did not provide adequate evidence to demonstrate that you have conducted a comprehensive assessment of all systems and adequately remediated the deficiencies related to your documentation practices. There is also no indication that you have implemented appropriate and effective corrective actions and preventive actions (CAPAs) throughout your drug manufacturing operations to ensure your manufacturing operation is under control and that your quality unit (QU) is adequately exercising its responsibilities.\u003C\u002Fp>\n\n\u003Cp>Data integrity is critical throughout the CGMP data life cycle, including in the creation, modification, processing, maintenance, archival, retrieval, transmission, and disposition of date after the record’s retention period ends.\u003C\u002Fp>\n\n\u003Cp>In your response to this letter, provide:\u003C\u002Fp>\n\n\u003Cp>• A comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\u003Cbr>\n&nbsp; o A determination of whether procedures used by your firm are robust and appropriate.\u003Cbr>\n&nbsp; o Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices.\u003Cbr>\n&nbsp; o A complete and final review of each batch and its related information before the QU disposition decision.\u003Cbr>\n&nbsp; o Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products.\u003C\u002Fp>\n\n\u003Cp>Also describe the plan to ensure your senior and executive management supports quality assurance and reliable operations, including but not limited to, timely provision of resources to proactively address emerging manufacturing\u002Fquality issues and to assure a continuing state of control.\u003Cbr>\n• A comprehensive, independent assessment of your overall system for investigating deviations, discrepancies, complaints, out-of-specification (OOS) results, and failures. Provide a detailed action plan to remediate this system. Your action plan should include, but not be limited to, significant improvements in investigation competencies, scope determination, root cause evaluation, CAPA effectiveness, QU oversight, and written procedures. Address how your firm will ensure all phases of investigations are appropriately conducted.\u003Cbr>\n• A comprehensive, independent assessment of documentation systems used throughout your manufacturing and laboratory operations to determine where documentation practices are insufficient. Include a detailed CAPA plan that comprehensively remediates your firm’s documentation practices to ensure you retain attributable, legible, complete, original, accurate, contemporaneous records throughout your operation.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>2. Your firm failed to exercise appropriate controls over computer or related systems to assure that only authorized personnel institute changes in master production and control records, or other records (21 CFR 211.68(b)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your ultraviolet-visible (UV-Vis) spectrophotometer computer system lacked appropriate controls to assure the integrity of electronic test data, such as an audit trail and defined user access levels. This UV-Vis system was used for release testing of drug product batches.\u003C\u002Fp>\n\n\u003Cp>In your response, you state that you “would like to update the UV\u002FVis [sic] software” to be compliant and provide a quote for new software.\u003C\u002Fp>\n\n\u003Cp>Your response is inadequate because it does not provide sufficient details describing:\u003C\u002Fp>\n\n\u003Cp>• Timeframe for your corrective action.\u003Cbr>\n• Security features of your updated UV-Vis computer system.\u003Cbr>\n• User access levels, access privileges, or authorized users to perform the analyses, collect data, review data, or perform other functions.\u003Cbr>\n• Integrity of data generated by your computerized systems in the interim and any other interim measures, prior to the full implementation of your corrective actions.\u003Cbr>\n• Extent of this practice and how you will fully secure other CGMP computer systems in your facility.\u003C\u002Fp>\n\n\u003Cp>It is essential that your firm keeps track of all changes made to your electronic data. The use of audit trails for computerized analytical instrumentation helps to ensure all additions, deletions, or modifications of information in your electronic records are authorized. It also allows you to verify the quality and integrity of the electronic data your laboratory generates.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cp>• A comprehensive, independent assessment and CAPA plan for computer system security and integrity. Include a report that identifies design and control vulnerabilities, and appropriate remediations for each of your laboratory and manufacturing computer systems. This should include, but not be limited to:\u003Cbr>\n&nbsp; o An evaluation of the impact of this violation.\u003Cbr>\n&nbsp; o A list of all hardware that includes all equipment, both standalone and network, in your laboratory and manufacturing.\u003Cbr>\n&nbsp; o Identification of vulnerabilities in hardware and software, encompassing both networked and non-networked systems.\u003Cbr>\n&nbsp; o A list of all software configurations (both equipment software and Laboratory Information Management System) and versions, details of all user privileges, and oversight responsibilities for your computerized systems. Regarding user privileges, specify user roles and associated user privileges (including the specific permissions allowed for anyone who has administrative rights) for all staff who have access to the laboratory and manufacturing computer systems, and their organizational affiliation and title. Also describe how you will ensure staff are not given administrative rights, or other permissions that compromise data retention or reliability.\u003Cbr>\n&nbsp; o System security provisions, including but not limited to, whether unique usernames\u002Fpasswords are always used, and their confidentiality safeguarded.\u003Cbr>\n&nbsp; o Detailed procedures for robust use and review of audit trail data, and current status of audit trail implementation for each of your systems.\u003Cbr>\n&nbsp; o Timeline for the implementation and qualification of your updated UV-Vis software.\u003Cbr>\n&nbsp; o Interim control measures and procedural changes for the control, review, and full retention of laboratory data.\u003Cbr>\n&nbsp; o Comprehensive and sustainable CAPA for retention of all CGMP data including interim data. This includes provisions that address not only the need to retain batch-related data for appropriate periods, but also the long-term retention of all source data from development studies that support design, qualification, validation, and application.\u003Cbr>\n&nbsp; o A detailed summary of your procedural updates and associated training, including but not limited to, system security control to prevent unauthorized access, and ensure appropriate user role assignments, secondary review of all analyses, and other system controls.\u003Cbr>\n&nbsp; o Your remediated program for ensuring strict ongoing control over electronic and paper-based data to ensure that all additions, deletions, or modifications of information in your records are authorized, and all data is retained. Provide your full CAPA plan and any improvements made to date.\u003Cbr>\n&nbsp; o Provisions for oversight from Quality Assurance managers, executives, and internal auditors with appropriate IT expertise (e.g., understanding of infrastructure, configuration, network requirements, strict segregation of administrative rights).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>3. Your firm failed to establish the accuracy, sensitivity, specificity, and reproducibility of its test methods (21 CFR 211.165(e)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>You did not use a United States Pharmacopeia (USP) method to test multiple drug products nor did you show equivalency or superiority for your alternate methods. For example, your \u003Cem>E. coli\u003C\u002Fem> test method for \u003Cstrong>(b)(4)\u003C\u002Fstrong> Solution and \u003Cstrong>(b)(4)\u003C\u002Fstrong> Tablets drug products only required sub-culturing if turbidity was observed. This differs from the USP method which proceeds with sub-culturing regardless of visual observation of turbidity. Additionally, you could not provide method validation data that established the adequacy of the test methods you use.\u003C\u002Fp>\n\n\u003Cp>Test methods must be validated to show they are suitable for their intended use, and equivalent or better than applicable USP compendial methods. The reproducibility of your test methods is essential to determine if your drug products meet established specifications for microbial attributes.\u003C\u002Fp>\n\n\u003Cp>In your response, you state that you revised your test method to align with the USP and retrained your microbiologists. You also state that you retested most batches of \u003Cstrong>(b)(4)\u003C\u002Fstrong> Solution within expiry using the revised method, all of which passed.\u003C\u002Fp>\n\n\u003Cp>Your response is inadequate. You do not commit to retest all products and batches within expiry with the revised method. In addition, there is no indication that your method is equivalent or superior to the USP. There is also no information to evaluate all your test methods to ensure they are aligned with the USP.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cp>• A comprehensive, independent assessment of your laboratory practices, procedures, methods, equipment, documentation, and analyst competencies. Based on this review, provide a detailed plan to remediate and evaluate the effectiveness of your laboratory system.\u003Cbr>\n• A summary of results from testing reserve samples of all drug product batches within expiry. You should test microbiological quality (total counts and identification of bioburden to detect any objectionable microbes) of each batch. If testing yields an OOS result, indicate the corrective actions you will take, including notifying customers and initiating recalls.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Data Integrity Remediation\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your quality system does not adequately ensure the accuracy and integrity of data to support the safety, effectiveness, and quality of the drugs you manufacture. See FDA’s guidance document \u003Cem>Data Integrity and Compliance With Drug CGMP\u003C\u002Fem> for guidance on establishing and following CGMP compliant data integrity practices at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F119267\u002Fdownload.\u003C\u002Fp>\n\n\u003Cp>We strongly recommend that you retain an independent third-party, qualified consultant to assist in your remediation. In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cp>• A comprehensive investigation into the extent of the inaccuracies in data records and reporting. Your investigation should include:\u003Cbr>\n&nbsp; o A detailed investigation protocol and methodology; a summary of all laboratories, manufacturing operations, and systems to be covered by the assessment; and a justification for any part of your operation that you propose to exclude.\u003Cbr>\n&nbsp; o Interviews of current and former employees to identify the nature, scope, and root cause of data inaccuracies. We recommend that these interviews be conducted by a qualified third party.\u003Cbr>\n&nbsp; o An assessment of the extent of data integrity deficiencies at your facility. Identify omissions, alterations, deletions, record destruction, non-contemporaneous record completion, and other deficiencies. Describe all parts of your facility’s operations in which you discovered data integrity lapses.\u003Cbr>\n&nbsp; o A comprehensive retrospective evaluation of the nature of the testing and manufacturing data integrity deficiencies. We recommend that a qualified third party with specific expertise in the area where potential breaches were identified should evaluate all data integrity lapses.\u003C\u002Fp>\n\n\u003Cp>• A current risk assessment of the potential effects of the observed failures on the quality of your drugs. Your assessment should include analyses of the risks to patients caused by the release of drugs affected by a lapse of data integrity and analyses of the risks posed by ongoing operations.\u003C\u002Fp>\n\n\u003Cp>• A management strategy for your firm that includes the details of your global CAPA plan. Your strategy should include:\u003Cbr>\n&nbsp; o A detailed corrective action plan that describes how you intend to ensure the reliability and completeness of all the data you generate including analytical data, manufacturing records, and all data submitted to FDA.\u003Cbr>\n&nbsp; o A comprehensive description of the root causes of your data integrity lapses including evidence that the scope and depth of the current action plan is commensurate with the findings of the investigation and risk assessment. Indicate whether individuals responsible for data integrity lapses remain able to influence CGMP-related or drug application data at your firm.\u003Cbr>\n&nbsp; o Interim measures describing the actions you have taken or will take to protect patients and to ensure the quality of your drugs, such as notifying your customers, recalling product, conducting additional testing, adding lots to your stability programs to assure stability, drug application actions, and enhanced complaint monitoring.\u003Cbr>\n&nbsp; o Long-term measures describing any remediation efforts and enhancements to procedures, processes, methods, controls, systems, management oversight, and human resources (e.g., training, staffing improvements) designed to ensure the integrity of your company’s data.\u003Cbr>\n&nbsp; o A commitment to have a qualified consultant conduct extensive annual audits, for at least 2 years, to assist in evaluating CAPA effectiveness after you have executed your data integrity remediation protocol.\u003Cbr>\n&nbsp; o Inform FDA if you will be hiring a Chief Integrity Officer who is fully empowered to receive anonymous complaints from employees reporting data integrity concerns and with the authority to ensure any potential breach is promptly investigated (by independent quality assurance function, along with expertise from outside entities whenever needed).\u003Cbr>\n&nbsp; o A status report for any of the above activities already underway or completed.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\n\n\u003Cp>FDA placed your firm on Import Alert 66-40 on September 6, 2024.\u003C\u002Fp>\n\n\u003Cp>Correct any violations promptly. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to any violations.\u003C\u002Fp>\n\n\u003Cp>Failure to address any violations may also result in the FDA continuing to refuse admission of articles manufactured at MMC Healthcare Ltd., 34-B Sidco Industrial Estate, Thirumazhisai, Chennai into the United States under section 801(a)(3) of the FD&amp;C Act, 21 U.S.C. 381(a)(3).\u003C\u002Fp>\n\n\u003Cp>Articles under this authority that appear to be adulterated may be detained or refused admission, in that the methods and controls used in their manufacture do not appear to conform to CGMP within the meaning of section 501(a)(2)(B) of the FD&amp;C Act, 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\n\n\u003Cp>Send your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3014773352 and ATTN: Russell Riley.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Francis Godwin\u003Cbr>\nDirector\u003Cbr>\nOffice of Manufacturing Quality\u003Cbr>\nOffice of Compliance\u003Cbr>\nCenter for Drug Evaluation and Research\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Email\n\nReference #:\n\n320-24-62\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMr. Nageswara Rao Gupta Manepalli\n\nRecipient Title\n\nManaging Director\u002FCEO\n\nMMC Healthcare Ltd.\n\n34-B Sidco Industrial Estate\n\nThirumazhisai, Chennai 600124\n\nTamil Nadu\n\nIndia\n\nceo@mmchealthcareltd.com\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWarning Letter 320-24-62\n\nSeptember 24, 2024\n\nDear Mr. Manepalli:\n\nThe U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility, MMC Healthcare Ltd., FEI 3014773352, at 34-B Sidco Industrial Estate, Thirumazhisai, Chennai, Tamil Nadu, from March 25 to 30, 2024.\n\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\n\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\n\nWe reviewed your April 18, 2024 response to our Form FDA 483 in detail.\n\nDuring our inspection, our investigator observed specific violations including, but not limited to, the following.\n\n1. Your firm failed to establish an adequate quality control unit with the responsibility and authority to approve or reject all components, drug product containers, closures, in-process materials, packaging materials, labeling, and drug products (21 CFR 211.22(a)).\n\nDuring the inspection of your facility our Investigator observed that your 2021 (b)(4) Tablets “PROCESS VALIDATION” report had data added, backdated signatures, and replaced pages. Your Quality Assurance Manager, Quality Control Manager, Formulation Research & Development Manager, and Production Manager admitted to participating in these practices.\n\nReview of the (b)(4) Capsules (b)(4) mg “PROCESS VALIDATION” report collected during the inspection also found a backdated approval stamp and signatures.\n\nIn your response, you state that “due to pressure and tensions the concerned team mentioned the back date instead of current date unintentionally.” Additionally, you provide evidence of training conducted with your validation team to prevent such issues from recurring.\n\nYour response is inadequate because you fail to fully review the extent of your practice of backdating CGMP documents. You did not provide adequate evidence to demonstrate that you have conducted a comprehensive assessment of all systems and adequately remediated the deficiencies related to your documentation practices. There is also no indication that you have implemented appropriate and effective corrective actions and preventive actions (CAPAs) throughout your drug manufacturing operations to ensure your manufacturing operation is under control and that your quality unit (QU) is adequately exercising its responsibilities.\n\nData integrity is critical throughout the CGMP data life cycle, including in the creation, modification, processing, maintenance, archival, retrieval, transmission, and disposition of date after the record’s retention period ends.\n\nIn your response to this letter, provide:\n\n• A comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\n\no A determination of whether procedures used by your firm are robust and appropriate.\n\no Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices.\n\no A complete and final review of each batch and its related information before the QU disposition decision.\n\no Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products.\n\nAlso describe the plan to ensure your senior and executive management supports quality assurance and reliable operations, including but not limited to, timely provision of resources to proactively address emerging manufacturing\u002Fquality issues and to assure a continuing state of control.\n\n• A comprehensive, independent assessment of your overall system for investigating deviations, discrepancies, complaints, out-of-specification (OOS) results, and failures. Provide a detailed action plan to remediate this system. Your action plan should include, but not be limited to, significant improvements in investigation competencies, scope determination, root cause evaluation, CAPA effectiveness, QU oversight, and written procedures. Address how your firm will ensure all phases of investigations are appropriately conducted.\n\n• A comprehensive, independent assessment of documentation systems used throughout your manufacturing and laboratory operations to determine where documentation practices are insufficient. Include a detailed CAPA plan that comprehensively remediates your firm’s documentation practices to ensure you retain attributable, legible, complete, original, accurate, contemporaneous records throughout your operation.\n\n2. Your firm failed to exercise appropriate controls over computer or related systems to assure that only authorized personnel institute changes in master production and control records, or other records (21 CFR 211.68(b)).\n\nYour ultraviolet-visible (UV-Vis) spectrophotometer computer system lacked appropriate controls to assure the integrity of electronic test data, such as an audit trail and defined user access levels. This UV-Vis system was used for release testing of drug product batches.\n\nIn your response, you state that you “would like to update the UV\u002FVis [sic] software” to be compliant and provide a quote for new software.\n\nYour response is inadequate because it does not provide sufficient details describing:\n\n• Timeframe for your corrective action.\n\n• Security features of your updated UV-Vis computer system.\n\n• User access levels, access privileges, or authorized users to perform the analyses, collect data, review data, or perform other functions.\n\n• Integrity of data generated by your computerized systems in the interim and any other interim measures, prior to the full implementation of your corrective actions.\n\n• Extent of this practice and how you will fully secure other CGMP computer systems in your facility.\n\nIt is essential that your firm keeps track of all changes made to your electronic data. The use of audit trails for computerized analytical instrumentation helps to ensure all additions, deletions, or modifications of information in your electronic records are authorized. It also allows you to verify the quality and integrity of the electronic data your laboratory generates.\n\nIn response to this letter, provide:\n\n• A comprehensive, independent assessment and CAPA plan for computer system security and integrity. Include a report that identifies design and control vulnerabilities, and appropriate remediations for each of your laboratory and manufacturing computer systems. This should include, but not be limited to:\n\no An evaluation of the impact of this violation.\n\no A list of all hardware that includes all equipment, both standalone and network, in your laboratory and manufacturing.\n\no Identification of vulnerabilities in hardware and software, encompassing both networked and non-networked systems.\n\no A list of all software configurations (both equipment software and Laboratory Information Management System) and versions, details of all user privileges, and oversight responsibilities for your computerized systems. Regarding user privileges, specify user roles and associated user privileges (including the specific permissions allowed for anyone who has administrative rights) for all staff who have access to the laboratory and manufacturing computer systems, and their organizational affiliation and title. Also describe how you will ensure staff are not given administrative rights, or other permissions that compromise data retention or reliability.\n\no System security provisions, including but not limited to, whether unique usernames\u002Fpasswords are always used, and their confidentiality safeguarded.\n\no Detailed procedures for robust use and review of audit trail data, and current status of audit trail implementation for each of your systems.\n\no Timeline for the implementation and qualification of your updated UV-Vis software.\n\no Interim control measures and procedural changes for the control, review, and full retention of laboratory data.\n\no Comprehensive and sustainable CAPA for retention of all CGMP data including interim data. This includes provisions that address not only the need to retain batch-related data for appropriate periods, but also the long-term retention of all source data from development studies that support design, qualification, validation, and application.\n\no A detailed summary of your procedural updates and associated training, including but not limited to, system security control to prevent unauthorized access, and ensure appropriate user role assignments, secondary review of all analyses, and other system controls.\n\no Your remediated program for ensuring strict ongoing control over electronic and paper-based data to ensure that all additions, deletions, or modifications of information in your records are authorized, and all data is retained. Provide your full CAPA plan and any improvements made to date.\n\no Provisions for oversight from Quality Assurance managers, executives, and internal auditors with appropriate IT expertise (e.g., understanding of infrastructure, configuration, network requirements, strict segregation of administrative rights).\n\n3. Your firm failed to establish the accuracy, sensitivity, specificity, and reproducibility of its test methods (21 CFR 211.165(e)).\n\nYou did not use a United States Pharmacopeia (USP) method to test multiple drug products nor did you show equivalency or superiority for your alternate methods. For example, your E. coli test method for (b)(4) Solution and (b)(4) Tablets drug products only required sub-culturing if turbidity was observed. This differs from the USP method which proceeds with sub-culturing regardless of visual observation of turbidity. Additionally, you could not provide method validation data that established the adequacy of the test methods you use.\n\nTest methods must be validated to show they are suitable for their intended use, and equivalent or better than applicable USP compendial methods. The reproducibility of your test methods is essential to determine if your drug products meet established specifications for microbial attributes.\n\nIn your response, you state that you revised your test method to align with the USP and retrained your microbiologists. You also state that you retested most batches of (b)(4) Solution within expiry using the revised method, all of which passed.\n\nYour response is inadequate. You do not commit to retest all products and batches within expiry with the revised method. In addition, there is no indication that your method is equivalent or superior to the USP. There is also no information to evaluate all your test methods to ensure they are aligned with the USP.\n\nIn response to this letter, provide:\n\n• A comprehensive, independent assessment of your laboratory practices, procedures, methods, equipment, documentation, and analyst competencies. Based on this review, provide a detailed plan to remediate and evaluate the effectiveness of your laboratory system.\n\n• A summary of results from testing reserve samples of all drug product batches within expiry. You should test microbiological quality (total counts and identification of bioburden to detect any objectionable microbes) of each batch. If testing yields an OOS result, indicate the corrective actions you will take, including notifying customers and initiating recalls.\n\nData Integrity Remediation\n\nYour quality system does not adequately ensure the accuracy and integrity of data to support the safety, effectiveness, and quality of the drugs you manufacture. See FDA’s guidance document Data Integrity and Compliance With Drug CGMP for guidance on establishing and following CGMP compliant data integrity practices at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F119267\u002Fdownload.\n\nWe strongly recommend that you retain an independent third-party, qualified consultant to assist in your remediation. In response to this letter, provide:\n\n• A comprehensive investigation into the extent of the inaccuracies in data records and reporting. Your investigation should include:\n\no A detailed investigation protocol and methodology; a summary of all laboratories, manufacturing operations, and systems to be covered by the assessment; and a justification for any part of your operation that you propose to exclude.\n\no Interviews of current and former employees to identify the nature, scope, and root cause of data inaccuracies. We recommend that these interviews be conducted by a qualified third party.\n\no An assessment of the extent of data integrity deficiencies at your facility. Identify omissions, alterations, deletions, record destruction, non-contemporaneous record completion, and other deficiencies. Describe all parts of your facility’s operations in which you discovered data integrity lapses.\n\no A comprehensive retrospective evaluation of the nature of the testing and manufacturing data integrity deficiencies. We recommend that a qualified third party with specific expertise in the area where potential breaches were identified should evaluate all data integrity lapses.\n\n• A current risk assessment of the potential effects of the observed failures on the quality of your drugs. Your assessment should include analyses of the risks to patients caused by the release of drugs affected by a lapse of data integrity and analyses of the risks posed by ongoing operations.\n\n• A management strategy for your firm that includes the details of your global CAPA plan. Your strategy should include:\n\no A detailed corrective action plan that describes how you intend to ensure the reliability and completeness of all the data you generate including analytical data, manufacturing records, and all data submitted to FDA.\n\no A comprehensive description of the root causes of your data integrity lapses including evidence that the scope and depth of the current action plan is commensurate with the findings of the investigation and risk assessment. Indicate whether individuals responsible for data integrity lapses remain able to influence CGMP-related or drug application data at your firm.\n\no Interim measures describing the actions you have taken or will take to protect patients and to ensure the quality of your drugs, such as notifying your customers, recalling product, conducting additional testing, adding lots to your stability programs to assure stability, drug application actions, and enhanced complaint monitoring.\n\no Long-term measures describing any remediation efforts and enhancements to procedures, processes, methods, controls, systems, management oversight, and human resources (e.g., training, staffing improvements) designed to ensure the integrity of your company’s data.\n\no A commitment to have a qualified consultant conduct extensive annual audits, for at least 2 years, to assist in evaluating CAPA effectiveness after you have executed your data integrity remediation protocol.\n\no Inform FDA if you will be hiring a Chief Integrity Officer who is fully empowered to receive anonymous complaints from employees reporting data integrity concerns and with the authority to ensure any potential breach is promptly investigated (by independent quality assurance function, along with expertise from outside entities whenever needed).\n\no A status report for any of the above activities already underway or completed.\n\nConclusion\n\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\n\nFDA placed your firm on Import Alert 66-40 on September 6, 2024.\n\nCorrect any violations promptly. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to any violations.\n\nFailure to address any violations may also result in the FDA continuing to refuse admission of articles manufactured at MMC Healthcare Ltd., 34-B Sidco Industrial Estate, Thirumazhisai, Chennai into the United States under section 801(a)(3) of the FD&C Act, 21 U.S.C. 381(a)(3).\n\nArticles under this authority that appear to be adulterated may be detained or refused admission, in that the methods and controls used in their manufacture do not appear to conform to CGMP within the meaning of section 501(a)(2)(B) of the FD&C Act, 21 U.S.C. 351(a)(2)(B).\n\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\n\nSend your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3014773352 and ATTN: Russell Riley.\n\nSincerely,\n\n\u002FS\u002F\n\nFrancis Godwin\n\nDirector\n\nOffice of Manufacturing Quality\n\nOffice of Compliance\n\nCenter for Drug Evaluation and Research","MMC Healthcare Ltd.","mmc-healthcare-ltd-684644-09242024","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmmc-healthcare-ltd-684644-09242024","2026-10-26T08:09:26.775337+00:00","2024-10-08","684644","Mr. Nageswara Rao Gupta Manepalli","2026-08-19T22:31:41.964+00:00","Via Email","320-24-62","2024-09-24",{"id":116,"raw":117,"subject":83,"body_html":119,"body_text":120,"firm_name":121,"letter_id":122,"created_at":18,"fei_number":19,"letter_url":123,"updated_at":124,"action_type":22,"case_status":23,"posted_date":90,"marcs_cms_no":125,"product_type":48,"closeout_date":19,"issuing_office":37,"recipient_name":19,"body_fetched_at":126,"delivery_method":73,"recipient_title":19,"reference_number":19,"action_taken_date":94,"medical_device_id":19,"response_letter_date":19},303,[79,80,118,37,82,13,13,13],"\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fweightless-medical-llc-dba-weightcare-721478-02202026\">Weightless Medical LLC dba WeightCare\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA ELECTRONIC MAIL READ\u002FDELIVERY RECEIPT REQUESTED\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\u003C\u002Fdd>\n                    \n            \u003Cdd>Weightless Medical LLC dba WeightCare\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:help@joinweightcare.com\"> help@joinweightcare.com \u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>February 20, 2026\u003C\u002Fp>\u003Cp>WeightCare:\u003C\u002Fp>\u003Cp>This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https:\u002F\u002Fjoinweightcare.com, in December 2025, and has observed that your website offers compounded drug products, including semaglutide and tirzepatide drug products.\u003Cem>\u003Cstrong>\u003Csup>1\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> As described below, your website’s false or misleading claims concerning compounded semaglutide and tirzepatide products under sections 502(a) and 502(bb) of the Federal Food, Drug, and Cosmetic Act (FDCA) [21 U.S.C. §§ 352(a) and 352(bb)], result in products being introduced or delivered for introduction into interstate commerce in violation of section 301(a) of the FDCA [21 U.S.C. § 331(a)].\u003C\u002Fp>\u003Cp>Under section 502(a) of the FDCA [21 U.S.C. § 352(a)] a drug is misbranded if its labeling is false or misleading in any particular. Furthermore, under section 502(bb) of the FDCA [21 U.S.C. § 352(bb)], a compounded drug is misbranded if its advertising or promotion is false or misleading in any particular.\u003C\u002Fp>\u003Cp>The compounded semaglutide and tirzepatide products displayed on your website identify “WeightCare” on the pictured label, suggesting WeightCare is the compounder of those drugs when in fact it is not.\u003Cem>\u003Cstrong>\u003Csup>2\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> Accordingly, the representations on your website that WeightCare is the compounder of these drug products are false or misleading, and the products are therefore misbranded under sections 502(a) and 502(bb) of the FDCA [21 U.S.C. §§ 352(a) and (bb)].\u003C\u002Fp>\u003Cp>The introduction or delivery for introduction into interstate commerce of these misbranded products is a prohibited act under section 301(a) of the FDCA [21 U.S.C. § 331(a)]. The representations identified in this letter put you on notice of our concerns but do not represent an exhaustive list of violations.\u003C\u002Fp>\u003Cp>For the reasons discussed above, your compounded semaglutide and tirzepatide products are misbranded drugs under sections 502(a) and 502(bb) of the FDCA [21 U.S.C. §§ 352(a) and 352(bb)], introduced or delivered for introduction into interstate commerce in violation of section 301(a) of the FDCA [21 U.S.C. § 331(a)]. Please be advised, the receipt in interstate commerce of misbranded drugs, and the delivery or proffered delivery thereof, is also a violation of section 301(c) of the FDCA [21 U.S.C. § 331(c)].\u003C\u002Fp>\u003Cp>As previously stated, the violations cited in this letter are not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your operations comply with all requirements of federal law, including FDA regulations. For example, compounded drug products must meet the conditions in sections 503A or 503B of the FD&amp;C Act [21 U.S.C. §§ 353a or 353b] in order to be exempt from certain requirements under the Act, including the new drug approval requirements.\u003C\u002Fp>\u003Cp>You should take immediate action to address any violations. Failure to adequately address any violations may result in legal action without further notice, including, without limitation, seizure and injunction.\u003C\u002Fp>\u003Cp>Within fifteen (15) working days of receipt of this letter, please provide a written response to the Office of Compounding Quality and Compliance (OCQC) within the Center for Drug Evaluation and Research (CDER)’s Office of Compliance describing the specific steps you have taken to address any violations. Please include an explanation of each step being taken to prevent the recurrence of any violations, as well as copies of related documentation. Such steps may include:\u003C\u002Fp>\u003Cp>1) Identifying the entities that produce the compounded products offered on your website;\u003C\u002Fp>\u003Cp>2) Providing a representative sample of labeling for such products; and\u003C\u002Fp>\u003Cp>3) Addressing the basis for other website claims that could be construed as false or misleading or demonstrating that such claims have been modified or removed in light of FDCA §§ 502(a) and 502(bb)) [21 U.S.C. §§ 352(a) and (bb)].\u003C\u002Fp>\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. In your written response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot completely address this matter within fifteen (15) working days, state the reason for the delay and the time within which you will do so.\u003C\u002Fp>\u003Cp>If you are not located in the U.S., please note that products that appear to be misbranded may be detained or refused admission. We may advise the appropriate regulatory officials in the country from which you operate that your products referenced above appear to be misbranded products that cannot be legally sold to consumers in the U.S.\u003C\u002Fp>\u003Cp>All correspondence should include a subject line that clearly identifies the submission as a Response to Warning Letter. If you have questions regarding the contents of this letter, please contact compoundinginspections@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Matthew J. Lash\u003Cbr>Acting Director\u003Cbr>Office of Compounding Quality and Compliance\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003C\u002Fp>\u003Cp>_________________\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> The semaglutide and tirzepatide products offered on your website are drugs within the meaning of section 201(g) of the FDCA [21 U.S.C. § 321(g)] because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of diseases and\u002For because they are intended to affect the structure or any function of the body. Further, they are “new drugs” within the meaning of section 201(p) of the FDCA [21 U.S.C. § 321(p)] because they are not generally recognized as safe and effective for their labeled uses.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> See also 21 CFR § 201.1(h)(2) (“The appearance on a drug product label of a person’s name without qualification is a representation that the named person is the sole manufacturer of the product. That representation is false and misleading, and the drug product is misbranded under section 502(a) of the act, if the person is not the manufacturer of the product in accordance with this section.”); FDCA §503(b) [21 § U.S.C. 353(b)], FDCA §503B(a)(10)(A)(ii) [21 U.S.C. § 353b(a)(10)(A)(ii)]. We note that 21 CFR § 201.1(a) does not apply to drug products dispensed in accordance with section 503(b)(1) of the FDCA [21 USC § 353(b)(1)]. However, see 45 Fed. Reg. 25760, 25765 (Apr. 15, 1980) (“…if the label of a prescription drug product dispensed by a pharmacist does contain arepresentation as to the manufacturer, packer, or distributor, it must comply with all the provisions of § 201.1…”). In addition, the labels of your drug products as depicted on the website do not indicate that they are dispensed under section 503(b)(1) of the FDCA [21 USC § 353(b)(1)], nor do they appear to comply with the requirements of section 503(b)(2) [21 USC § 353(b)(2)].\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA ELECTRONIC MAIL READ\u002FDELIVERY RECEIPT REQUESTED\n\nProduct:\n\nDrugs\n\nRecipient:\n\nWeightless Medical LLC dba WeightCare\n\nUnited States\n\nhelp@joinweightcare.com\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWARNING LETTER\nFebruary 20, 2026\nWeightCare:\nThis letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https:\u002F\u002Fjoinweightcare.com, in December 2025, and has observed that your website offers compounded drug products, including semaglutide and tirzepatide drug products.1 As described below, your website’s false or misleading claims concerning compounded semaglutide and tirzepatide products under sections 502(a) and 502(bb) of the Federal Food, Drug, and Cosmetic Act (FDCA) [21 U.S.C. §§ 352(a) and 352(bb)], result in products being introduced or delivered for introduction into interstate commerce in violation of section 301(a) of the FDCA [21 U.S.C. § 331(a)].\nUnder section 502(a) of the FDCA [21 U.S.C. § 352(a)] a drug is misbranded if its labeling is false or misleading in any particular. Furthermore, under section 502(bb) of the FDCA [21 U.S.C. § 352(bb)], a compounded drug is misbranded if its advertising or promotion is false or misleading in any particular.\nThe compounded semaglutide and tirzepatide products displayed on your website identify “WeightCare” on the pictured label, suggesting WeightCare is the compounder of those drugs when in fact it is not.2 Accordingly, the representations on your website that WeightCare is the compounder of these drug products are false or misleading, and the products are therefore misbranded under sections 502(a) and 502(bb) of the FDCA [21 U.S.C. §§ 352(a) and (bb)].\nThe introduction or delivery for introduction into interstate commerce of these misbranded products is a prohibited act under section 301(a) of the FDCA [21 U.S.C. § 331(a)]. The representations identified in this letter put you on notice of our concerns but do not represent an exhaustive list of violations.\nFor the reasons discussed above, your compounded semaglutide and tirzepatide products are misbranded drugs under sections 502(a) and 502(bb) of the FDCA [21 U.S.C. §§ 352(a) and 352(bb)], introduced or delivered for introduction into interstate commerce in violation of section 301(a) of the FDCA [21 U.S.C. § 331(a)]. Please be advised, the receipt in interstate commerce of misbranded drugs, and the delivery or proffered delivery thereof, is also a violation of section 301(c) of the FDCA [21 U.S.C. § 331(c)].\nAs previously stated, the violations cited in this letter are not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your operations comply with all requirements of federal law, including FDA regulations. For example, compounded drug products must meet the conditions in sections 503A or 503B of the FD&C Act [21 U.S.C. §§ 353a or 353b] in order to be exempt from certain requirements under the Act, including the new drug approval requirements.\nYou should take immediate action to address any violations. Failure to adequately address any violations may result in legal action without further notice, including, without limitation, seizure and injunction.\nWithin fifteen (15) working days of receipt of this letter, please provide a written response to the Office of Compounding Quality and Compliance (OCQC) within the Center for Drug Evaluation and Research (CDER)’s Office of Compliance describing the specific steps you have taken to address any violations. Please include an explanation of each step being taken to prevent the recurrence of any violations, as well as copies of related documentation. Such steps may include:\n1) Identifying the entities that produce the compounded products offered on your website;\n2) Providing a representative sample of labeling for such products; and\n3) Addressing the basis for other website claims that could be construed as false or misleading or demonstrating that such claims have been modified or removed in light of FDCA §§ 502(a) and 502(bb)) [21 U.S.C. §§ 352(a) and (bb)].\nThis letter notifies you of our concerns and provides you an opportunity to address them. In your written response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot completely address this matter within fifteen (15) working days, state the reason for the delay and the time within which you will do so.\nIf you are not located in the U.S., please note that products that appear to be misbranded may be detained or refused admission. We may advise the appropriate regulatory officials in the country from which you operate that your products referenced above appear to be misbranded products that cannot be legally sold to consumers in the U.S.\nAll correspondence should include a subject line that clearly identifies the submission as a Response to Warning Letter. If you have questions regarding the contents of this letter, please contact compoundinginspections@fda.hhs.gov.\nSincerely,\n\u002FS\u002F\nMatthew J. Lash\nActing Director\nOffice of Compounding Quality and Compliance\nOffice of Compliance\nCenter for Drug Evaluation and Research\n_________________\n1 The semaglutide and tirzepatide products offered on your website are drugs within the meaning of section 201(g) of the FDCA [21 U.S.C. § 321(g)] because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of diseases and\u002For because they are intended to affect the structure or any function of the body. Further, they are “new drugs” within the meaning of section 201(p) of the FDCA [21 U.S.C. § 321(p)] because they are not generally recognized as safe and effective for their labeled uses.\n2 See also 21 CFR § 201.1(h)(2) (“The appearance on a drug product label of a person’s name without qualification is a representation that the named person is the sole manufacturer of the product. That representation is false and misleading, and the drug product is misbranded under section 502(a) of the act, if the person is not the manufacturer of the product in accordance with this section.”); FDCA §503(b) [21 § U.S.C. 353(b)], FDCA §503B(a)(10)(A)(ii) [21 U.S.C. § 353b(a)(10)(A)(ii)]. We note that 21 CFR § 201.1(a) does not apply to drug products dispensed in accordance with section 503(b)(1) of the FDCA [21 USC § 353(b)(1)]. However, see 45 Fed. Reg. 25760, 25765 (Apr. 15, 1980) (“…if the label of a prescription drug product dispensed by a pharmacist does contain arepresentation as to the manufacturer, packer, or distributor, it must comply with all the provisions of § 201.1…”). In addition, the labels of your drug products as depicted on the website do not indicate that they are dispensed under section 503(b)(1) of the FDCA [21 USC § 353(b)(1)], nor do they appear to comply with the requirements of section 503(b)(2) [21 USC § 353(b)(2)].","Weightless Medical LLC dba WeightCare","weightless-medical-llc-dba-weightcare-721478-02202026","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fweightless-medical-llc-dba-weightcare-721478-02202026","2026-10-26T08:10:30.891039+00:00","721478","2026-08-19T04:56:23.344+00:00",{"id":128,"raw":129,"subject":134,"body_html":135,"body_text":136,"firm_name":137,"letter_id":138,"created_at":139,"fei_number":19,"letter_url":140,"updated_at":141,"action_type":22,"case_status":23,"posted_date":142,"marcs_cms_no":143,"product_type":144,"closeout_date":19,"issuing_office":133,"recipient_name":145,"body_fetched_at":146,"delivery_method":112,"recipient_title":19,"reference_number":19,"action_taken_date":147,"medical_device_id":19,"response_letter_date":19},21708,[130,131,132,133,134,13,13,13],"\u003Ctime datetime=\"2026-09-29T04:00:00Z\">09\u002F29\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-08-04T04:00:00Z\">08\u002F04\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fstokes-healthcare-inc-dba-epicur-pharma-733243-08042026\">Stokes Healthcare Inc. dba Epicur Pharma\u003C\u002Fa>","Center for Veterinary Medicine","Animal Drugs\u002FAdulterated","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Email\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Animal &amp; Veterinary\u003Cbr>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Michael Tursi\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>CEO\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Stokes Healthcare Inc. dba Epicur Pharma\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>8000 Commerce Parkway, Ste. 600\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Mount Laurel\u003C\u002Fspan>, \u003Cspan>NJ\u003C\u002Fspan> \u003Cspan>08054\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:mtursi@stokespharmacy.com\"> mtursi@stokespharmacy.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Veterinary Medicine\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>August 4, 2026\u003C\u002Fp>\u003Cp>Re: 733243\u003C\u002Fp>\u003Cp>Dear Michael Tursi:\u003C\u002Fp>\u003Cp>This letter is to advise you that the United States Food and Drug Administration (FDA) has reviewed your website https:\u002F\u002Fepicurpharma.com, where you market various compounded animal drugs in violation of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act). As explained further below, the claims on your website concerning your compounded animal drugs, including buprenorphine ER injection solution and omeprazole injection suspension, are false or misleading and the drugs are therefore misbranded under sections 502(a), 502(bb), and 201(n) of the FD&amp;C Act (21 U.S.C. §§ 352(a), 352(bb) and 321(n)). Your statements create a false or misleading impression about the safety and effectiveness of your compounded drugs, which are not FDA-approved or indexed. By encouraging use of these treatments instead of drugs that have been through FDA approval or indexing, you expose patients to unknown risks, including the risk of ineffective treatment.\u003C\u002Fp>\u003Cp>\u003Cstrong>Unsubstantiated Claims\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your compounded drugs are not FDA-approved, conditionally approved, or index listed.\u003Cem>\u003Cstrong>\u003Csup>1\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> Animal drugs produced in human drug outsourcing facilities, registered under section 503B of the Act, are not exempt from the FD&amp;C Act’s requirements for adequate directions for use or approval.\u003Cem>\u003Cstrong>\u003Csup>2\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> Unless a drug is compounded using FDA-approved drugs (i.e., using the approved drug as the source of active ingredients) in compliance with 21 CFR Part 530, it violates the FD&amp;C Act because it is not approved or indexed, and cannot satisfy the FD&amp;C Act’s adequate directions for use provision (which requires, among other things, that a prescription drug have an FDA-approved labeling).\u003Cem>\u003Cstrong>\u003Csup>3\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fp>\u003Cp>Promotional materials misbrand a drug if they contain false or misleading comparisons that represent or suggest that it is safer or more effective than another drug when this has not been demonstrated. You make such claims for the following products:\u003C\u002Fp>\u003Cp>\u003Cu>Compounded Omeprazole Injection Suspension\u003C\u002Fu>\u003C\u002Fp>\u003Cp>Omeprazole is the active ingredient in multiple, FDA approved animal drugs, including GastroGard (NADA 141-123), UlcerGard (NADA 141-227), and Gastrobim (ANADA 200-842). The following are examples of claims made through your website, epicurpharma.com, where you state or imply your unapproved drugs are safe, effective, comparable, and\u002For superior to FDA-approved drugs:\u003C\u002Fp>\u003Cul>\u003Cli>“Changing the game for equine gastric ulcers.”\u003C\u002Fli>\u003Cli>“…an innovative alternative for equine gastric ulcers”\u003C\u002Fli>\u003Cli>“…Epicur is bringing the same unique, proven formulation of omeprazole injection to the U.S. for the treatment of equine gastric ulcers.”\u003C\u002Fli>\u003Cli>“Benefits of this formulation over the traditional oral paste include: …\u003Cbr>o More rapid healing with [Equine Squamous Gastric Disease (ESGD)] healing in 10 days and [Equine Glandular Gastric Disease (EGGD)] in 20 days with the injection, compared to the traditional month of treatment with oral treatment (Sundra T, Kelty E, Rendle D, 2024)”\u003C\u002Fli>\u003C\u002Ful>\u003Cp>Compounded drug products are not FDA-approved or indexed. The claims on your website misleadingly suggest that your compounded omeprazole injection suspension is comparable or superior to FDA-approved omeprazole drugs. FDA-approved drugs have been reviewed to ensure they are safe and effective. Neither the safety nor the effectiveness of your product has been reviewed by FDA. Additionally, the literature cited does not appear to support the statement listed above because the study did not review treatment at 10 days, did not find a significant result for ESGD, and did not review records for horses treated with oral omeprazole drugs. The study by Sundra et al. 2024 reviewed the veterinary records of horses that had received four doses of an injectable omeprazole drug at either 5-day or 7-day dosing intervals. The study compared effectiveness of the two dosing intervals using gastroscopy images collected 5 to 7 days after the fourth dose. The study concluded that 5-day intervals resulted in more horses with EGGD healing compared with 7-day intervals, but did not find a significant difference for ESGD healing. The study did not review records for horses that received oral omeprazole drugs or compare the effectiveness of 5-day vs. 7-day dosing intervals for the oral omeprazole drugs. As a result, these claims are false or misleading and your product is therefore misbranded under sections 502(a), 502(bb) and 201(n) of the FD&amp;C Act.\u003C\u002Fp>\u003Cp>\u003Cu>Compounded Buprenorphine ER Injection Solution\u003C\u002Fu>\u003C\u002Fp>\u003Cp>Buprenorphine is the active ingredient in three drugs on the Index of Legally Marketed Unapproved New Animal Drugs for Minor Species, including one marketed drug, ETHIQA XR (MIF 900-014). The following are examples of claims on your website, epicurpharma.com, where you state or imply your unapproved drugs are safe, effective, comparable and\u002For superior to legally marketed indexed drugs:\u003C\u002Fp>\u003Cul>\u003Cli>“Next-Generation Buprenorphine Analgesia for Rats and Mice”\u003C\u002Fli>\u003Cli>“Meet the new gold standard in lab animal pain relief”\u003C\u002Fli>\u003C\u002Ful>\u003Cp>Comparisons are made between your buprenorphine ER injection solution and “Buprenorphine ER Alternatives” as shown in the table below.\u003C\u002Fp>\u003Cdiv>  \u003Cimg src=\"https:\u002F\u002Fwww.fda.gov\u002Ffiles\u002FStokes%20733243.png\" alt=\"Stokes WL\">\n\n\u003C\u002Fdiv>\n\u003Cp>The claims on your website misleadingly suggest that your compounded buprenorphine ER injection solution is comparable or superior to FDA-indexed drugs. FDA-indexed drugs have had their safety and effectiveness affirmed through an alternative FDA review process. Neither the safety nor the effectiveness of your compounded product has been reviewed by FDA.\u003C\u002Fp>\u003Cp>Furthermore, your claim that “FDA indexing [is] underway” is false or misleading because it implies that you have started the indexing process by submitting information to FDA that is under review by FDA.\u003Cem>\u003Cstrong>\u003Csup>4\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> \u003Cstrong>(b)(4)\u003C\u002Fstrong>. However, as of the date of this letter, you have not opened a file or submitted information to FDA for review for indexing, so “FDA indexing” is not currently underway.\u003C\u002Fp>\u003Cp>You state that the FDA-indexed buprenorphine ER alternative has a 2-month shelf life. This is false. Ethiqa XR™ is a buprenorphine extended-release injectable suspension that is FDA-indexed and is currently marketed. Ethiqa has a 36-month shelf life and its label states “once broached, the multi-dose vial should be discarded after 90 days”.\u003C\u002Fp>\u003Cp>\u003Cstrong>False or Misleading Risk Presentation\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Promotional materials misbrand a drug if they are false or misleading with respect to risk. Among other reasons, promotional material can be misleading due to the representations it makes or suggests.\u003Cem>\u003Cstrong>\u003Csup>5\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> It can also be misleading if it fails to reveal facts that are material when viewed in light of the representations made, including facts related to the potential consequences (e.g., adverse effects) of using the drug either as suggested in the promotion or under the usual conditions of use.\u003C\u002Fp>\u003Cp>The promotional materials for your compounded buprenorphine ER injection solution fail to communicate risk information associated with the product. This is particularly concerning in light of the known risks associated with buprenorphine as explained in the product labeling of the drugs approved and indexed by the FDA that contain buprenorphine. Buprenorphine is classified as a Schedule III narcotic due to human abuse and addiction potential and poses severe human exposure risks, including accidental skin absorption or ingestion dangers. Additionally, your promotional materials for the omeprazole injection suspension drug product do not sufficiently communicate risk information associated with the use of the drug.\u003C\u002Fp>\u003Cp>\u003Cstrong>False and\u002For Misleading Advertising about the FDA and the Legality of Compounded Animal Drugs\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cu>False or Misleading Advertising Regarding FDA’s Animal Drug Compounding Guidance\u003C\u002Fu>\u003C\u002Fp>\u003Cp>Your website states that your buprenorphine ER injection solution is “Compliant with GFI #256” and available for office use. This statement is false. Buprenorphine injectable polymeric matrix solution for use in rodents (e.g., mice and rats) is on the list of \u003Cu>Bulk Drug Substances Reviewed and Not Listed\u003C\u002Fu>. Therefore, buprenorphine ER injection solution compounded for use as office stock in rats and mice is not consistent with the recommendations in GFI #256, and your assertion otherwise is false or misleading.\u003C\u002Fp>\u003Cp>\u003Cu>False or Misleading Advertising About FDA’s Oversight of Compounded Drugs\u003C\u002Fu>\u003C\u002Fp>\u003Cp>On your website, you make the following claim about all of your compounded tablets:\u003C\u002Fp>\u003Cul>\u003Cli>“…All Epicur® tablets are manufactured to FDA specifications”\u003Cbr>This statement is false or misleading because FDA does not review, set, or approve specifications for compounded drugs.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cu>False or Misleading Advertising About the Legality of Compounded Animal Drugs\u003C\u002Fu>\u003C\u002Fp>\u003Cp>On your website, you make the following claims about the legal status of animal drugs (including your drugs) compounded in a human drug outsourcing facility:\u003C\u002Fp>\u003Cul>\u003Cli>“Available for dispensing and unlimited hospital administration FDA Federal SEC. 503B. [21 U.S.C. 353b]”\u003C\u002Fli>\u003C\u002Ful>\u003Cp>This statement suggests that the animal drugs listed on the page are legal for dispensing as office stock under FD&amp;C Act section 503B, which is false, because the exemptions in section 503B do not apply to animal drugs.\u003C\u002Fp>\u003Cul>\u003Cli>“…Buprenorphine Injection is on the \u003Cstrong>do not compound List\u003C\u002Fstrong> for office use under GFI #256 which means you must order compounded Buprenorphine from a 503B like Epicur! Stay FDA &amp; DEA complia\u003Ca>nt…”\u003C\u002Fa>\u003C\u002Fli>\u003C\u002Ful>\u003Cp>This statement suggests Buprenorphine Injection is legal for dispensing as office stock if produced in a 503B human drug outsourcing facility, which is false because the exemptions in section 503B do not apply to animal drugs.\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>This letter notifies you of our concerns and provides you with an opportunity to address them. Failure to address this matter may lead to legal action without further notice, including, without limitation, seizure and injunction.\u003C\u002Fp>\u003Cp>This letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products or operations. It is your responsibility to ensure that your firm complies with all requirements of federal law and FDA’s implementing regulations.\u003C\u002Fp>\u003Cp>Within fifteen (15) working days of receipt of this letter, please notify this office in writing of the specific steps you have taken to correct any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective action within fifteen (15) working days, state the reason for the delay and the time within which you will complete the correction. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\u003Cp>Please direct your response to U.S. Food and Drug Administration, Center for Veterinary Medicine, Office of Surveillance and Compliance, Division of Drug Compliance by email to CVMUnapprovedDrugs@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Johnetta Walters, Ph.D.\u003Cbr>Acting Division Director\u003Cbr>Division of Drug Compliance\u003Cbr>Office of Surveillance and Compliance\u003Cbr>Center for Veterinary Medicine\u003Cbr>U.S. Food &amp; Drug Administration\u003C\u002Fp>\u003Cp>________________________\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> Sections 512, 571, and 572 of the FD&amp;C Act (21 U.S.C. §§ 360b, 360ccc, 360ccc-1).\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> Section 503B(a) of the FD&amp;C Act exempts human drugs from the new drug approval requirements of section 505, but section 503B(a) (21 U.S.C. § 353b) omits any reference to the new animal drug approval requirements in section 512 of the FD&amp;C Act. The exemptions in section 503B apply only to human drugs.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem> FD&amp;C Act sections 512(a) and 502(f) (21 U.S.C. §§ 360b(a), 352(f)).\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>4\u003C\u002Fstrong>\u003C\u002Fem> See FD&amp;C Act section 572(c) (21 U.S.C. § 360ccc-1(c)).\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>5\u003C\u002Fstrong>\u003C\u002Fem> See FD&amp;C Act section 201(n), 21 U.S.C. 321(n).\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Email\n\nProduct:\n\nAnimal & Veterinary\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMichael Tursi\n\nRecipient Title\n\nCEO\n\nStokes Healthcare Inc. dba Epicur Pharma\n\n8000 Commerce Parkway, Ste. 600\n\nMount Laurel, NJ 08054\n\nUnited States\n\nmtursi@stokespharmacy.com\n\nIssuing Office:\n\nCenter for Veterinary Medicine\n\nUnited States\n\nWARNING LETTER\nAugust 4, 2026\nRe: 733243\nDear Michael Tursi:\nThis letter is to advise you that the United States Food and Drug Administration (FDA) has reviewed your website https:\u002F\u002Fepicurpharma.com, where you market various compounded animal drugs in violation of the Federal Food, Drug, and Cosmetic Act (FD&C Act). As explained further below, the claims on your website concerning your compounded animal drugs, including buprenorphine ER injection solution and omeprazole injection suspension, are false or misleading and the drugs are therefore misbranded under sections 502(a), 502(bb), and 201(n) of the FD&C Act (21 U.S.C. §§ 352(a), 352(bb) and 321(n)). Your statements create a false or misleading impression about the safety and effectiveness of your compounded drugs, which are not FDA-approved or indexed. By encouraging use of these treatments instead of drugs that have been through FDA approval or indexing, you expose patients to unknown risks, including the risk of ineffective treatment.\nUnsubstantiated Claims\nYour compounded drugs are not FDA-approved, conditionally approved, or index listed.1 Animal drugs produced in human drug outsourcing facilities, registered under section 503B of the Act, are not exempt from the FD&C Act’s requirements for adequate directions for use or approval.2 Unless a drug is compounded using FDA-approved drugs (i.e., using the approved drug as the source of active ingredients) in compliance with 21 CFR Part 530, it violates the FD&C Act because it is not approved or indexed, and cannot satisfy the FD&C Act’s adequate directions for use provision (which requires, among other things, that a prescription drug have an FDA-approved labeling).3\nPromotional materials misbrand a drug if they contain false or misleading comparisons that represent or suggest that it is safer or more effective than another drug when this has not been demonstrated. You make such claims for the following products:\nCompounded Omeprazole Injection Suspension\nOmeprazole is the active ingredient in multiple, FDA approved animal drugs, including GastroGard (NADA 141-123), UlcerGard (NADA 141-227), and Gastrobim (ANADA 200-842). The following are examples of claims made through your website, epicurpharma.com, where you state or imply your unapproved drugs are safe, effective, comparable, and\u002For superior to FDA-approved drugs:\n“Changing the game for equine gastric ulcers.”\n“…an innovative alternative for equine gastric ulcers”\n“…Epicur is bringing the same unique, proven formulation of omeprazole injection to the U.S. for the treatment of equine gastric ulcers.”\n“Benefits of this formulation over the traditional oral paste include: …\no More rapid healing with [Equine Squamous Gastric Disease (ESGD)] healing in 10 days and [Equine Glandular Gastric Disease (EGGD)] in 20 days with the injection, compared to the traditional month of treatment with oral treatment (Sundra T, Kelty E, Rendle D, 2024)”\nCompounded drug products are not FDA-approved or indexed. The claims on your website misleadingly suggest that your compounded omeprazole injection suspension is comparable or superior to FDA-approved omeprazole drugs. FDA-approved drugs have been reviewed to ensure they are safe and effective. Neither the safety nor the effectiveness of your product has been reviewed by FDA. Additionally, the literature cited does not appear to support the statement listed above because the study did not review treatment at 10 days, did not find a significant result for ESGD, and did not review records for horses treated with oral omeprazole drugs. The study by Sundra et al. 2024 reviewed the veterinary records of horses that had received four doses of an injectable omeprazole drug at either 5-day or 7-day dosing intervals. The study compared effectiveness of the two dosing intervals using gastroscopy images collected 5 to 7 days after the fourth dose. The study concluded that 5-day intervals resulted in more horses with EGGD healing compared with 7-day intervals, but did not find a significant difference for ESGD healing. The study did not review records for horses that received oral omeprazole drugs or compare the effectiveness of 5-day vs. 7-day dosing intervals for the oral omeprazole drugs. As a result, these claims are false or misleading and your product is therefore misbranded under sections 502(a), 502(bb) and 201(n) of the FD&C Act.\nCompounded Buprenorphine ER Injection Solution\nBuprenorphine is the active ingredient in three drugs on the Index of Legally Marketed Unapproved New Animal Drugs for Minor Species, including one marketed drug, ETHIQA XR (MIF 900-014). The following are examples of claims on your website, epicurpharma.com, where you state or imply your unapproved drugs are safe, effective, comparable and\u002For superior to legally marketed indexed drugs:\n“Next-Generation Buprenorphine Analgesia for Rats and Mice”\n“Meet the new gold standard in lab animal pain relief”\nComparisons are made between your buprenorphine ER injection solution and “Buprenorphine ER Alternatives” as shown in the table below.\n\nThe claims on your website misleadingly suggest that your compounded buprenorphine ER injection solution is comparable or superior to FDA-indexed drugs. FDA-indexed drugs have had their safety and effectiveness affirmed through an alternative FDA review process. Neither the safety nor the effectiveness of your compounded product has been reviewed by FDA.\nFurthermore, your claim that “FDA indexing [is] underway” is false or misleading because it implies that you have started the indexing process by submitting information to FDA that is under review by FDA.4 (b)(4). However, as of the date of this letter, you have not opened a file or submitted information to FDA for review for indexing, so “FDA indexing” is not currently underway.\nYou state that the FDA-indexed buprenorphine ER alternative has a 2-month shelf life. This is false. Ethiqa XR™ is a buprenorphine extended-release injectable suspension that is FDA-indexed and is currently marketed. Ethiqa has a 36-month shelf life and its label states “once broached, the multi-dose vial should be discarded after 90 days”.\nFalse or Misleading Risk Presentation\nPromotional materials misbrand a drug if they are false or misleading with respect to risk. Among other reasons, promotional material can be misleading due to the representations it makes or suggests.5 It can also be misleading if it fails to reveal facts that are material when viewed in light of the representations made, including facts related to the potential consequences (e.g., adverse effects) of using the drug either as suggested in the promotion or under the usual conditions of use.\nThe promotional materials for your compounded buprenorphine ER injection solution fail to communicate risk information associated with the product. This is particularly concerning in light of the known risks associated with buprenorphine as explained in the product labeling of the drugs approved and indexed by the FDA that contain buprenorphine. Buprenorphine is classified as a Schedule III narcotic due to human abuse and addiction potential and poses severe human exposure risks, including accidental skin absorption or ingestion dangers. Additionally, your promotional materials for the omeprazole injection suspension drug product do not sufficiently communicate risk information associated with the use of the drug.\nFalse and\u002For Misleading Advertising about the FDA and the Legality of Compounded Animal Drugs\nFalse or Misleading Advertising Regarding FDA’s Animal Drug Compounding Guidance\nYour website states that your buprenorphine ER injection solution is “Compliant with GFI #256” and available for office use. This statement is false. Buprenorphine injectable polymeric matrix solution for use in rodents (e.g., mice and rats) is on the list of Bulk Drug Substances Reviewed and Not Listed. Therefore, buprenorphine ER injection solution compounded for use as office stock in rats and mice is not consistent with the recommendations in GFI #256, and your assertion otherwise is false or misleading.\nFalse or Misleading Advertising About FDA’s Oversight of Compounded Drugs\nOn your website, you make the following claim about all of your compounded tablets:\n“…All Epicur® tablets are manufactured to FDA specifications”\nThis statement is false or misleading because FDA does not review, set, or approve specifications for compounded drugs.\nFalse or Misleading Advertising About the Legality of Compounded Animal Drugs\nOn your website, you make the following claims about the legal status of animal drugs (including your drugs) compounded in a human drug outsourcing facility:\n“Available for dispensing and unlimited hospital administration FDA Federal SEC. 503B. [21 U.S.C. 353b]”\nThis statement suggests that the animal drugs listed on the page are legal for dispensing as office stock under FD&C Act section 503B, which is false, because the exemptions in section 503B do not apply to animal drugs.\n“…Buprenorphine Injection is on the do not compound List for office use under GFI #256 which means you must order compounded Buprenorphine from a 503B like Epicur! Stay FDA & DEA compliant…”\nThis statement suggests Buprenorphine Injection is legal for dispensing as office stock if produced in a 503B human drug outsourcing facility, which is false because the exemptions in section 503B do not apply to animal drugs.\nConclusion\nThis letter notifies you of our concerns and provides you with an opportunity to address them. Failure to address this matter may lead to legal action without further notice, including, without limitation, seizure and injunction.\nThis letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products or operations. It is your responsibility to ensure that your firm complies with all requirements of federal law and FDA’s implementing regulations.\nWithin fifteen (15) working days of receipt of this letter, please notify this office in writing of the specific steps you have taken to correct any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective action within fifteen (15) working days, state the reason for the delay and the time within which you will complete the correction. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration.\nPlease direct your response to U.S. Food and Drug Administration, Center for Veterinary Medicine, Office of Surveillance and Compliance, Division of Drug Compliance by email to CVMUnapprovedDrugs@fda.hhs.gov.\nSincerely,\n\u002FS\u002F\nJohnetta Walters, Ph.D.\nActing Division Director\nDivision of Drug Compliance\nOffice of Surveillance and Compliance\nCenter for Veterinary Medicine\nU.S. Food & Drug Administration\n________________________\n1 Sections 512, 571, and 572 of the FD&C Act (21 U.S.C. §§ 360b, 360ccc, 360ccc-1).\n2 Section 503B(a) of the FD&C Act exempts human drugs from the new drug approval requirements of section 505, but section 503B(a) (21 U.S.C. § 353b) omits any reference to the new animal drug approval requirements in section 512 of the FD&C Act. The exemptions in section 503B apply only to human drugs.\n3 FD&C Act sections 512(a) and 502(f) (21 U.S.C. §§ 360b(a), 352(f)).\n4 See FD&C Act section 572(c) (21 U.S.C. § 360ccc-1(c)).\n5 See FD&C Act section 201(n), 21 U.S.C. 321(n).","Stokes Healthcare Inc. dba Epicur Pharma","stokes-healthcare-inc-dba-epicur-pharma-733243-08042026","2026-10-14T12:31:16.41489+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fstokes-healthcare-inc-dba-epicur-pharma-733243-08042026","2026-11-10T01:02:16.121874+00:00","2026-09-29","733243","Animal & VeterinaryDrugs","Michael Tursi","2026-10-14T12:35:39.359+00:00","2026-08-04",{"id":149,"raw":150,"subject":155,"body_html":156,"body_text":157,"firm_name":137,"letter_id":158,"created_at":43,"fei_number":19,"letter_url":159,"updated_at":160,"action_type":22,"case_status":23,"posted_date":161,"marcs_cms_no":162,"product_type":48,"closeout_date":19,"issuing_office":154,"recipient_name":145,"body_fetched_at":163,"delivery_method":29,"recipient_title":19,"reference_number":19,"action_taken_date":164,"medical_device_id":19,"response_letter_date":19},1209,[151,152,153,154,155,13,13,13],"\u003Ctime datetime=\"2024-10-22T13:20:00Z\">10\u002F22\u002F2024\u003C\u002Ftime>\n","\u003Ctime datetime=\"2024-04-02T04:00:00Z\">04\u002F02\u002F2024\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fstokes-healthcare-inc-dba-epicur-pharma-677624-04022024\">Stokes Healthcare Inc. dba Epicur Pharma\u003C\u002Fa>","Division of Pharmaceutical Quality Operations I","Compounding Pharmacy\u002FAdulterated Drug Products","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Michael Tursi\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>CEO\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Stokes Healthcare Inc. dba Epicur Pharma\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>8000 Commerce Parkway, Suite 600\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Mount Laurel\u003C\u002Fspan>, \u003Cspan>NJ\u003C\u002Fspan> \u003Cspan>08054-2211\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:mtursi@stokespharmacy.com\"> mtursi@stokespharmacy.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Division of Pharmaceutical Quality Operations I\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER \u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>WL # 677624\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>April 2, 2024\u003C\u002Fp>\n\n\u003Cp>FEI: 3002815949\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Tursi:\u003C\u002Fp>\n\n\u003Cp>You registered your facility with the U.S. Food and Drug Administration (FDA) as an outsourcing facility under section 503B of the Federal Food, Drug, and Cosmetic Act (FDCA) [21 U.S.C. § 353b]\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> on January 30, 2018, and most recently on October 11, 2023. &nbsp;From September 26, 2023, to October 25, 2023, FDA investigators inspected your facility, Stokes Healthcare Inc. dba Epicur Pharma, located at 8000 Commerce Parkway, Suite 600, Mount Laurel, NJ 08054. &nbsp;During the inspection, the investigators collected evidence indicating that drug products you produced failed to meet the conditions of section 503B of the FDCA necessary for drugs produced by an outsourcing facility to qualify for exemptions from certain provisions of the FDCA. &nbsp;In addition, the investigators noted serious deficiencies in your practices for producing drug products intended or expected to be sterile, which put patients at risk. &nbsp; &nbsp;\u003C\u002Fp>\n\n\u003Cp>FDA issued a Form FDA 483 to your facility on October 25, 2023. &nbsp;FDA acknowledges receipt of your facility’s response, dated November 15, 2023. &nbsp;Based on this inspection, it appears you produced drugs that violate the FDCA. &nbsp;\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>A. &nbsp;Compounded Drug Products under the FDCA\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Under section 503B(b) of the FDCA, a compounder can register as an outsourcing facility with FDA. &nbsp;Drug products compounded by or under the direct supervision of a licensed pharmacist in an outsourcing facility qualify for exemptions from the drug approval requirements in section 505 of the FDCA [21 U.S.C. § 355(a)], the requirement in section 502(f)(1) of the FDCA [21 U.S.C. § 352(f)(1)] that labeling bear adequate directions for use and the Drug Supply Chain Security Act requirements in Section 582 of the FDCA [21 U.S.C. § 360eee1] if the conditions in section 503B of the FDCA are met.\u003Csup>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> &nbsp;\u003C\u002Fp>\n\n\u003Cp>An outsourcing facility, which is defined in section 503B(d)(4) of the FDCA [21 U.S.C. § 353b(d)(4)], is a facility at one geographic location or address that — (i) is engaged in the compounding of sterile drugs; (ii) has elected to register as an outsourcing facility; and (iii) complies with all of the requirements of this section. &nbsp;Outsourcing facilities must comply with other applicable provisions of the FDCA, including section 501(a)(2)(B) [21 U.S.C. § 351(a)(2)(B)], regarding current good manufacturing practice (CGMP), and section 501(a)(2)(A) [21 U.S.C. § 351(a)(2)(A)], regarding insanitary conditions. &nbsp;Generally, CGMP requirements for the preparation of drug products are established in Title 21 of the Code of Federal Regulations (CFR) parts 210 and 211.\u003C\u002Fp>\n\n\u003Cp>For a compounded drug product to qualify for the exemptions under section 503B, the labeling of the drug must include certain information (section 503B(a)(10) of the FDCA [21 U.S.C. §353b(a)(10)]). &nbsp;\u003C\u002Fp>\n\n\u003Cp>In addition, for a compounded drug product to qualify for the exemptions under section 503B, it must be compounded in an outsourcing facility that is in compliance with the registration and reporting requirements in section 503B(b), including the requirement to submit adverse event reports to FDA “in accordance with the content and format requirements established through guidance or regulation under section 310.305 of title 21, Code of Federal Regulations (or any successor &nbsp;regulations)” (section 503B(a)(1), (b)(5) of the FDCA [21 U.S.C. § 353b(a)(1), (b)(5)]). &nbsp;\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>B. &nbsp;Failure to Meet the Conditions of Section 503B\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>During the inspection, FDA investigators collected evidence indicating that drug products produced by your facility failed to meet the conditions of section 503B. &nbsp;For example, the investigators collected evidence indicating: &nbsp;\u003C\u002Fp>\n\n\u003Cp>1. Some of your facility’s drug products, such as various strengths of Tacrolimus (Aqueous) Ophthalmic Suspensions did not include the following information on the label: The quantity or proportion of each inactive ingredient. &nbsp;Additionally, some of your facility’s drug products, such as Tacrolimus (AQ) 0.5% Ophthalmic Suspension 10mL and Fluorouracil (AQ) PF 50mg\u002FmL Injection Solution 50ms, did not include the following information on the container: Information to facilitate adverse event reporting: www.fda.gov\u002Fmedwatch and 1-800-FDA-1088.&nbsp;\u003C\u002Fp>\n\n\u003Cp>2. Your facility did not submit adverse event reports to FDA in accordance with the content and format requirements established through guidance or regulation under section 310.305 of title 21, Code of Federal Regulations (or any successor regulations).\u003Csup>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> For example, your documented Standard Operating Procedures (SOPs) for reporting adverse events do not state that a follow-up report is to be submitted to FDA within 15 calendar days of receipt of new information or as requested by FDA (21 CFR 310.305(c)(2)).\u003C\u002Fp>\n\n\u003Cp>Because your compounded drug products have not met all of the conditions of section 503B, they are not eligible for the exemptions in that section from the FDA approval requirements of section 505, the requirement under section 502(f)(1) that labeling bear adequate directions for use, and the Drug Supply Chain Security Act requirements described in section 582 of the FDCA. &nbsp;\u003C\u002Fp>\n\n\u003Cp>Specific violations are described below.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>C. &nbsp;Violations of the FDCA\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Adulterated Drug Products\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>FDA investigators noted that drug products intended or expected to be sterile were prepared, packed, or held under insanitary conditions, whereby they may have become contaminated with filth or rendered injurious to health, causing your drug products to be adulterated under section 501(a)(2)(A) of the FDCA. &nbsp;For example, the investigators observed that:\u003C\u002Fp>\n\n\u003Cp>1. Your firm failed to conduct \u003Cstrong>(b)(4)\u003C\u002Fstrong> testing on \u003Cstrong>(b)(4)\u003C\u002Fstrong> used to sterilize the human drug product Fluorouracil PF. &nbsp;Therefore, you do not have assurance that the \u003Cstrong>(b)(4)\u003C\u002Fstrong> was integral throughout use. &nbsp;\u003C\u002Fp>\n\n\u003Cp>2. Your media fills were not performed under the most challenging or stressful conditions. &nbsp;Therefore, there is a lack of assurance that your firm can aseptically produce drug products within your facility. Specifically, your firm did not include higher risk production steps in your media fills, such as \u003Cstrong>(b)(4)\u003C\u002Fstrong> mixing of drug components in large vessels and \u003Cstrong>(b)(4)\u003C\u002Fstrong> to the finished drug product suspension. Additionally, sealed \u003Cstrong>(b)(4)\u003C\u002Fstrong> were used during media fills to protect media bottles during transfer from the \u003Cstrong>(b)(4)\u003C\u002Fstrong> to the ISO 5 classified critical areas, but these \u003Cstrong>(b)(4)\u003C\u002Fstrong> were not used during human drug production. &nbsp;\u003C\u002Fp>\n\n\u003Cp>3. Your firm failed to perform adequate smoke studies under dynamic conditions to demonstrate unidirectional airflow within the ISO 5 classified critical area, in that you did not include production steps that may impede airflow such as mixing drug lots in \u003Cstrong>(b)(4)\u003C\u002Fstrong> vessels. Therefore, your products intended to be sterile are produced in an environment that may not provide adequate protection against the risk of contamination. &nbsp;\u003C\u002Fp>\n\n\u003Cp>4. Your firm failed to ensure an adequate contact time for your sporicidal agent used to disinfect your aseptic processing areas. &nbsp;According to the \u003Cstrong>(b)(4)\u003C\u002Fstrong> label, the required dwell time for \u003Cstrong>(b)(4)\u003C\u002Fstrong> is \u003Cstrong>(b)(4)\u003C\u002Fstrong>, but your firm's SOP only requires a \u003Cstrong>(b)(4)\u003C\u002Fstrong> dwell time. &nbsp;Further, the investigators observed that a \u003Cstrong>(b)(4)\u003C\u002Fstrong> dwell time is not always achieved during cleaning and disinfection. &nbsp;\u003C\u002Fp>\n\n\u003Cp>FDA investigators also noted CGMP violations at your facility, that caused your drug products to be adulterated within the meaning of section 501(a)(2)(B) of the FDCA. &nbsp;The violations include, for example:\u003C\u002Fp>\n\n\u003Cp>1. Your firm failed to establish written responsibilities and procedures applicable to the quality control unit and to follow such written procedures (21 CFR 211.22(d)).\u003C\u002Fp>\n\n\u003Cp>2. Your firm failed to establish an adequate quality control unit with the responsibility and authority to approve or reject all components, drug product containers, closures, in-process materials, packaging materials, labeling, and drug products (21 CFR 211.22(a)).\u003C\u002Fp>\n\n\u003Cp>3. Your firm’s quality control unit failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).\u003C\u002Fp>\n\n\u003Cp>4. Your firm failed to establish written procedures for production and process control designed to assure that the drug products you manufacture have the identity, strength, quality, and purity they purport or are represented to possess (21 CFR 211.100(a)).\u003C\u002Fp>\n\n\u003Cp>5. Your firm failed to establish laboratory controls that include scientifically sound and appropriate specifications, standards, sampling plans, and test procedures designed to assure that components, drug product containers, closures, in-process materials, labeling, and drug products conform to appropriate standards of identity, strength, quality, and purity (21 CFR 211.160(b)).\u003C\u002Fp>\n\n\u003Cp>6. Your firm failed to establish and follow appropriate written procedures that are designed to prevent microbiological contamination of drug products purporting to be sterile, and that include validation of all aseptic and sterilization processes (21 CFR 211.113(b)).\u003C\u002Fp>\n\n\u003Cp>7. Your firm failed to establish an adequate system for monitoring environmental conditions in aseptic processing areas (21 CFR 211.42(c)(10)(iv)).\u003C\u002Fp>\n\n\u003Cp>8. Your firm failed to establish an adequate air supply filtered through high-efficiency particulate air filters under positive pressure in the aseptic processing areas (21 CFR 211.42(c)(10)(iii)).\u003C\u002Fp>\n\n\u003Cp>9. Your firm failed to establish an adequate system for cleaning and disinfecting the room and equipment to produce aseptic conditions (21 CFR 211.42(c)(10)(v)).\u003C\u002Fp>\n\n\u003Cp>Outsourcing facilities must comply with CGMP requirements under section 501(a)(2)(B) of the FDCA. &nbsp;FDA’s regulations regarding CGMP requirements for the preparation of drug products have been established in 21 CFR parts 210 and 211. &nbsp;FDA intends to promulgate more specific CGMP regulations for outsourcing facilities. &nbsp;FDA has issued a revised draft guidance, \u003Cem>Current Good Manufacturing Practice — Guidance for Human Drug Compounding Outsourcing Facilities under Section 503B of the FD&amp;C Act\u003C\u002Fem>. &nbsp;This draft guidance, when finalized, will describe FDA’s expectations regarding outsourcing facilities and the CGMP requirements in 21 CFR parts 210 and 211 until more specific CGMP regulations for outsourcing facilities are promulgated. &nbsp;\u003C\u002Fp>\n\n\u003Cp>It is a prohibited act under section 301(k) of the FDCA [21 U.S.C. § 331(k)] to do any act with respect to a drug, if such act is done while the drug is held for sale after shipment in interstate commerce and results in the drug being adulterated.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Misbranded Drug Products\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>You compound drug products that are intended for conditions not amenable to self-diagnosis and treatment by individuals who are not medical practitioners; therefore, adequate directions for use cannot be written so that a layman can use these products safely for their intended uses. &nbsp;Consequently, their labeling fails to bear adequate directions for their intended uses causing them to be misbranded under section 502(f)(1) of the FDCA.\u003Csup>\u003Cem>\u003Cstrong>4\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> &nbsp;It is a prohibited act under section 301(k) of the FDCA to do any act with respect to a drug, if such act is done while the drug is held for sale after shipment in interstate commerce and results in the drug being misbranded.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>D. &nbsp;Corrective Actions\u003C\u002Fstrong> &nbsp;\u003C\u002Fp>\n\n\u003Cp>We have reviewed your facility’s responses to the Form FDA 483. &nbsp;\u003C\u002Fp>\n\n\u003Cp>Regarding your responses related to the insanitary conditions and CGMP violations, some of your proposed corrective actions appear adequate. &nbsp;However, the following corrective actions appear deficient:\u003C\u002Fp>\n\n\u003Cp>1. In your response regarding your Quality Unit failing to prevent numerous significant deficiencies, you did not assess the need and develop plans to strengthen quality oversight to ensure deficiencies do not reoccur. &nbsp;\u003C\u002Fp>\n\n\u003Cp>2. Concerning the release of non-conforming human drug products, you did not commit to improving Quality Unit training and oversight to prevent recurrence. &nbsp;Additionally, your response did not consider the unsuitability of:\u003C\u002Fp>\n\n\u003Cp>&nbsp; a. Modifying the potency test method to obtain passing potency results without scientific justification and revalidation, and without assessing the impact of these changes on the accuracy of the potency results for all previously distributed batches within expiry; &nbsp;\u003C\u002Fp>\n\n\u003Cp>&nbsp; b. Invalidating original potency results based on resampling results without scientific justification. &nbsp;\u003C\u002Fp>\n\n\u003Cp>3. Regarding process validation for your human drug products, you stated that you would execute the necessary validations; however, you did not perform a risk assessment to determine the impact of failing to perform process validations on the quality of the drug products that you previously and continue to distribute. &nbsp;Additionally, you did not provide validation plans or executed validation studies for FDA’s evaluation. &nbsp;\u003C\u002Fp>\n\n\u003Cp>4. In your response, you provided an executed potency test method validation protocol for your Tacrolimus AQ human drug products; however, this test method remains unvalidated because the validation study:\u003C\u002Fp>\n\n\u003Cp>&nbsp; a. Lacked scientific rationale to justify establishing some of the relative standard deviations limits at \u003Cstrong>(b)(4)\u003C\u002Fstrong>; &nbsp;\u003C\u002Fp>\n\n\u003Cp>&nbsp; b. Documented significant intra-batch potency variability; &nbsp;\u003C\u002Fp>\n\n\u003Cp>&nbsp; c. Did not record chromatography column temperature information for specificity, limit of quantification, limit of detection, linearity, accuracy, precision, intermediate precision, and stability testing; &nbsp;\u003C\u002Fp>\n\n\u003Cp>&nbsp; d. Concluded that the analytical results meet all acceptance criteria, although some sample results failed to meet specifications. &nbsp;\u003C\u002Fp>\n\n\u003Cp>Additionally, you did not consider the impact of these test method changes on the accuracy of the potency results for all previously distributed batches within expiry. &nbsp;\u003C\u002Fp>\n\n\u003Cp>5. In your response, you commit to completing new media fill studies; however, the provided media fill protocol does not include simulating the high-risk step of \u003Cstrong>(b)(4)\u003C\u002Fstrong> drug product suspension. &nbsp;\u003C\u002Fp>\n\n\u003Cp>6. In your response, you stated that you provided a smoke study capturing the missing production activities cited in the FDA observation. &nbsp;However, our review of this new smoke study finds it to be inadequate because it does not include simulating the higher risk production steps of diluting and mixing the drug components using large volume vessels. &nbsp;\u003C\u002Fp>\n\n\u003Cp>7. Regarding your environmental monitoring program response, you indicated in your response that historical data will be used to justify sampling locations; however, you have not performed a risk assessment to determine if historical sampling sites meaningfully represent high risk operating conditions. &nbsp;Further, you did not provide the referenced change control CC-23-021 or details about your proposed risk assessment. &nbsp;\u003C\u002Fp>\n\n\u003Cp>8. In your response, you stated that your firm’s media fill studies, smoke studies, and environmental monitoring program are supporting indicators that your HEPA filter airflow velocities are adequate; however, the current FDA inspection found deficiencies in each of these areas. As such, you have not provided scientific evidence to demonstrate that the wide ranges of airflow velocities generated by your HEPA filters do not adversely impact the airflow patterns inside your ISO 5 classified critical areas.\u003C\u002Fp>\n\n\u003Cp>9. &nbsp;You did not provide a response regarding your investigations failing to include root cause analysis and extension to other lots that may have been associated.\u003C\u002Fp>\n\n\u003Cp>Additionally, we are unable to fully evaluate some of your corrective actions due to lack of adequate supporting documentation: &nbsp;\u003C\u002Fp>\n\n\u003Cp>1. In your response, you commit to improving the timely closing of your investigations; however, you did not provide the referenced revised standard operating procedures and the Interim Status Report form. &nbsp;\u003C\u002Fp>\n\n\u003Cp>2. In your response, you commit to performing \u003Cstrong>(b)(4)\u003C\u002Fstrong> testing; however, your firm did not provide evidence that you have purchased the referenced \u003Cstrong>(b)(4)\u003C\u002Fstrong> Tester, or revised your standard operating procedures and master batch records. &nbsp;Additionally, while you stated you would perform additional sterility testing, the sterility test in itself is not indicative that the batch is sterile, because when contamination is present, it is not uniformly distributed throughout the batch. &nbsp;Therefore, aseptic processing controls, such as \u003Cstrong>(b)(4)\u003C\u002Fstrong> testing, are critical for ensuring the sterility of the finished drug products. &nbsp;\u003C\u002Fp>\n\n\u003Cp>3. We acknowledge that you commit to performing a disinfection efficacy study; however, you did not provide information about the study goals and the protocol details. &nbsp;\u003C\u002Fp>\n\n\u003Cp>Furthermore, our review of data collected during the inspection revealed that your firm detected an adverse trend of \u003Cem>Mucor circinelloides\u003C\u002Fem> fungal contamination between November 3, 2022, and July 10, 2023, in your ISO 8 classified cleanrooms C715, C711, and C735. &nbsp;The \u003Cstrong>(b)(4)\u003C\u002Fstrong> located in cleanroom C715 is used to sterilize the drug components for Tacrolimus AQ, a human drug product intended to be sterile, which are then transported through C711 and C735 on route to the cleanrooms C704 and C706 where aseptic mixing and filling operations occur. &nbsp;Your Quality Unit did not investigate this adverse trend to determine and correct the root cause of the contamination and the impact the contamination may have had on the human drug product components that were exposed to these cleanrooms, and instead produced and distributed \u003Cstrong>(b)(4)\u003C\u002Fstrong> lots of Tacrolimus AQ during this period. &nbsp;\u003C\u002Fp>\n\n\u003Cp>In addition to the issues discussed above, you should note that CGMP requires the implementation of quality oversight and controls over the manufacture of drugs, including the safety of raw materials, materials used in drug manufacturing, and finished drug products. See section 501 of the FDCA. &nbsp;If you choose to contract with a laboratory to perform some functions required by CGMP, it is essential that you select a qualified contractor and that you maintain sufficient oversight of the contractor’s operations to ensure that it is fully CGMP compliant. &nbsp;Regardless of whether you rely on a contract facility, you are responsible for assuring that drugs you produce are neither adulterated nor misbranded. &nbsp;[See 21 CFR 210.1(b), 21 CFR 200.10(b).]\u003C\u002Fp>\n\n\u003Cp>In addition, regarding observations related to the conditions of section 503B of the FDCA, some of your corrective actions appear adequate: You state that the adverse event reporting information will be added to the packaging for the drug product. &nbsp;\u003C\u002Fp>\n\n\u003Cp>You did not address certain observations related to the conditions of section 503B of the FDCA, for example: You state that you list inactive ingredients proportionally from largest to smallest on your product labels and that each label states “INACTIVE(S) (proportional from largest to smallest amount)”, but such a list does not provide the quantity or proportion of each inactive ingredient. &nbsp;\u003C\u002Fp>\n\n\u003Cp>With respect to your documented SOPs for reporting adverse events, FDA expects to evaluate compliance with section 503B(b)(5) of the FDCA upon reviewing any updated copy of your adverse event reporting SOPs that you submit in response to this letter. &nbsp;\u003C\u002Fp>\n\n\u003Cp>Should you continue to compound and distribute drug products that do not meet the conditions of section 503B, the compounding and distribution of your drugs would be subject to the new drug approval requirement, the requirement to label drug products with adequate directions for use, and the Drug Supply Chain Security Act requirements. &nbsp;\u003C\u002Fp>\n\n\u003Cp>FDA strongly recommends that your management undertake a comprehensive assessment of operations, including facility design, procedures, personnel, processes, maintenance, materials, and systems. &nbsp;In particular, this review should assess your aseptic processing operations. &nbsp;A third-party consultant with relevant sterile drug manufacturing expertise should assist you in conducting this comprehensive evaluation. &nbsp;\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>E. &nbsp;Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The violations cited in this letter are not intended to be an all-inclusive statement of violations at your facility. &nbsp;You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. &nbsp;It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\n\n\u003Cp>You should take prompt action to address any violations. &nbsp;Failure to adequately address any violations may result in legal action without further notice, including, without limitation, seizure and injunction. &nbsp;\u003C\u002Fp>\n\n\u003Cp>Within fifteen (15) working days of receipt of this letter, please notify this office in writing of the specific steps that you have taken to address any violations. &nbsp;Please include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. &nbsp;This letter notifies you of our concerns and provides you an opportunity to address them. &nbsp;If you believe your products are not in violation of the FDCA, include your reasoning and any supporting information for our consideration. &nbsp;If you cannot completely address this matter within fifteen (15) working days, state the reason for the delay and the time within which you will do so. &nbsp;\u003C\u002Fp>\n\n\u003Cp>Your written notification should refer to the Warning Letter Number above (\u003Cstrong>WL #677624\u003C\u002Fstrong>). Please address your reply to: CAPT Liatte Closs, Acting Director of Compliance, orapharm1_responses@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>If you have questions regarding the contents of this letter, please contact Compliance Officer, Juan Jimenez, at orapharm1_responses@fda.hhs.gov and juan.jimenez@fda.hhs.gov or at 973-832-9409. Please identify your communications with \u003Cstrong>FEI: 3002815949\u003C\u002Fstrong>.\u003C\u002Fp>\n\n\u003Cp>We appreciate your acknowledgement in receipt of this communication.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003Cbr>\nLisa Harlan\u003Cbr>\nProgram Division Director\u003Cbr>\nOffice of Pharmaceutical Quality Operations Division I &nbsp;\u003C\u002Fp>\n\n\u003Cp>_________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1&nbsp;\u003C\u002Fstrong>\u003C\u002Fem>See Pub. L. No. 113-54, § 102(a), 127 Stat. 587, 587-588 (2013).\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>2&nbsp;\u003C\u002Fstrong>\u003C\u002Fem>We remind you that there are conditions, other than those discussed in this letter, that must be satisfied to qualify for the exemptions in section 503B of the FDCA.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>3&nbsp;\u003C\u002Fstrong>\u003C\u002Fem>For more information, see, FDA’s guidance, “Adverse Event Reporting for Outsourcing Facilities Under Section 503B of the Federal Food, Drug, and Cosmetic Act,” which can be found at https:\u002F\u002Fwww.fda.gov\u002Fdownloads\u002FDrugs\u002FGuidanceComplianceRegulatoryInformation\u002FGuidances\u002FUCM434188.pdf.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>4&nbsp;\u003C\u002Fstrong>\u003C\u002Fem>Your compounded drug products are not exempted from the requirements of section 502(f)(1) of the FDCA by regulations issued by the FDA (see, e.g., 21 CFR 201.115).\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMichael Tursi\n\nRecipient Title\n\nCEO\n\nStokes Healthcare Inc. dba Epicur Pharma\n\n8000 Commerce Parkway, Suite 600\n\nMount Laurel, NJ 08054-2211\n\nUnited States\n\nmtursi@stokespharmacy.com\n\nIssuing Office:\n\nDivision of Pharmaceutical Quality Operations I\n\nUnited States\n\nWARNING LETTER\n\nWL # 677624\n\nApril 2, 2024\n\nFEI: 3002815949\n\nDear Mr. Tursi:\n\nYou registered your facility with the U.S. Food and Drug Administration (FDA) as an outsourcing facility under section 503B of the Federal Food, Drug, and Cosmetic Act (FDCA) [21 U.S.C. § 353b]1 on January 30, 2018, and most recently on October 11, 2023. From September 26, 2023, to October 25, 2023, FDA investigators inspected your facility, Stokes Healthcare Inc. dba Epicur Pharma, located at 8000 Commerce Parkway, Suite 600, Mount Laurel, NJ 08054. During the inspection, the investigators collected evidence indicating that drug products you produced failed to meet the conditions of section 503B of the FDCA necessary for drugs produced by an outsourcing facility to qualify for exemptions from certain provisions of the FDCA. In addition, the investigators noted serious deficiencies in your practices for producing drug products intended or expected to be sterile, which put patients at risk.\n\nFDA issued a Form FDA 483 to your facility on October 25, 2023. FDA acknowledges receipt of your facility’s response, dated November 15, 2023. Based on this inspection, it appears you produced drugs that violate the FDCA.\n\nA. Compounded Drug Products under the FDCA\n\nUnder section 503B(b) of the FDCA, a compounder can register as an outsourcing facility with FDA. Drug products compounded by or under the direct supervision of a licensed pharmacist in an outsourcing facility qualify for exemptions from the drug approval requirements in section 505 of the FDCA [21 U.S.C. § 355(a)], the requirement in section 502(f)(1) of the FDCA [21 U.S.C. § 352(f)(1)] that labeling bear adequate directions for use and the Drug Supply Chain Security Act requirements in Section 582 of the FDCA [21 U.S.C. § 360eee1] if the conditions in section 503B of the FDCA are met.2\n\nAn outsourcing facility, which is defined in section 503B(d)(4) of the FDCA [21 U.S.C. § 353b(d)(4)], is a facility at one geographic location or address that — (i) is engaged in the compounding of sterile drugs; (ii) has elected to register as an outsourcing facility; and (iii) complies with all of the requirements of this section. Outsourcing facilities must comply with other applicable provisions of the FDCA, including section 501(a)(2)(B) [21 U.S.C. § 351(a)(2)(B)], regarding current good manufacturing practice (CGMP), and section 501(a)(2)(A) [21 U.S.C. § 351(a)(2)(A)], regarding insanitary conditions. Generally, CGMP requirements for the preparation of drug products are established in Title 21 of the Code of Federal Regulations (CFR) parts 210 and 211.\n\nFor a compounded drug product to qualify for the exemptions under section 503B, the labeling of the drug must include certain information (section 503B(a)(10) of the FDCA [21 U.S.C. §353b(a)(10)]).\n\nIn addition, for a compounded drug product to qualify for the exemptions under section 503B, it must be compounded in an outsourcing facility that is in compliance with the registration and reporting requirements in section 503B(b), including the requirement to submit adverse event reports to FDA “in accordance with the content and format requirements established through guidance or regulation under section 310.305 of title 21, Code of Federal Regulations (or any successor regulations)” (section 503B(a)(1), (b)(5) of the FDCA [21 U.S.C. § 353b(a)(1), (b)(5)]).\n\nB. Failure to Meet the Conditions of Section 503B\n\nDuring the inspection, FDA investigators collected evidence indicating that drug products produced by your facility failed to meet the conditions of section 503B. For example, the investigators collected evidence indicating:\n\n1. Some of your facility’s drug products, such as various strengths of Tacrolimus (Aqueous) Ophthalmic Suspensions did not include the following information on the label: The quantity or proportion of each inactive ingredient. Additionally, some of your facility’s drug products, such as Tacrolimus (AQ) 0.5% Ophthalmic Suspension 10mL and Fluorouracil (AQ) PF 50mg\u002FmL Injection Solution 50ms, did not include the following information on the container: Information to facilitate adverse event reporting: www.fda.gov\u002Fmedwatch and 1-800-FDA-1088.\n\n2. Your facility did not submit adverse event reports to FDA in accordance with the content and format requirements established through guidance or regulation under section 310.305 of title 21, Code of Federal Regulations (or any successor regulations).3 For example, your documented Standard Operating Procedures (SOPs) for reporting adverse events do not state that a follow-up report is to be submitted to FDA within 15 calendar days of receipt of new information or as requested by FDA (21 CFR 310.305(c)(2)).\n\nBecause your compounded drug products have not met all of the conditions of section 503B, they are not eligible for the exemptions in that section from the FDA approval requirements of section 505, the requirement under section 502(f)(1) that labeling bear adequate directions for use, and the Drug Supply Chain Security Act requirements described in section 582 of the FDCA.\n\nSpecific violations are described below.\n\nC. Violations of the FDCA\n\nAdulterated Drug Products\n\nFDA investigators noted that drug products intended or expected to be sterile were prepared, packed, or held under insanitary conditions, whereby they may have become contaminated with filth or rendered injurious to health, causing your drug products to be adulterated under section 501(a)(2)(A) of the FDCA. For example, the investigators observed that:\n\n1. Your firm failed to conduct (b)(4) testing on (b)(4) used to sterilize the human drug product Fluorouracil PF. Therefore, you do not have assurance that the (b)(4) was integral throughout use.\n\n2. Your media fills were not performed under the most challenging or stressful conditions. Therefore, there is a lack of assurance that your firm can aseptically produce drug products within your facility. Specifically, your firm did not include higher risk production steps in your media fills, such as (b)(4) mixing of drug components in large vessels and (b)(4) to the finished drug product suspension. Additionally, sealed (b)(4) were used during media fills to protect media bottles during transfer from the (b)(4) to the ISO 5 classified critical areas, but these (b)(4) were not used during human drug production.\n\n3. Your firm failed to perform adequate smoke studies under dynamic conditions to demonstrate unidirectional airflow within the ISO 5 classified critical area, in that you did not include production steps that may impede airflow such as mixing drug lots in (b)(4) vessels. Therefore, your products intended to be sterile are produced in an environment that may not provide adequate protection against the risk of contamination.\n\n4. Your firm failed to ensure an adequate contact time for your sporicidal agent used to disinfect your aseptic processing areas. According to the (b)(4) label, the required dwell time for (b)(4) is (b)(4), but your firm's SOP only requires a (b)(4) dwell time. Further, the investigators observed that a (b)(4) dwell time is not always achieved during cleaning and disinfection.\n\nFDA investigators also noted CGMP violations at your facility, that caused your drug products to be adulterated within the meaning of section 501(a)(2)(B) of the FDCA. The violations include, for example:\n\n1. Your firm failed to establish written responsibilities and procedures applicable to the quality control unit and to follow such written procedures (21 CFR 211.22(d)).\n\n2. Your firm failed to establish an adequate quality control unit with the responsibility and authority to approve or reject all components, drug product containers, closures, in-process materials, packaging materials, labeling, and drug products (21 CFR 211.22(a)).\n\n3. Your firm’s quality control unit failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).\n\n4. Your firm failed to establish written procedures for production and process control designed to assure that the drug products you manufacture have the identity, strength, quality, and purity they purport or are represented to possess (21 CFR 211.100(a)).\n\n5. Your firm failed to establish laboratory controls that include scientifically sound and appropriate specifications, standards, sampling plans, and test procedures designed to assure that components, drug product containers, closures, in-process materials, labeling, and drug products conform to appropriate standards of identity, strength, quality, and purity (21 CFR 211.160(b)).\n\n6. Your firm failed to establish and follow appropriate written procedures that are designed to prevent microbiological contamination of drug products purporting to be sterile, and that include validation of all aseptic and sterilization processes (21 CFR 211.113(b)).\n\n7. Your firm failed to establish an adequate system for monitoring environmental conditions in aseptic processing areas (21 CFR 211.42(c)(10)(iv)).\n\n8. Your firm failed to establish an adequate air supply filtered through high-efficiency particulate air filters under positive pressure in the aseptic processing areas (21 CFR 211.42(c)(10)(iii)).\n\n9. Your firm failed to establish an adequate system for cleaning and disinfecting the room and equipment to produce aseptic conditions (21 CFR 211.42(c)(10)(v)).\n\nOutsourcing facilities must comply with CGMP requirements under section 501(a)(2)(B) of the FDCA. FDA’s regulations regarding CGMP requirements for the preparation of drug products have been established in 21 CFR parts 210 and 211. FDA intends to promulgate more specific CGMP regulations for outsourcing facilities. FDA has issued a revised draft guidance, Current Good Manufacturing Practice — Guidance for Human Drug Compounding Outsourcing Facilities under Section 503B of the FD&C Act. This draft guidance, when finalized, will describe FDA’s expectations regarding outsourcing facilities and the CGMP requirements in 21 CFR parts 210 and 211 until more specific CGMP regulations for outsourcing facilities are promulgated.\n\nIt is a prohibited act under section 301(k) of the FDCA [21 U.S.C. § 331(k)] to do any act with respect to a drug, if such act is done while the drug is held for sale after shipment in interstate commerce and results in the drug being adulterated.\n\nMisbranded Drug Products\n\nYou compound drug products that are intended for conditions not amenable to self-diagnosis and treatment by individuals who are not medical practitioners; therefore, adequate directions for use cannot be written so that a layman can use these products safely for their intended uses. Consequently, their labeling fails to bear adequate directions for their intended uses causing them to be misbranded under section 502(f)(1) of the FDCA.4 It is a prohibited act under section 301(k) of the FDCA to do any act with respect to a drug, if such act is done while the drug is held for sale after shipment in interstate commerce and results in the drug being misbranded.\n\nD. Corrective Actions\n\nWe have reviewed your facility’s responses to the Form FDA 483.\n\nRegarding your responses related to the insanitary conditions and CGMP violations, some of your proposed corrective actions appear adequate. However, the following corrective actions appear deficient:\n\n1. In your response regarding your Quality Unit failing to prevent numerous significant deficiencies, you did not assess the need and develop plans to strengthen quality oversight to ensure deficiencies do not reoccur.\n\n2. Concerning the release of non-conforming human drug products, you did not commit to improving Quality Unit training and oversight to prevent recurrence. Additionally, your response did not consider the unsuitability of:\n\na. Modifying the potency test method to obtain passing potency results without scientific justification and revalidation, and without assessing the impact of these changes on the accuracy of the potency results for all previously distributed batches within expiry;\n\nb. Invalidating original potency results based on resampling results without scientific justification.\n\n3. Regarding process validation for your human drug products, you stated that you would execute the necessary validations; however, you did not perform a risk assessment to determine the impact of failing to perform process validations on the quality of the drug products that you previously and continue to distribute. Additionally, you did not provide validation plans or executed validation studies for FDA’s evaluation.\n\n4. In your response, you provided an executed potency test method validation protocol for your Tacrolimus AQ human drug products; however, this test method remains unvalidated because the validation study:\n\na. Lacked scientific rationale to justify establishing some of the relative standard deviations limits at (b)(4);\n\nb. Documented significant intra-batch potency variability;\n\nc. Did not record chromatography column temperature information for specificity, limit of quantification, limit of detection, linearity, accuracy, precision, intermediate precision, and stability testing;\n\nd. Concluded that the analytical results meet all acceptance criteria, although some sample results failed to meet specifications.\n\nAdditionally, you did not consider the impact of these test method changes on the accuracy of the potency results for all previously distributed batches within expiry.\n\n5. In your response, you commit to completing new media fill studies; however, the provided media fill protocol does not include simulating the high-risk step of (b)(4) drug product suspension.\n\n6. In your response, you stated that you provided a smoke study capturing the missing production activities cited in the FDA observation. However, our review of this new smoke study finds it to be inadequate because it does not include simulating the higher risk production steps of diluting and mixing the drug components using large volume vessels.\n\n7. Regarding your environmental monitoring program response, you indicated in your response that historical data will be used to justify sampling locations; however, you have not performed a risk assessment to determine if historical sampling sites meaningfully represent high risk operating conditions. Further, you did not provide the referenced change control CC-23-021 or details about your proposed risk assessment.\n\n8. In your response, you stated that your firm’s media fill studies, smoke studies, and environmental monitoring program are supporting indicators that your HEPA filter airflow velocities are adequate; however, the current FDA inspection found deficiencies in each of these areas. As such, you have not provided scientific evidence to demonstrate that the wide ranges of airflow velocities generated by your HEPA filters do not adversely impact the airflow patterns inside your ISO 5 classified critical areas.\n\n9. You did not provide a response regarding your investigations failing to include root cause analysis and extension to other lots that may have been associated.\n\nAdditionally, we are unable to fully evaluate some of your corrective actions due to lack of adequate supporting documentation:\n\n1. In your response, you commit to improving the timely closing of your investigations; however, you did not provide the referenced revised standard operating procedures and the Interim Status Report form.\n\n2. In your response, you commit to performing (b)(4) testing; however, your firm did not provide evidence that you have purchased the referenced (b)(4) Tester, or revised your standard operating procedures and master batch records. Additionally, while you stated you would perform additional sterility testing, the sterility test in itself is not indicative that the batch is sterile, because when contamination is present, it is not uniformly distributed throughout the batch. Therefore, aseptic processing controls, such as (b)(4) testing, are critical for ensuring the sterility of the finished drug products.\n\n3. We acknowledge that you commit to performing a disinfection efficacy study; however, you did not provide information about the study goals and the protocol details.\n\nFurthermore, our review of data collected during the inspection revealed that your firm detected an adverse trend of Mucor circinelloides fungal contamination between November 3, 2022, and July 10, 2023, in your ISO 8 classified cleanrooms C715, C711, and C735. The (b)(4) located in cleanroom C715 is used to sterilize the drug components for Tacrolimus AQ, a human drug product intended to be sterile, which are then transported through C711 and C735 on route to the cleanrooms C704 and C706 where aseptic mixing and filling operations occur. Your Quality Unit did not investigate this adverse trend to determine and correct the root cause of the contamination and the impact the contamination may have had on the human drug product components that were exposed to these cleanrooms, and instead produced and distributed (b)(4) lots of Tacrolimus AQ during this period.\n\nIn addition to the issues discussed above, you should note that CGMP requires the implementation of quality oversight and controls over the manufacture of drugs, including the safety of raw materials, materials used in drug manufacturing, and finished drug products. See section 501 of the FDCA. If you choose to contract with a laboratory to perform some functions required by CGMP, it is essential that you select a qualified contractor and that you maintain sufficient oversight of the contractor’s operations to ensure that it is fully CGMP compliant. Regardless of whether you rely on a contract facility, you are responsible for assuring that drugs you produce are neither adulterated nor misbranded. [See 21 CFR 210.1(b), 21 CFR 200.10(b).]\n\nIn addition, regarding observations related to the conditions of section 503B of the FDCA, some of your corrective actions appear adequate: You state that the adverse event reporting information will be added to the packaging for the drug product.\n\nYou did not address certain observations related to the conditions of section 503B of the FDCA, for example: You state that you list inactive ingredients proportionally from largest to smallest on your product labels and that each label states “INACTIVE(S) (proportional from largest to smallest amount)”, but such a list does not provide the quantity or proportion of each inactive ingredient.\n\nWith respect to your documented SOPs for reporting adverse events, FDA expects to evaluate compliance with section 503B(b)(5) of the FDCA upon reviewing any updated copy of your adverse event reporting SOPs that you submit in response to this letter.\n\nShould you continue to compound and distribute drug products that do not meet the conditions of section 503B, the compounding and distribution of your drugs would be subject to the new drug approval requirement, the requirement to label drug products with adequate directions for use, and the Drug Supply Chain Security Act requirements.\n\nFDA strongly recommends that your management undertake a comprehensive assessment of operations, including facility design, procedures, personnel, processes, maintenance, materials, and systems. In particular, this review should assess your aseptic processing operations. A third-party consultant with relevant sterile drug manufacturing expertise should assist you in conducting this comprehensive evaluation.\n\nE. Conclusion\n\nThe violations cited in this letter are not intended to be an all-inclusive statement of violations at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\n\nYou should take prompt action to address any violations. Failure to adequately address any violations may result in legal action without further notice, including, without limitation, seizure and injunction.\n\nWithin fifteen (15) working days of receipt of this letter, please notify this office in writing of the specific steps that you have taken to address any violations. Please include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. This letter notifies you of our concerns and provides you an opportunity to address them. If you believe your products are not in violation of the FDCA, include your reasoning and any supporting information for our consideration. If you cannot completely address this matter within fifteen (15) working days, state the reason for the delay and the time within which you will do so.\n\nYour written notification should refer to the Warning Letter Number above (WL #677624). Please address your reply to: CAPT Liatte Closs, Acting Director of Compliance, orapharm1_responses@fda.hhs.gov.\n\nIf you have questions regarding the contents of this letter, please contact Compliance Officer, Juan Jimenez, at orapharm1_responses@fda.hhs.gov and juan.jimenez@fda.hhs.gov or at 973-832-9409. Please identify your communications with FEI: 3002815949.\n\nWe appreciate your acknowledgement in receipt of this communication.\n\nSincerely,\n\n\u002FS\u002F\n\nLisa Harlan\n\nProgram Division Director\n\nOffice of Pharmaceutical Quality Operations Division I\n\n_________________\n\n1 See Pub. L. No. 113-54, § 102(a), 127 Stat. 587, 587-588 (2013).\n\n2 We remind you that there are conditions, other than those discussed in this letter, that must be satisfied to qualify for the exemptions in section 503B of the FDCA.\n\n3 For more information, see, FDA’s guidance, “Adverse Event Reporting for Outsourcing Facilities Under Section 503B of the Federal Food, Drug, and Cosmetic Act,” which can be found at https:\u002F\u002Fwww.fda.gov\u002Fdownloads\u002FDrugs\u002FGuidanceComplianceRegulatoryInformation\u002FGuidances\u002FUCM434188.pdf.\n\n4 Your compounded drug products are not exempted from the requirements of section 502(f)(1) of the FDCA by regulations issued by the FDA (see, e.g., 21 CFR 201.115).","stokes-healthcare-inc-dba-epicur-pharma-677624-04022024","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fstokes-healthcare-inc-dba-epicur-pharma-677624-04022024","2026-10-26T08:10:06.14804+00:00","2024-10-22","677624","2026-08-19T22:17:46.429+00:00","2024-04-02",{"id":166,"raw":167,"subject":83,"body_html":172,"body_text":173,"firm_name":174,"letter_id":175,"created_at":18,"fei_number":19,"letter_url":176,"updated_at":177,"action_type":22,"case_status":23,"posted_date":178,"marcs_cms_no":179,"product_type":48,"closeout_date":19,"issuing_office":37,"recipient_name":19,"body_fetched_at":180,"delivery_method":73,"recipient_title":19,"reference_number":19,"action_taken_date":181,"medical_device_id":19,"response_letter_date":19},96,[168,169,170,37,171,13,13,13],"\u003Ctime datetime=\"2026-06-16T04:00:00Z\">06\u002F16\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-06-08T04:00:00Z\">06\u002F08\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Ftrinity-healthcare-supply-llc-dba-altrx-728236-06082026\">Trinity HealthCare Supply, LLC dba altRx\u003C\u002Fa>","False &amp; Misleading Claims\u002FMisbranded (Telehealth)\u003Cbr \u002F>\r\n","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA ELECTRONIC MAIL READ\u002FDELIVERY RECEIPT REQUESTED\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\u003C\u002Fdd>\n                    \n            \u003Cdd>Trinity HealthCare Supply, LLC dba altRx\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>3206 NE 2nd Ave, Suite 3013\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Miami\u003C\u002Fspan>, \u003Cspan>FL\u003C\u002Fspan> \u003Cspan>33137\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:help@altrx.com\"> help@altrx.com \u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>June 8, 2026\u003C\u002Fp>\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003Cbr>Reference number: MARCS-CMS 728236\u003C\u002Fp>\u003Cp>To altRx:\u003C\u002Fp>\u003Cp>This warning letter advises you of significant violations identified during a U.S. Food and Drug Administration (FDA) review of your website. Promptly address the violations described herein without delay, including ensuring that appropriate resources are allocated to fully address the violations and prevent their recurrence. The violations cited in this letter are not intended to be an all-inclusive list of violations that may exist in connection with your products. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations. Failure to adequately address any violations may result in legal action without further notice, including, without limitation, seizure and injunction.\u003C\u002Fp>\u003Cp>\u003Cstrong>FDA Review\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Violations were identified and documented during a review of altRx’s website, https:\u002F\u002Fwww.altrx.com, FDA Establishment Identifier (FEI) 3044175714, in May 2026. FDA observed that your website offers compounded drug products, including semaglutide and tirzepatide products.\u003Cem>\u003Cstrong>\u003Csup>1\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> As described below, your website’s false or misleading claims concerning compounded semaglutide and tirzepatide products under sections 502(a) and 502(bb) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) [21 U.S.C. §§ 352(a) and 352(bb)], result in products being introduced or delivered for introduction into interstate commerce in violation of section 301(a) of the FD&amp;C Act [21 U.S.C. § 331(a)]. This review was conducted under FDA’s public health responsibilities to protect the public from unsafe, ineffective, and poor quality drug products.\u003C\u002Fp>\u003Cp>\u003Cstrong>Violations of the Federal Food, Drug, and Cosmetic Act\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The following are violations identified during our review. As a reminder, this is not an all-inclusive list of violations that may exist in connection with your products or operations.\u003C\u002Fp>\u003Cp>Your representations regarding compounded semaglutide and tirzepatide products are false or misleading. Under section 502(a) of the FD&amp;C Act [21 U.S.C. § 352(a)], a drug product is misbranded if its labeling is false or misleading in any particular. Furthermore, under section 502(bb) of the FD&amp;C Act [21 U.S.C. § 352(bb)], a compounded drug product is misbranded if its advertising or promotion is false or misleading in any particular.\u003C\u002Fp>\u003Cp>More specifically,\u003C\u002Fp>\u003Cp>1. The compounded semaglutide and tirzepatide products displayed on your website identify “altRx” on the pictured label, suggesting altRx is the compounder of those drugs when in fact it is not.\u003Cem>\u003Cstrong>\u003Csup>2\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fp>\u003Cp>2. The following claims concerning compounded semaglutide and tirzepatide products appear on your website:\u003C\u002Fp>\u003Cul>\u003Cli>“GLP-1s are clinically proven medications….”\u003C\u002Fli>\u003Cli>“…clinically proven weight loss.”\u003C\u002Fli>\u003C\u002Ful>\u003Cp>Compounded drug products are not FDA-approved. Your claims represent that the compounded drug products you offer have been FDA-approved or otherwise evaluated for safety and effectiveness when they have not.\u003C\u002Fp>\u003Cp>Accordingly, these representations cause your compounded drug products to be misbranded under sections 502(a) and 502(bb) of the FD&amp;C Act [21 U.S.C. §§ 352(a) and (bb)]. The introduction or delivery for introduction into interstate commerce of these misbranded drug products is a prohibited act under section 301(a) of the FD&amp;C Act [21 U.S.C. § 331(a)]. The violations described in this letter put you on notice of our concerns but may not represent an exhaustive list of violations. Please be advised, the receipt in interstate commerce of misbranded drug products, and the delivery or proffered delivery thereof, is also a violation of section 301(c) of the FD&amp;C Act [21 U.S.C. § 331(c)].\u003C\u002Fp>\u003Cp>You are responsible for investigating and determining the root causes of any violations and implementing corrective and preventative measures to ensure future and sustained compliance so that these violations and any others do not occur. It is your responsibility to ensure that your operations comply with all requirements of federal law, including FDA regulations. For example, compounded drug products must meet the conditions in sections 503A or 503B of the FD&amp;C Act [21 U.S.C. §§ 353a or 353b] in order to be exempt from certain requirements under the FD&amp;C Act, including the new drug approval requirements.\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>As previously stated, you are responsible for investigating and determining the root causes of any violations and implementing corrective and preventative measures to ensure future and sustained compliance so that these violations and any others do not occur.\u003C\u002Fp>\u003Cp>Send your written response to the Office of Compounding Quality and Compliance (OCQC) within the Center for Drug Evaluation and Research (CDER)’s Office of Compliance at compoundinginspections@fda.hhs.gov within fifteen (15) business days of receipt of this letter. Identify your written response with reference number MARCS-CMS 728236 and Response to Warning Letter in the subject line of the email. Include the specific steps you have taken to correct any violations, an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. Such steps may include the following:\u003C\u002Fp>\u003Cp>1. Identifying the entities that produce the compounded drug products offered on your website;\u003C\u002Fp>\u003Cp>2. Providing a representative sample of labeling for such drug products; and\u003C\u002Fp>\u003Cp>3. Addressing other website claims that contain false or misleading representations about your compounded drug products or demonstrating that such claims have been modified or removed in light of FD&amp;C Act §§ 502(a) and 502(bb) [21 U.S.C. §§ 352(a) and 352(bb)].\u003C\u002Fp>\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. If you have information that you believe demonstrates that your products are not in violation of the FD&amp;C Act and FDA regulations, include that information for our consideration. If you cannot completely address this matter within fifteen (15) business days, state the reason for the delay and the time within which you will do so.\u003C\u002Fp>\u003Cp>If you are not located in the U.S., please note that drug products that appear to be misbranded may be detained or refused admission. We may advise the appropriate regulatory officials in the country from which you operate that your drug products referenced above appear to be misbranded drug products that cannot be legally sold to consumers in the U.S.\u003C\u002Fp>\u003Cp>Please note FDA posts warning letters on www.FDA.gov.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Matthew J. Lash, JD\u003Cbr>Acting Director\u003Cbr>Office of Compounding Quality and Compliance\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003Cbr>U.S. Food and Drug Administration\u003C\u002Fp>\u003Cp>__________________________\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> The semaglutide and tirzepatide products offered on your website are drugs within the meaning of section 201(g) of the FD&amp;C Act [21 U.S.C. § 321(g)] because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of diseases and\u002For because they are intended to affect the structure or any function of the body. Further, they are “new drugs” within the meaning of section 201(p) of the FD&amp;C Act [21 U.S.C. § 321(p)] because they are not generally recognized as safe and effective for their labeled uses.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> See 21 C.F.R. § 201.1(h)(2) (“The appearance on a drug product label of a person’s name without qualification is a representation that the named person is the sole manufacturer of the product. That representation is false and misleading, and the drug product is misbranded under section 502(a) of the act, if the person is not the manufacturer of the product in accordance with this section.”); see also FD&amp;C Act § 503(b) [21 U.S.C. § 353(b)], FD&amp;C Act § 503B(a)(10)(A)(ii) [21 U.S.C. § 353b(a)(10)(A)(ii)]. We note that 21 C.F.R. § 201.1(a) does not apply to drug products dispensed in accordance with section 503(b)(1) of the FD&amp;C Act [21 U.S.C. § 353(b)(1)]. However, see 45 Fed. Reg. 25760, 25765 (Apr. 15, 1980) (“…if the label of a prescription drug product dispensed by a pharmacist does contain a representation as to the manufacturer, packer, or distributor, it must comply with all the provisions of § 201.1….”). In addition, the labels of your drug products as depicted on the website do not indicate that they are dispensed under section 503(b)(1) of the FD&amp;C Act [21 U.S.C. § 353(b)(1)], nor do they appear to comply with the requirements of section 503(b)(2) [21 U.S.C. § 353(b)(2)].\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA ELECTRONIC MAIL READ\u002FDELIVERY RECEIPT REQUESTED\n\nProduct:\n\nDrugs\n\nRecipient:\n\nTrinity HealthCare Supply, LLC dba altRx\n\n3206 NE 2nd Ave, Suite 3013\n\nMiami, FL 33137\n\nUnited States\n\nhelp@altrx.com\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nJune 8, 2026\nWARNING LETTER\nReference number: MARCS-CMS 728236\nTo altRx:\nThis warning letter advises you of significant violations identified during a U.S. Food and Drug Administration (FDA) review of your website. Promptly address the violations described herein without delay, including ensuring that appropriate resources are allocated to fully address the violations and prevent their recurrence. The violations cited in this letter are not intended to be an all-inclusive list of violations that may exist in connection with your products. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations. Failure to adequately address any violations may result in legal action without further notice, including, without limitation, seizure and injunction.\nFDA Review\nViolations were identified and documented during a review of altRx’s website, https:\u002F\u002Fwww.altrx.com, FDA Establishment Identifier (FEI) 3044175714, in May 2026. FDA observed that your website offers compounded drug products, including semaglutide and tirzepatide products.1 As described below, your website’s false or misleading claims concerning compounded semaglutide and tirzepatide products under sections 502(a) and 502(bb) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) [21 U.S.C. §§ 352(a) and 352(bb)], result in products being introduced or delivered for introduction into interstate commerce in violation of section 301(a) of the FD&C Act [21 U.S.C. § 331(a)]. This review was conducted under FDA’s public health responsibilities to protect the public from unsafe, ineffective, and poor quality drug products.\nViolations of the Federal Food, Drug, and Cosmetic Act\nThe following are violations identified during our review. As a reminder, this is not an all-inclusive list of violations that may exist in connection with your products or operations.\nYour representations regarding compounded semaglutide and tirzepatide products are false or misleading. Under section 502(a) of the FD&C Act [21 U.S.C. § 352(a)], a drug product is misbranded if its labeling is false or misleading in any particular. Furthermore, under section 502(bb) of the FD&C Act [21 U.S.C. § 352(bb)], a compounded drug product is misbranded if its advertising or promotion is false or misleading in any particular.\nMore specifically,\n1. The compounded semaglutide and tirzepatide products displayed on your website identify “altRx” on the pictured label, suggesting altRx is the compounder of those drugs when in fact it is not.2\n2. The following claims concerning compounded semaglutide and tirzepatide products appear on your website:\n“GLP-1s are clinically proven medications….”\n“…clinically proven weight loss.”\nCompounded drug products are not FDA-approved. Your claims represent that the compounded drug products you offer have been FDA-approved or otherwise evaluated for safety and effectiveness when they have not.\nAccordingly, these representations cause your compounded drug products to be misbranded under sections 502(a) and 502(bb) of the FD&C Act [21 U.S.C. §§ 352(a) and (bb)]. The introduction or delivery for introduction into interstate commerce of these misbranded drug products is a prohibited act under section 301(a) of the FD&C Act [21 U.S.C. § 331(a)]. The violations described in this letter put you on notice of our concerns but may not represent an exhaustive list of violations. Please be advised, the receipt in interstate commerce of misbranded drug products, and the delivery or proffered delivery thereof, is also a violation of section 301(c) of the FD&C Act [21 U.S.C. § 331(c)].\nYou are responsible for investigating and determining the root causes of any violations and implementing corrective and preventative measures to ensure future and sustained compliance so that these violations and any others do not occur. It is your responsibility to ensure that your operations comply with all requirements of federal law, including FDA regulations. For example, compounded drug products must meet the conditions in sections 503A or 503B of the FD&C Act [21 U.S.C. §§ 353a or 353b] in order to be exempt from certain requirements under the FD&C Act, including the new drug approval requirements.\nConclusion\nAs previously stated, you are responsible for investigating and determining the root causes of any violations and implementing corrective and preventative measures to ensure future and sustained compliance so that these violations and any others do not occur.\nSend your written response to the Office of Compounding Quality and Compliance (OCQC) within the Center for Drug Evaluation and Research (CDER)’s Office of Compliance at compoundinginspections@fda.hhs.gov within fifteen (15) business days of receipt of this letter. Identify your written response with reference number MARCS-CMS 728236 and Response to Warning Letter in the subject line of the email. Include the specific steps you have taken to correct any violations, an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. Such steps may include the following:\n1. Identifying the entities that produce the compounded drug products offered on your website;\n2. Providing a representative sample of labeling for such drug products; and\n3. Addressing other website claims that contain false or misleading representations about your compounded drug products or demonstrating that such claims have been modified or removed in light of FD&C Act §§ 502(a) and 502(bb) [21 U.S.C. §§ 352(a) and 352(bb)].\nThis letter notifies you of our concerns and provides you an opportunity to address them. If you have information that you believe demonstrates that your products are not in violation of the FD&C Act and FDA regulations, include that information for our consideration. If you cannot completely address this matter within fifteen (15) business days, state the reason for the delay and the time within which you will do so.\nIf you are not located in the U.S., please note that drug products that appear to be misbranded may be detained or refused admission. We may advise the appropriate regulatory officials in the country from which you operate that your drug products referenced above appear to be misbranded drug products that cannot be legally sold to consumers in the U.S.\nPlease note FDA posts warning letters on www.FDA.gov.\nSincerely,\n\u002FS\u002F\nMatthew J. Lash, JD\nActing Director\nOffice of Compounding Quality and Compliance\nOffice of Compliance\nCenter for Drug Evaluation and Research\nU.S. Food and Drug Administration\n__________________________\n1 The semaglutide and tirzepatide products offered on your website are drugs within the meaning of section 201(g) of the FD&C Act [21 U.S.C. § 321(g)] because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of diseases and\u002For because they are intended to affect the structure or any function of the body. Further, they are “new drugs” within the meaning of section 201(p) of the FD&C Act [21 U.S.C. § 321(p)] because they are not generally recognized as safe and effective for their labeled uses.\n2 See 21 C.F.R. § 201.1(h)(2) (“The appearance on a drug product label of a person’s name without qualification is a representation that the named person is the sole manufacturer of the product. That representation is false and misleading, and the drug product is misbranded under section 502(a) of the act, if the person is not the manufacturer of the product in accordance with this section.”); see also FD&C Act § 503(b) [21 U.S.C. § 353(b)], FD&C Act § 503B(a)(10)(A)(ii) [21 U.S.C. § 353b(a)(10)(A)(ii)]. We note that 21 C.F.R. § 201.1(a) does not apply to drug products dispensed in accordance with section 503(b)(1) of the FD&C Act [21 U.S.C. § 353(b)(1)]. However, see 45 Fed. Reg. 25760, 25765 (Apr. 15, 1980) (“…if the label of a prescription drug product dispensed by a pharmacist does contain a representation as to the manufacturer, packer, or distributor, it must comply with all the provisions of § 201.1….”). In addition, the labels of your drug products as depicted on the website do not indicate that they are dispensed under section 503(b)(1) of the FD&C Act [21 U.S.C. § 353(b)(1)], nor do they appear to comply with the requirements of section 503(b)(2) [21 U.S.C. § 353(b)(2)].","Trinity HealthCare Supply, LLC dba altRx","trinity-healthcare-supply-llc-dba-altrx-728236-06082026","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Ftrinity-healthcare-supply-llc-dba-altrx-728236-06082026","2026-10-26T08:10:14.815507+00:00","2026-06-16","728236","2026-08-19T04:37:00.579+00:00","2026-06-08",{"id":183,"raw":184,"subject":188,"body_html":189,"body_text":190,"firm_name":191,"letter_id":192,"created_at":193,"fei_number":19,"letter_url":194,"updated_at":195,"action_type":22,"case_status":23,"posted_date":196,"marcs_cms_no":197,"product_type":48,"closeout_date":19,"issuing_office":37,"recipient_name":19,"body_fetched_at":198,"delivery_method":199,"recipient_title":19,"reference_number":19,"action_taken_date":200,"medical_device_id":19,"response_letter_date":19},637,[185,186,187,37,188,13,13,13],"\u003Ctime datetime=\"2025-09-16T04:00:00Z\">09\u002F16\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-09-09T04:00:00Z\">09\u002F09\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fcosmo-medical-spa-dba-cosmo-med-spa-715873-09092025\">Cosmo Medical Spa dba Cosmo Med Spa\u003C\u002Fa>","Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Electronic Mail - Delivery and Read Receipt Requested\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\u003C\u002Fdd>\n                    \n            \u003Cdd>Cosmo Medical Spa dba Cosmo Med Spa\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>1068-8321 Kennedy Rd\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Markham\u003C\u002Fspan> \u003Cspan>ON\u003C\u002Fspan> \u003Cspan>L3R5N4\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Canada\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:info@cosmomedspa.com\"> info@cosmomedspa.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>September 9, 2025\u003C\u002Fp>\u003Cp>Cosmo Med Spa:\u003C\u002Fp>\u003Cp>This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https:\u002F\u002Fcosmomedspa.com in August 2025 and has observed that your website offers various compounded drug products, including semaglutide.\u003Cem>\u003Cstrong>\u003Csup>1\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> As described below, your claims concerning compounded semaglutide products are false or misleading under sections 502(a) and 502(bb) of the Federal Food, Drug, and Cosmetic Act (FDCA) [21 U.S.C. §§ 352(a) and 352(bb)], resulting in products being introduced or delivered for introduction into interstate commerce in violation of section 301(a) of the FDCA [21 U.S.C. § 331(a)].\u003C\u002Fp>\u003Cp>Under section 502(a) of the FDCA [21 U.S.C. § 352(a)] a drug is misbranded if its labeling is false or misleading in any particular. Furthermore, under section 502(bb) of the FDCA [21 U.S.C. § 352(bb)], a compounded drug is misbranded if its advertising or promotion is false or misleading in any particular.\u003C\u002Fp>\u003Cp>The following claims concerning compounded semaglutide products appear on your website:\u003C\u002Fp>\u003Cul>\u003Cli>“Ozempic (semaglutide) injection (4 weeks supply)”\u003C\u002Fli>\u003Cli>“Ozempic (semaglutide) injection (10 weeks supply)”\u003C\u002Fli>\u003C\u002Ful>\u003Cp>Compounded drug products are not FDA-approved. Your claim implies that your products are the same as an FDA-approved product when they are not. As a result, these claims are false or misleading and your products are therefore misbranded under sections 502(a) and 502(bb) of the FDCA [21 U.S.C. §§ 352(a) and (bb)].\u003C\u002Fp>\u003Cp>The introduction or delivery for introduction into interstate commerce of these misbranded products is a prohibited act under section 301(a) of the FDCA [21 U.S.C. § 331(a)]. The claims identified in this letter put you on notice of our concerns but do not represent an exhaustive list of misbranding violations.\u003Cem>\u003Cstrong>\u003Csup>2\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fp>\u003Cp>For the reasons discussed above, your compounded semaglutide products are misbranded drugs under sections 502(a) and 502(bb) of the FDCA [21 U.S.C. §§ 352(a) and 352(bb)], introduced or delivered for introduction into interstate commerce in violation of section 301(a) of the FDCA [21 U.S.C. § 331(a)]. Please be advised, the receipt in interstate commerce of misbranded drugs, and the delivery or proffered delivery thereof, is also a violation of section 301(c) of the FDCA [21 U.S.C. § 331(c)].\u003C\u002Fp>\u003Cp>As previously stated, the violations cited in this letter are not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your operations comply with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\u003Cp>You should take immediate action to address any violations (including, for example, ceasing and desisting from using the language cited above that misbrands the product). Failure to adequately address any violations may result in legal action without further notice, including, without limitation, seizure and injunction.\u003C\u002Fp>\u003Cp>Within fifteen (15) working days of receipt of this letter, please provide a written response to the Office of Compounding Quality and Compliance (OCQC) within the Center for Drug Evaluation and Research (CDER)’s Office of Compliance describing the specific steps you have taken to address any violations. Please include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. This letter notifies you of our concerns and provides you an opportunity to address them. If you believe your products are not in violation of the FDCA, include your reasoning and any supporting information for our consideration. If you cannot completely address this matter within fifteen (15) working days, state the reason for the delay and the time within which you will do so.\u003C\u002Fp>\u003Cp>If you are not located in the U.S., please note that products that appear to be misbranded may be detained or refused admission. We may advise the appropriate regulatory officials in the country from which you operate that your products referenced above appear to be misbranded drugs that cannot be legally sold to consumers in the U.S.\u003C\u002Fp>\u003Cp>All correspondence should include a subject line that clearly identifies the submission as a Response to Warning Letter. If you have questions regarding the contents of this letter, please contact compoundinginspections@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003Cbr>George Tidmarsh, M.D., Ph.D. Director\u003Cbr>Center for Drug Evaluation and Research\u003Cbr>U.S. Food and Drug Administration\u003C\u002Fp>\u003Cp>______________________\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> The semaglutide products offered on your website are drugs within the meaning of section 201(g) of the FDCA [21 U.S.C. § 321(g)] because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of diseases and\u002For because they are intended to affect the structure or any function of the body. Further, they are “new drugs” within the meaning of section 201(p) of the FDCA [21 U.S.C. § 321(p)] because they are not generally recognized as safe and effective for their labeled uses.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> Overstatements of efficacy or minimization of risk are of particular concern and may constitute misbranding.\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Electronic Mail - Delivery and Read Receipt Requested\n\nProduct:\n\nDrugs\n\nRecipient:\n\nCosmo Medical Spa dba Cosmo Med Spa\n\n1068-8321 Kennedy Rd\n\nMarkham ON L3R5N4\n\nCanada\n\ninfo@cosmomedspa.com\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWARNING LETTER\nSeptember 9, 2025\nCosmo Med Spa:\nThis letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https:\u002F\u002Fcosmomedspa.com in August 2025 and has observed that your website offers various compounded drug products, including semaglutide.1 As described below, your claims concerning compounded semaglutide products are false or misleading under sections 502(a) and 502(bb) of the Federal Food, Drug, and Cosmetic Act (FDCA) [21 U.S.C. §§ 352(a) and 352(bb)], resulting in products being introduced or delivered for introduction into interstate commerce in violation of section 301(a) of the FDCA [21 U.S.C. § 331(a)].\nUnder section 502(a) of the FDCA [21 U.S.C. § 352(a)] a drug is misbranded if its labeling is false or misleading in any particular. Furthermore, under section 502(bb) of the FDCA [21 U.S.C. § 352(bb)], a compounded drug is misbranded if its advertising or promotion is false or misleading in any particular.\nThe following claims concerning compounded semaglutide products appear on your website:\n“Ozempic (semaglutide) injection (4 weeks supply)”\n“Ozempic (semaglutide) injection (10 weeks supply)”\nCompounded drug products are not FDA-approved. Your claim implies that your products are the same as an FDA-approved product when they are not. As a result, these claims are false or misleading and your products are therefore misbranded under sections 502(a) and 502(bb) of the FDCA [21 U.S.C. §§ 352(a) and (bb)].\nThe introduction or delivery for introduction into interstate commerce of these misbranded products is a prohibited act under section 301(a) of the FDCA [21 U.S.C. § 331(a)]. The claims identified in this letter put you on notice of our concerns but do not represent an exhaustive list of misbranding violations.2\nFor the reasons discussed above, your compounded semaglutide products are misbranded drugs under sections 502(a) and 502(bb) of the FDCA [21 U.S.C. §§ 352(a) and 352(bb)], introduced or delivered for introduction into interstate commerce in violation of section 301(a) of the FDCA [21 U.S.C. § 331(a)]. Please be advised, the receipt in interstate commerce of misbranded drugs, and the delivery or proffered delivery thereof, is also a violation of section 301(c) of the FDCA [21 U.S.C. § 331(c)].\nAs previously stated, the violations cited in this letter are not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your operations comply with all requirements of federal law, including FDA regulations.\nYou should take immediate action to address any violations (including, for example, ceasing and desisting from using the language cited above that misbrands the product). Failure to adequately address any violations may result in legal action without further notice, including, without limitation, seizure and injunction.\nWithin fifteen (15) working days of receipt of this letter, please provide a written response to the Office of Compounding Quality and Compliance (OCQC) within the Center for Drug Evaluation and Research (CDER)’s Office of Compliance describing the specific steps you have taken to address any violations. Please include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. This letter notifies you of our concerns and provides you an opportunity to address them. If you believe your products are not in violation of the FDCA, include your reasoning and any supporting information for our consideration. If you cannot completely address this matter within fifteen (15) working days, state the reason for the delay and the time within which you will do so.\nIf you are not located in the U.S., please note that products that appear to be misbranded may be detained or refused admission. We may advise the appropriate regulatory officials in the country from which you operate that your products referenced above appear to be misbranded drugs that cannot be legally sold to consumers in the U.S.\nAll correspondence should include a subject line that clearly identifies the submission as a Response to Warning Letter. If you have questions regarding the contents of this letter, please contact compoundinginspections@fda.hhs.gov.\nSincerely,\n\u002FS\u002F\nGeorge Tidmarsh, M.D., Ph.D. Director\nCenter for Drug Evaluation and Research\nU.S. Food and Drug Administration\n______________________\n1 The semaglutide products offered on your website are drugs within the meaning of section 201(g) of the FDCA [21 U.S.C. § 321(g)] because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of diseases and\u002For because they are intended to affect the structure or any function of the body. Further, they are “new drugs” within the meaning of section 201(p) of the FDCA [21 U.S.C. § 321(p)] because they are not generally recognized as safe and effective for their labeled uses.\n2 Overstatements of efficacy or minimization of risk are of particular concern and may constitute misbranding.","Cosmo Medical Spa dba Cosmo Med Spa","cosmo-medical-spa-dba-cosmo-med-spa-715873-09092025","2026-08-18T06:42:28.676509+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fcosmo-medical-spa-dba-cosmo-med-spa-715873-09092025","2026-10-26T08:08:18.730704+00:00","2025-09-16","715873","2026-08-19T16:19:52.144+00:00","Via Electronic Mail - Delivery and Read Receipt Requested","2025-09-09",{"id":202,"raw":203,"subject":207,"body_html":208,"body_text":209,"firm_name":210,"letter_id":211,"created_at":43,"fei_number":19,"letter_url":212,"updated_at":213,"action_type":22,"case_status":23,"posted_date":214,"marcs_cms_no":215,"product_type":48,"closeout_date":19,"issuing_office":37,"recipient_name":216,"body_fetched_at":217,"delivery_method":29,"recipient_title":19,"reference_number":218,"action_taken_date":219,"medical_device_id":19,"response_letter_date":19},1053,[204,205,206,37,207,13,13,13],"\u003Ctime datetime=\"2025-02-18T05:00:00Z\">02\u002F18\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-02-10T05:00:00Z\">02\u002F10\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmarshalls-traditional-healthcare-cc-697697-02102025\">Marshalls Traditional Healthcare CC\u003C\u002Fa>","CGMP\u002FFinished Pharmaceutical\u002FAdulterated","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>320-25-43\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Vick Maharaj\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Chief Executive Officer \u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Marshalls Traditional Healthcare CC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>560 Main Reef Road\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Germiston\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Gauteng\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>1400\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>South Africa\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter\u003C\u002Fstrong> 320-25-43\u003C\u002Fp>\u003Cp>February 10, 2025\u003C\u002Fp>\u003Cp>Dear Mr. Maharaj:\u003C\u002Fp>\u003Cp>The U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility, Marshalls Traditional Healthcare CC, FEI 3014740544, at 560 Main Reef Road, Germiston, from September 19 to 23, 2024.\u003C\u002Fp>\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\u003C\u002Fp>\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug product is adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\u003Cp>We reviewed your October 11, 2024, response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\u003C\u002Fp>\u003Cp>\u003Cstrong>CGMP Violations\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong>1. Your firm failed to have, for each batch of drug product, appropriate laboratory determination of satisfactory conformance to final specifications for the drug product, including the identity and strength of each active ingredient, prior to release. Your firm also failed to conduct, for each batch of drug product, appropriate laboratory testing, as necessary, required to be free of objectionable microorganisms (21 CFR 211.165(a) and 211.165(b)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your firm manufactures an over-the-counter (OTC) \u003Cstrong>(b)(4)\u003C\u002Fstrong> drug product. Your firm failed to conduct adequate finished product release testing for each batch of your drug product, including but not limited to, testing the identity and strength of the active ingredient, \u003Cstrong>(b)(4)\u003C\u002Fstrong> and testing for objectionable microorganisms.\u003C\u002Fp>\u003Cp>In your response, you state that you developed and validated an updated test method, and updated release specifications, for the labeled active ingredient, \u003Cstrong>(b)(4)\u003C\u002Fstrong>. You also state that you will perform all appropriate USP &lt;61&gt; and &lt;62&gt; testing for your finished drug products. Your response is inadequate as you did not provide sufficient details regarding the specific tests to be performed for each batch of finished drug product. You also did not consider a risk assessment or retrospective review of products that have been released without appropriate testing.\u003C\u002Fp>\u003Cp>Without adequate finished product release testing, you do not have scientific evidence that each batch of drug product conforms to appropriate specifications before release.\u003C\u002Fp>\u003Cp>In your response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A comprehensive, independent assessment of your laboratory practices, procedures, methods, equipment, documentation, and analyst competencies. Based on this review, provide a detailed plan to remediate and evaluate the effectiveness of your laboratory system.\u003C\u002Fli>\u003Cli>A list of chemical and microbial specifications, including test methods, used to analyze each lot of your drug products before a lot disposition decision.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>2. Your firm failed to establish adequate written procedures for production and process control designed to assure that the drug products you manufacture have the identity, strength, quality, and purity they purport or are represented to possess, and to follow all of your written production and process control procedures (21 CFR 211.100(a) and 211.100(b)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cem>Inadequate Process Validation\u003C\u002Fem>\u003C\u002Fp>\u003Cp>You did not have data to demonstrate that you adequately validate your manufacturing processes used to manufacture your OTC drug products and demonstrate that your processes are reproducible and controlled to consistently yield drugs of uniform character and quality. For example, your validation plan, “VALIDATOIN MASTER PLAN (VMP),” describes requirements for process validation and hold time studies. However, the protocol implementing your validation planed, “PROCESS VALIDATION PROTOCOL,” failed to include operating parameters, such as bulk hold times, or processing limits, such as acceptance criteria for process parameters.\u003C\u002Fp>\u003Cp>In your response, you provided your updated process validation protocol. Your response is inadequate as it did not include hold times and lacked appropriate details such as adequate sampling instructions. The updated protocol also did not include the batch production record associated with the first validation batch.\u003C\u002Fp>\u003Cp>Process validation evaluates the soundness of design and state of control of a process throughout its lifecycle. Each significant stage of a manufacturing process must be designed appropriately and assure the quality of raw material inputs, in-process materials, and finished drugs. Process qualification studies determine whether an initial state of control has been established. Successful process qualification studies are necessary before commercial distribution. Thereafter, ongoing vigilant oversight of process performance and product quality is necessary to ensure you maintain a stable manufacturing operation throughout the product lifecycle.\u003C\u002Fp>\u003Cp>See FDA's guidance for industry, Process Validation: General Principles and Practices for general principles and approaches that FDA considers appropriate elements of process validation at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71021\u002Fdownload.\">https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71021\u002Fdownload.\u003C\u002Fa>\u003C\u002Fp>\u003Cp>\u003Cem>Inadequate Control of \u003Cstrong>(b)(4)\u003C\u002Fstrong> System\u003C\u002Fem>\u003C\u002Fp>\u003Cp>Your firm uses \u003Cstrong>(b)(4)\u003C\u002Fstrong> as a component to manufacture your OTC drug product. You failed to ensure that your \u003Cstrong>(b)(4)\u003C\u002Fstrong> system is suitable for producing \u003Cstrong>(b)(4)\u003C\u002Fstrong> used in the formulation of your drug product. For example, you turned your \u003Cstrong>(b)(4)\u003C\u002Fstrong> system off when not in use, stopping its circulation, which deviates from its design use as a continuously recirculating system. In addition, you failed to demonstrate that your \u003Cstrong>(b)(4)\u003C\u002Fstrong> system is adequately monitored to ensure it consistently produces \u003Cstrong>(b)(4)\u003C\u002Fstrong> that meets appropriate chemical and microbial attributes.\u003C\u002Fp>\u003Cp>In your response, you state that your \u003Cstrong>(b)(4)\u003C\u002Fstrong> system will continuously \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Your response is inadequate. You did not address the adequacy of your overall \u003Cstrong>(b)(4)\u003C\u002Fstrong> system design to ensure that your \u003Cstrong>(b)(4)\u003C\u002Fstrong> meets, at a minimum, the USP \u003Cstrong>(b)(4)\u003C\u002Fstrong> monograph and appropriate microbial limits. You also did not provide interim measures and assess the impact of using \u003Cstrong>(b)(4)\u003C\u002Fstrong> from an inadequately validated \u003Cstrong>(b)(4)\u003C\u002Fstrong> system on the quality of drug products you manufacture.\u003C\u002Fp>\u003Cp>Pharmaceutical \u003Cstrong>(b)(4)\u003C\u002Fstrong> must be suitable for its intended use and routinely tested to ensure ongoing conformance with appropriate chemical and microbiological attributes. Routine monitoring of microbial counts and identity of contamination in the system is integral to maintaining a state of control and suitability of \u003Cstrong>(b)(4)\u003C\u002Fstrong> for use in manufacturing operations.\u003C\u002Fp>\u003Cp>In your response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A detailed summary of your validation program for ensuring a state of control throughout the product lifecycle, along with associated procedures. Describe your program for process performance qualification (PPQ), and ongoing monitoring of both intra-batch and inter-batch variation to ensure a continuing state of control.\u003C\u002Fli>\u003Cli>A timeline for performing appropriate PPQ for each of your marketed drug products.\u003C\u002Fli>\u003Cli>Process performance protocol(s), and written procedures for qualification of equipment and facilities.\u003C\u002Fli>\u003Cli>A detailed program for designing, validating, maintaining, controlling and monitoring each of your manufacturing processes that includes vigilant monitoring of intra-batch and inter-batch variation to ensure an ongoing state of control. Also, include your program for qualification of your equipment and facility.\u003C\u002Fli>\u003Cli>A comprehensive remediation plan for the design, control, and maintenance of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> system.\u003C\u002Fli>\u003Cli>A \u003Cstrong>(b)(4)\u003C\u002Fstrong> system validation report. Also include the summary of any improvements made to system design and to the program for ongoing control and maintenance.\u003C\u002Fli>\u003Cli>Your total microbial count limits to monitor whether this system is producing \u003Cstrong>(b)(4)\u003C\u002Fstrong> suitable for the intended uses for each of your products.\u003C\u002Fli>\u003Cli>A detailed risk assessment addressing the potential effects of the observed \u003Cstrong>(b)(4)\u003C\u002Fstrong> system failures on the quality of all drug product lots currently in U.S. distribution. Specify actions that you will take in response to the risk assessment, such as customer notifications and product recalls.\u003C\u002Fli>\u003Cli>A procedure for your \u003Cstrong>(b)(4)\u003C\u002Fstrong> system monitoring that specifies routine microbial testing of \u003Cstrong>(b)(4)\u003C\u002Fstrong> to ensure its acceptability for use in each batch of drug products produced by your firm.\u003C\u002Fli>\u003Cli>A procedure governing your program for ongoing control, maintenance, and monitoring that ensures the remediated system consistently produces \u003Cstrong>(b)(4)\u003C\u002Fstrong> that meets \u003Cstrong>(b)(4)\u003C\u002Fstrong>, USP monograph specifications and appropriate microbial limits.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>Drug Production Suspended\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>We acknowledge that you delisted your OTC drug product with FDA. In response to this letter, clarify whether you intend to resume manufacturing drugs for the U.S. market at this facility in the future.\u003C\u002Fp>\u003Cp>If you plan to resume any manufacturing operations regulated under the FD&amp;C Act, notify this office before resuming your drug manufacturing operations. You are responsible for resolving all deficiencies and systemic flaws to ensure your firm is capable of ongoing CGMP compliance. In your notification to the Agency, provide a summary of your remediations to demonstrate that you have appropriately completed all corrective actions and preventive actions (CAPAs).\u003C\u002Fp>\u003Cp>\u003Cstrong>CGMP Consultant Recommended\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Based upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to assist your firm in meeting CGMP requirements. The qualified consultant should also perform a comprehensive six-system audit of your entire operation for CGMP compliance and evaluate the completion and efficacy of your corrective actions and preventive actions before you pursue resolution of your firm’s compliance status with FDA. Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\u003C\u002Fp>\u003Cp>See FDA’s guidance document \u003Cem>Quality Systems Approach to Pharmaceutical CGMP Regulations\u003C\u002Fem> for help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211 at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload.\u003C\u002Fp>\u003Cp>\u003Cstrong>Cosmetics Manufactured for Distribution in the United States\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>In addition, we note that some of the products you manufacture may be regulated as cosmetics, as defined in section 201(i) of the FD&amp;C Act [21 U.S.C. 321(i)]. Any cosmetics you manufacture must comply with applicable statutory and regulatory requirements, including the FD&amp;C Act. Under section 301(a) of the FD&amp;C Act [21 U.S.C. 331(a)], it is a prohibited act to introduce or deliver for introduction into interstate commerce a cosmetic that is adulterated or misbranded.\u003C\u002Fp>\u003Cp>Further, your facility may be subject to requirements of the Modernization of Cosmetics Regulation Act of 2022 (MoCRA). Information on MoCRA requirements may be found at\u003Cbr>https:\u002F\u002Fwww.fda.gov\u002Fcosmetics\u002Fcosmetics-laws-regulations\u002Fmodernization-cosmetics-regulation-act-2022-mocra.\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\u003Cp>Correct any violations promptly. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to any violations.\u003C\u002Fp>\u003Cp>Failure to address any violations may also result in the FDA refusing admission of articles manufactured at Marshalls Traditional Healthcare CC, FEI 3014740544, at 560 Main Reef Road, Germiston, Gauteng 1400, South Africa, into the United States under section 801(a)(3) of the FD&amp;C Act, 21 U.S.C. 381(a)(3). Articles under this authority that appear to be adulterated may be detained or refused admission, in that the methods and controls used in their manufacture do not appear to conform to CGMP within the meaning of section 501(a)(2)(B) of the FD&amp;C Act, 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\u003Cp>Send your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3014740544 and ATTN: Christopher M. Jenner.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Francis Godwin\u003Cbr>Director\u003Cbr>Office of Manufacturing Quality\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nReference #:\n\n320-25-43\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMr. Vick Maharaj\n\nRecipient Title\n\nChief Executive Officer\n\nMarshalls Traditional Healthcare CC\n\n560 Main Reef Road\n\nGermiston\n\nGauteng\n\n1400\n\nSouth Africa\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWarning Letter 320-25-43\nFebruary 10, 2025\nDear Mr. Maharaj:\nThe U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility, Marshalls Traditional Healthcare CC, FEI 3014740544, at 560 Main Reef Road, Germiston, from September 19 to 23, 2024.\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug product is adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\nWe reviewed your October 11, 2024, response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\nCGMP Violations\n1. Your firm failed to have, for each batch of drug product, appropriate laboratory determination of satisfactory conformance to final specifications for the drug product, including the identity and strength of each active ingredient, prior to release. Your firm also failed to conduct, for each batch of drug product, appropriate laboratory testing, as necessary, required to be free of objectionable microorganisms (21 CFR 211.165(a) and 211.165(b)).\nYour firm manufactures an over-the-counter (OTC) (b)(4) drug product. Your firm failed to conduct adequate finished product release testing for each batch of your drug product, including but not limited to, testing the identity and strength of the active ingredient, (b)(4) and testing for objectionable microorganisms.\nIn your response, you state that you developed and validated an updated test method, and updated release specifications, for the labeled active ingredient, (b)(4). You also state that you will perform all appropriate USP \u003C61> and \u003C62> testing for your finished drug products. Your response is inadequate as you did not provide sufficient details regarding the specific tests to be performed for each batch of finished drug product. You also did not consider a risk assessment or retrospective review of products that have been released without appropriate testing.\nWithout adequate finished product release testing, you do not have scientific evidence that each batch of drug product conforms to appropriate specifications before release.\nIn your response to this letter, provide:\nA comprehensive, independent assessment of your laboratory practices, procedures, methods, equipment, documentation, and analyst competencies. Based on this review, provide a detailed plan to remediate and evaluate the effectiveness of your laboratory system.\nA list of chemical and microbial specifications, including test methods, used to analyze each lot of your drug products before a lot disposition decision.\n2. Your firm failed to establish adequate written procedures for production and process control designed to assure that the drug products you manufacture have the identity, strength, quality, and purity they purport or are represented to possess, and to follow all of your written production and process control procedures (21 CFR 211.100(a) and 211.100(b)).\nInadequate Process Validation\nYou did not have data to demonstrate that you adequately validate your manufacturing processes used to manufacture your OTC drug products and demonstrate that your processes are reproducible and controlled to consistently yield drugs of uniform character and quality. For example, your validation plan, “VALIDATOIN MASTER PLAN (VMP),” describes requirements for process validation and hold time studies. However, the protocol implementing your validation planed, “PROCESS VALIDATION PROTOCOL,” failed to include operating parameters, such as bulk hold times, or processing limits, such as acceptance criteria for process parameters.\nIn your response, you provided your updated process validation protocol. Your response is inadequate as it did not include hold times and lacked appropriate details such as adequate sampling instructions. The updated protocol also did not include the batch production record associated with the first validation batch.\nProcess validation evaluates the soundness of design and state of control of a process throughout its lifecycle. Each significant stage of a manufacturing process must be designed appropriately and assure the quality of raw material inputs, in-process materials, and finished drugs. Process qualification studies determine whether an initial state of control has been established. Successful process qualification studies are necessary before commercial distribution. Thereafter, ongoing vigilant oversight of process performance and product quality is necessary to ensure you maintain a stable manufacturing operation throughout the product lifecycle.\nSee FDA's guidance for industry, Process Validation: General Principles and Practices for general principles and approaches that FDA considers appropriate elements of process validation at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71021\u002Fdownload.\nInadequate Control of (b)(4) System\nYour firm uses (b)(4) as a component to manufacture your OTC drug product. You failed to ensure that your (b)(4) system is suitable for producing (b)(4) used in the formulation of your drug product. For example, you turned your (b)(4) system off when not in use, stopping its circulation, which deviates from its design use as a continuously recirculating system. In addition, you failed to demonstrate that your (b)(4) system is adequately monitored to ensure it consistently produces (b)(4) that meets appropriate chemical and microbial attributes.\nIn your response, you state that your (b)(4) system will continuously (b)(4). Your response is inadequate. You did not address the adequacy of your overall (b)(4) system design to ensure that your (b)(4) meets, at a minimum, the USP (b)(4) monograph and appropriate microbial limits. You also did not provide interim measures and assess the impact of using (b)(4) from an inadequately validated (b)(4) system on the quality of drug products you manufacture.\nPharmaceutical (b)(4) must be suitable for its intended use and routinely tested to ensure ongoing conformance with appropriate chemical and microbiological attributes. Routine monitoring of microbial counts and identity of contamination in the system is integral to maintaining a state of control and suitability of (b)(4) for use in manufacturing operations.\nIn your response to this letter, provide:\nA detailed summary of your validation program for ensuring a state of control throughout the product lifecycle, along with associated procedures. Describe your program for process performance qualification (PPQ), and ongoing monitoring of both intra-batch and inter-batch variation to ensure a continuing state of control.\nA timeline for performing appropriate PPQ for each of your marketed drug products.\nProcess performance protocol(s), and written procedures for qualification of equipment and facilities.\nA detailed program for designing, validating, maintaining, controlling and monitoring each of your manufacturing processes that includes vigilant monitoring of intra-batch and inter-batch variation to ensure an ongoing state of control. Also, include your program for qualification of your equipment and facility.\nA comprehensive remediation plan for the design, control, and maintenance of the (b)(4) system.\nA (b)(4) system validation report. Also include the summary of any improvements made to system design and to the program for ongoing control and maintenance.\nYour total microbial count limits to monitor whether this system is producing (b)(4) suitable for the intended uses for each of your products.\nA detailed risk assessment addressing the potential effects of the observed (b)(4) system failures on the quality of all drug product lots currently in U.S. distribution. Specify actions that you will take in response to the risk assessment, such as customer notifications and product recalls.\nA procedure for your (b)(4) system monitoring that specifies routine microbial testing of (b)(4) to ensure its acceptability for use in each batch of drug products produced by your firm.\nA procedure governing your program for ongoing control, maintenance, and monitoring that ensures the remediated system consistently produces (b)(4) that meets (b)(4), USP monograph specifications and appropriate microbial limits.\nDrug Production Suspended\nWe acknowledge that you delisted your OTC drug product with FDA. In response to this letter, clarify whether you intend to resume manufacturing drugs for the U.S. market at this facility in the future.\nIf you plan to resume any manufacturing operations regulated under the FD&C Act, notify this office before resuming your drug manufacturing operations. You are responsible for resolving all deficiencies and systemic flaws to ensure your firm is capable of ongoing CGMP compliance. In your notification to the Agency, provide a summary of your remediations to demonstrate that you have appropriately completed all corrective actions and preventive actions (CAPAs).\nCGMP Consultant Recommended\nBased upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to assist your firm in meeting CGMP requirements. The qualified consultant should also perform a comprehensive six-system audit of your entire operation for CGMP compliance and evaluate the completion and efficacy of your corrective actions and preventive actions before you pursue resolution of your firm’s compliance status with FDA. Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\nSee FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations for help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211 at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload.\nCosmetics Manufactured for Distribution in the United States\nIn addition, we note that some of the products you manufacture may be regulated as cosmetics, as defined in section 201(i) of the FD&C Act [21 U.S.C. 321(i)]. Any cosmetics you manufacture must comply with applicable statutory and regulatory requirements, including the FD&C Act. Under section 301(a) of the FD&C Act [21 U.S.C. 331(a)], it is a prohibited act to introduce or deliver for introduction into interstate commerce a cosmetic that is adulterated or misbranded.\nFurther, your facility may be subject to requirements of the Modernization of Cosmetics Regulation Act of 2022 (MoCRA). Information on MoCRA requirements may be found at\nhttps:\u002F\u002Fwww.fda.gov\u002Fcosmetics\u002Fcosmetics-laws-regulations\u002Fmodernization-cosmetics-regulation-act-2022-mocra.\nConclusion\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\nCorrect any violations promptly. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to any violations.\nFailure to address any violations may also result in the FDA refusing admission of articles manufactured at Marshalls Traditional Healthcare CC, FEI 3014740544, at 560 Main Reef Road, Germiston, Gauteng 1400, South Africa, into the United States under section 801(a)(3) of the FD&C Act, 21 U.S.C. 381(a)(3). Articles under this authority that appear to be adulterated may be detained or refused admission, in that the methods and controls used in their manufacture do not appear to conform to CGMP within the meaning of section 501(a)(2)(B) of the FD&C Act, 21 U.S.C. 351(a)(2)(B).\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\nSend your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3014740544 and ATTN: Christopher M. Jenner.\nSincerely,\n\u002FS\u002F\nFrancis Godwin\nDirector\nOffice of Manufacturing Quality\nOffice of Compliance\nCenter for Drug Evaluation and Research","Marshalls Traditional Healthcare CC","marshalls-traditional-healthcare-cc-697697-02102025","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmarshalls-traditional-healthcare-cc-697697-02102025","2026-10-26T08:09:20.909625+00:00","2025-02-18","697697","Mr. Vick Maharaj","2026-08-19T17:01:31.89+00:00","320-25-43","2025-02-10",{"id":221,"raw":222,"subject":188,"body_html":225,"body_text":226,"firm_name":227,"letter_id":228,"created_at":193,"fei_number":19,"letter_url":229,"updated_at":230,"action_type":22,"case_status":23,"posted_date":196,"marcs_cms_no":231,"product_type":48,"closeout_date":19,"issuing_office":37,"recipient_name":19,"body_fetched_at":232,"delivery_method":73,"recipient_title":19,"reference_number":19,"action_taken_date":200,"medical_device_id":19,"response_letter_date":19},591,[223,186,224,37,188,13,13,13],"\u003Ctime datetime=\"2025-09-16T13:20:00Z\">09\u002F16\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fgetfitmedical-llc-dba-getfitmedical-715801-09092025\">Get.Fit.Medical, LLC dba Get.Fit.Medical\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA ELECTRONIC MAIL READ\u002FDELIVERY RECEIPT REQUESTED\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\u003C\u002Fdd>\n                    \n            \u003Cdd>Get.Fit.Medical, LLC dba Get.Fit.Medical\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:https:\u002F\u002Fwww.getfitmedical.com\"> https:\u002F\u002Fwww.getfitmedical.com\u003C\u002Fa>\u003C\u002Fdd>\n    \u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:drewcromer@getfitmedical.com\"> drewcromer@getfitmedical.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n  \u003Cdiv>\n    \u003Cdiv>Secondary Issuing Offices\u003C\u002Fdiv>\n          \u003Cdiv>\n              \u003Cdiv>    \u003Cbr>\n    \n     \n        \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n    \n    \n    \n    \n\u003C\u002Fdiv>\n              \u003C\u002Fdiv>\n      \u003C\u002Fdiv>\n\n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>September 9, 2025\u003C\u002Fp>\u003Cp>Get.Fit.Medical:\u003C\u002Fp>\u003Cp>This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https:\u002F\u002Fwww.getfitmedical.com in August 2025 and has observed that your website offers various compounded drug products, including sildenafil, tadalafil, semaglutide, and tirzepatide.\u003Ca id=\"footnoteref1_9e35aee\" href=\"#footnote1_9e35aee\">\u003Csup>1\u003C\u002Fsup>\u003C\u002Fa>&nbsp;As described below, your claims concerning compounded sildenafil, tadalafil, semaglutide, and tirzepatide products are false or misleading under sections 502(a) and 502(bb) of the Federal Food, Drug, and Cosmetic Act (FDCA) [21 U.S.C. §§ 352(a) and 352(bb)], resulting in products being introduced or delivered for introduction into interstate commerce in violation of section 301(a) of the FDCA [21 U.S.C. § 331(a)].\u003C\u002Fp>\u003Cp>Under section 502(a) of the FDCA [21 U.S.C. § 352(a)] a drug is misbranded if its labeling is false or misleading in any particular. Furthermore, under section 502(bb) of the FDCA [21 U.S.C. § 352(bb)], a compounded drug is misbranded if its advertising or promotion is false or misleading in any particular.\u003C\u002Fp>\u003Cp>The following claims concerning compounded sildenafil, tadalafil, semaglutide, and tirzepatide products appear on webpages that offer only compounded products:\u003Cbr>• “SILDENAFIL (GENERIC VIAGRA)”\u003Cbr>• “TADALAFIL (GENERIC CIALIS)”\u003Cbr>• “SEMAGLUTIDE (GENERIC OZEMPIC\u002FWEGOVY)”\u003Cbr>• “TIRZEPATIDE (GENERIC MOUNJARO)”\u003C\u002Fp>\u003Cp>Compounded drug products are not FDA-approved. Your claims imply that your products are the same as an FDA-approved product when they are not. As a result, these claims are false or misleading and your products are therefore misbranded under sections 502(a) and 502(bb) of the FDCA [21 U.S.C. §§ 352(a) and (bb)].\u003C\u002Fp>\u003Cp>The introduction or delivery for introduction into interstate commerce of these misbranded products is a prohibited act under section 301(a) of the FDCA [21 U.S.C. § 331(a)]. The claims identified in this letter put you on notice of our concerns but do not represent an exhaustive list of misbranding violations.\u003Ca id=\"footnoteref2_gm2b1es\" href=\"#footnote2_gm2b1es\">\u003Csup>2\u003C\u002Fsup>\u003C\u002Fa>\u003C\u002Fp>\u003Cp>For the reasons discussed above, your compounded sildenafil, tadalafil, semaglutide, and tirzepatide products are misbranded drugs under sections 502(a) and 502(bb) of the FDCA [21 U.S.C. §§ 352(a) and 352(bb)], introduced or delivered for introduction into interstate commerce in violation of section 301(a) of the FDCA [21 U.S.C. § 331(a)]. Please be advised, the receipt in interstate commerce of misbranded drugs, and the delivery or proffered delivery thereof, is also a violation of section 301(c) of the FDCA [21 U.S.C. § 331(c)].\u003C\u002Fp>\u003Cp>As previously stated, the violations cited in this letter are not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your operations comply with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\u003Cp>You should take immediate action to address any violations (including, for example, ceasing and desisting from using the language cited above that misbrands the product). Failure to adequately address any violations may result in legal action without further notice, including, without limitation, seizure and injunction.\u003C\u002Fp>\u003Cp>Within fifteen (15) working days of receipt of this letter, please provide a written response to the Office of Compounding Quality and Compliance (OCQC) within the Center for Drug Evaluation and Research (CDER)’s Office of Compliance describing the specific steps you have taken to address any violations. Please include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. This letter notifies you of our concerns and provides you an opportunity to address them. If you believe your products are not in violation of the FDCA, include your reasoning and any supporting information for our consideration. If you cannot completely address this matter within fifteen (15) working days, state the reason for the delay and the time within which you will do so.\u003C\u002Fp>\u003Cp>If you are not located in the U.S., please note that products that appear to be misbranded may be detained or refused admission. We may advise the appropriate regulatory officials in the country from which you operate that your products referenced above appear to be misbranded drugs that cannot be legally sold to consumers in the U.S.\u003C\u002Fp>\u003Cp>All correspondence should include a subject line that clearly identifies the submission as a Response to Warning Letter. If you have questions regarding the contents of this letter, please contact compoundinginspections@fda.hhs.gov.\u003C\u002Fp>\u003Cp>\u003Cbr>Sincerely,\u003Cbr>\u002FS\u002F\u003Cbr>George Tidmarsh, M.D., Ph.D.\u003Cbr>Director\u003Cbr>Center for Drug Evaluation and Research\u003Cbr>U.S. Food and Drug Administration\u003C\u002Fp>\n\n\u003Col>\n                  \u003Cli id=\"footnote1_9e35aee\">\u003Ca href=\"#footnoteref1_9e35aee\">1\u003C\u002Fa>The sildenafil, tadalafil, semaglutide, and tirzepatide products offered on your website are drugs within the meaning of section 201(g) of the FDCA [21 U.S.C. § 321(g)] because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of diseases and\u002For because they are intended to affect the structure or any function of the body. Further, they are “new drugs” within the meaning of section 201(p) of the FDCA [21 U.S.C. § 321(p)] because they are not generally recognized as safe and effective for their labeled uses.\u003C\u002Fli>\n                      \u003Cli id=\"footnote2_gm2b1es\">\u003Ca href=\"#footnoteref2_gm2b1es\">2\u003C\u002Fa>Overstatements of efficacy or minimization of risk are of particular concern and may constitute misbranding.\u003C\u002Fli>\n      \u003C\u002Fol>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA ELECTRONIC MAIL READ\u002FDELIVERY RECEIPT REQUESTED\n\nProduct:\n\nDrugs\n\nRecipient:\n\nGet.Fit.Medical, LLC dba Get.Fit.Medical\n\nUnited States\n\nhttps:\u002F\u002Fwww.getfitmedical.com\n\ndrewcromer@getfitmedical.com\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nSecondary Issuing Offices\n\nUnited States\n\nWARNING LETTER\nSeptember 9, 2025\nGet.Fit.Medical:\nThis letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https:\u002F\u002Fwww.getfitmedical.com in August 2025 and has observed that your website offers various compounded drug products, including sildenafil, tadalafil, semaglutide, and tirzepatide.1 As described below, your claims concerning compounded sildenafil, tadalafil, semaglutide, and tirzepatide products are false or misleading under sections 502(a) and 502(bb) of the Federal Food, Drug, and Cosmetic Act (FDCA) [21 U.S.C. §§ 352(a) and 352(bb)], resulting in products being introduced or delivered for introduction into interstate commerce in violation of section 301(a) of the FDCA [21 U.S.C. § 331(a)].\nUnder section 502(a) of the FDCA [21 U.S.C. § 352(a)] a drug is misbranded if its labeling is false or misleading in any particular. Furthermore, under section 502(bb) of the FDCA [21 U.S.C. § 352(bb)], a compounded drug is misbranded if its advertising or promotion is false or misleading in any particular.\nThe following claims concerning compounded sildenafil, tadalafil, semaglutide, and tirzepatide products appear on webpages that offer only compounded products:\n• “SILDENAFIL (GENERIC VIAGRA)”\n• “TADALAFIL (GENERIC CIALIS)”\n• “SEMAGLUTIDE (GENERIC OZEMPIC\u002FWEGOVY)”\n• “TIRZEPATIDE (GENERIC MOUNJARO)”\nCompounded drug products are not FDA-approved. Your claims imply that your products are the same as an FDA-approved product when they are not. As a result, these claims are false or misleading and your products are therefore misbranded under sections 502(a) and 502(bb) of the FDCA [21 U.S.C. §§ 352(a) and (bb)].\nThe introduction or delivery for introduction into interstate commerce of these misbranded products is a prohibited act under section 301(a) of the FDCA [21 U.S.C. § 331(a)]. The claims identified in this letter put you on notice of our concerns but do not represent an exhaustive list of misbranding violations.2\nFor the reasons discussed above, your compounded sildenafil, tadalafil, semaglutide, and tirzepatide products are misbranded drugs under sections 502(a) and 502(bb) of the FDCA [21 U.S.C. §§ 352(a) and 352(bb)], introduced or delivered for introduction into interstate commerce in violation of section 301(a) of the FDCA [21 U.S.C. § 331(a)]. Please be advised, the receipt in interstate commerce of misbranded drugs, and the delivery or proffered delivery thereof, is also a violation of section 301(c) of the FDCA [21 U.S.C. § 331(c)].\nAs previously stated, the violations cited in this letter are not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your operations comply with all requirements of federal law, including FDA regulations.\nYou should take immediate action to address any violations (including, for example, ceasing and desisting from using the language cited above that misbrands the product). Failure to adequately address any violations may result in legal action without further notice, including, without limitation, seizure and injunction.\nWithin fifteen (15) working days of receipt of this letter, please provide a written response to the Office of Compounding Quality and Compliance (OCQC) within the Center for Drug Evaluation and Research (CDER)’s Office of Compliance describing the specific steps you have taken to address any violations. Please include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. This letter notifies you of our concerns and provides you an opportunity to address them. If you believe your products are not in violation of the FDCA, include your reasoning and any supporting information for our consideration. If you cannot completely address this matter within fifteen (15) working days, state the reason for the delay and the time within which you will do so.\nIf you are not located in the U.S., please note that products that appear to be misbranded may be detained or refused admission. We may advise the appropriate regulatory officials in the country from which you operate that your products referenced above appear to be misbranded drugs that cannot be legally sold to consumers in the U.S.\nAll correspondence should include a subject line that clearly identifies the submission as a Response to Warning Letter. If you have questions regarding the contents of this letter, please contact compoundinginspections@fda.hhs.gov.\n\nSincerely,\n\u002FS\u002F\nGeorge Tidmarsh, M.D., Ph.D.\nDirector\nCenter for Drug Evaluation and Research\nU.S. Food and Drug Administration\n\n1The sildenafil, tadalafil, semaglutide, and tirzepatide products offered on your website are drugs within the meaning of section 201(g) of the FDCA [21 U.S.C. § 321(g)] because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of diseases and\u002For because they are intended to affect the structure or any function of the body. Further, they are “new drugs” within the meaning of section 201(p) of the FDCA [21 U.S.C. § 321(p)] because they are not generally recognized as safe and effective for their labeled uses.\n\n2Overstatements of efficacy or minimization of risk are of particular concern and may constitute misbranding.","Get.Fit.Medical, LLC dba Get.Fit.Medical","getfitmedical-llc-dba-getfitmedical-715801-09092025","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fgetfitmedical-llc-dba-getfitmedical-715801-09092025","2026-10-26T08:08:45.732183+00:00","715801","2026-08-19T16:21:40.471+00:00",{"id":234,"raw":235,"subject":188,"body_html":237,"body_text":238,"firm_name":239,"letter_id":240,"created_at":193,"fei_number":19,"letter_url":241,"updated_at":242,"action_type":22,"case_status":23,"posted_date":196,"marcs_cms_no":243,"product_type":48,"closeout_date":19,"issuing_office":37,"recipient_name":19,"body_fetched_at":244,"delivery_method":73,"recipient_title":19,"reference_number":19,"action_taken_date":200,"medical_device_id":19,"response_letter_date":19},608,[223,186,236,37,188,13,13,13],"\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Flas-villas-health-care-llc-dba-villas-health-716504-09092025\">Las Villas Health Care LLC dba Villas Health\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA ELECTRONIC MAIL READ\u002FDELIVERY RECEIPT REQUESTED\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\u003C\u002Fdd>\n                    \n            \u003Cdd>Las Villas Health Care LLC dba Villas Health\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>401 Coral Way Suite 201\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Coral Gables\u003C\u002Fspan>, \u003Cspan>FL\u003C\u002Fspan> \u003Cspan>33134\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:office@villashealth.com\"> office@villashealth.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n  \u003Cdiv>\n    \u003Cdiv>Secondary Issuing Offices\u003C\u002Fdiv>\n          \u003Cdiv>\n              \u003Cdiv>    \u003Cbr>\n    \n     \n        \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n    \n    \n    \n    \n\u003C\u002Fdiv>\n              \u003C\u002Fdiv>\n      \u003C\u002Fdiv>\n\n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>September 9, 2025\u003C\u002Fp>\u003Cp>Villas Health:\u003C\u002Fp>\u003Cp>This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https:\u002F\u002Fvillashealth.com in August 2025 and has observed that your website offers various compounded drug products, including semaglutide and sildenafil.\u003Ca id=\"footnoteref1_f0fiwhc\" href=\"#footnote1_f0fiwhc\">\u003Csup>1\u003C\u002Fsup>\u003C\u002Fa>&nbsp;As described below, your claims concerning compounded semaglutide and sildenafil products are false or misleading under sections 502(a) and 502(bb) of the Federal Food, Drug, and Cosmetic Act (FDCA) [21 U.S.C. §§ 352(a) and 352(bb)], resulting in products being introduced or delivered for introduction into interstate commerce in violation of section 301(a) of the FDCA [21 U.S.C. § 331(a)].\u003C\u002Fp>\u003Cp>Under section 502(a) of the FDCA [21 U.S.C. § 352(a)] a drug is misbranded if its labeling is false or misleading in any particular. Furthermore, under section 502(bb) of the FDCA [21 U.S.C. § 352(bb)], a compounded drug is misbranded if its advertising or promotion is false or misleading in any particular.\u003C\u002Fp>\u003Cp>The following claims concerning compounded semaglutide and sildenafil products appear on your website:\u003Cbr>• “Semaglutide GLP-1 is a once-a-week injection that contains the same active ingredient as Ozempic and Wegovy….”\u003Cbr>• “Sildenafil 2%: the active ingredient in Viagra. Clinically proven to improve outcomes in women with sexual arousal disorder by increasing blood flow to the genitals.”\u003C\u002Fp>\u003Cp>Compounded drug products are not FDA-approved. Your claims imply that your products are the same as an FDA-approved product when they are not. As a result, these claims are false or misleading and your products are therefore misbranded under sections 502(a) and 502(bb) of the FDCA [21 U.S.C. §§ 352(a) and (bb)].\u003C\u002Fp>\u003Cp>The introduction or delivery for introduction into interstate commerce of these misbranded products is a prohibited act under section 301(a) of the FDCA [21 U.S.C. § 331(a)]. The claims identified in this letter put you on notice of our concerns but do not represent an exhaustive list of misbranding violations.\u003Ca id=\"footnoteref2_f907p23\" href=\"#footnote2_f907p23\">\u003Csup>2\u003C\u002Fsup>\u003C\u002Fa>\u003C\u002Fp>\u003Cp>For the reasons discussed above, your compounded semaglutide and sildenafil products are misbranded drugs under sections 502(a) and 502(bb) of the FDCA [21 U.S.C. §§ 352(a) and 352(bb)], introduced or delivered for introduction into interstate commerce in violation of section 301(a) of the FDCA [21 U.S.C. § 331(a)]. Please be advised, the receipt in interstate commerce of misbranded drugs, and the delivery or proffered delivery thereof, is also a violation of section 301(c) of the FDCA [21 U.S.C. § 331(c)].\u003C\u002Fp>\u003Cp>As previously stated, the violations cited in this letter are not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your operations comply with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\u003Cp>You should take immediate action to address any violations (including, for example, ceasing and desisting from using the language cited above that misbrands the product). Failure to adequately address any violations may result in legal action without further notice, including, without limitation, seizure and injunction.\u003C\u002Fp>\u003Cp>Within fifteen (15) working days of receipt of this letter, please provide a written response to the Office of Compounding Quality and Compliance (OCQC) within the Center for Drug Evaluation and Research (CDER)’s Office of Compliance describing the specific steps you have taken to address any violations. Please include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. This letter notifies you of our concerns and provides you an opportunity to address them. If you believe your products are not in violation of the FDCA, include your reasoning and any supporting information for our consideration. If you cannot completely address this matter within fifteen (15) working days, state the reason for the delay and the time within which you will do so.\u003C\u002Fp>\u003Cp>If you are not located in the U.S., please note that products that appear to be misbranded may be detained or refused admission. We may advise the appropriate regulatory officials in the country from which you operate that your products referenced above appear to be misbranded drugs that cannot be legally sold to consumers in the U.S.\u003C\u002Fp>\u003Cp>All correspondence should include a subject line that clearly identifies the submission as a Response to Warning Letter. If you have questions regarding the contents of this letter, please contact compoundinginspections@fda.hhs.gov.\u003C\u002Fp>\u003Cp>\u003Cbr>Sincerely,\u003Cbr>\u002FS\u002F\u003Cbr>George Tidmarsh, M.D., Ph.D.\u003Cbr>Director\u003Cbr>Center for Drug Evaluation and Research\u003Cbr>U.S. Food and Drug Administration\u003C\u002Fp>\n\n\u003Col>\n                  \u003Cli id=\"footnote1_f0fiwhc\">\u003Ca href=\"#footnoteref1_f0fiwhc\">1\u003C\u002Fa>The semaglutide and sildenafil products offered on your website are drugs within the meaning of section 201(g) of the FDCA [21 U.S.C. § 321(g)] because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of diseases and\u002For because they are intended to affect the structure or any function of the body. Further, they are “new drugs” within the meaning of section 201(p) of the FDCA [21 U.S.C. § 321(p)] because they are not generally recognized as safe and effective for their labeled uses.\u003C\u002Fli>\n                      \u003Cli id=\"footnote2_f907p23\">\u003Ca href=\"#footnoteref2_f907p23\">2\u003C\u002Fa>Overstatements of efficacy or minimization of risk are of particular concern and may constitute misbranding.\u003C\u002Fli>\n      \u003C\u002Fol>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA ELECTRONIC MAIL READ\u002FDELIVERY RECEIPT REQUESTED\n\nProduct:\n\nDrugs\n\nRecipient:\n\nLas Villas Health Care LLC dba Villas Health\n\n401 Coral Way Suite 201\n\nCoral Gables, FL 33134\n\nUnited States\n\noffice@villashealth.com\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nSecondary Issuing Offices\n\nUnited States\n\nWARNING LETTER\nSeptember 9, 2025\nVillas Health:\nThis letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https:\u002F\u002Fvillashealth.com in August 2025 and has observed that your website offers various compounded drug products, including semaglutide and sildenafil.1 As described below, your claims concerning compounded semaglutide and sildenafil products are false or misleading under sections 502(a) and 502(bb) of the Federal Food, Drug, and Cosmetic Act (FDCA) [21 U.S.C. §§ 352(a) and 352(bb)], resulting in products being introduced or delivered for introduction into interstate commerce in violation of section 301(a) of the FDCA [21 U.S.C. § 331(a)].\nUnder section 502(a) of the FDCA [21 U.S.C. § 352(a)] a drug is misbranded if its labeling is false or misleading in any particular. Furthermore, under section 502(bb) of the FDCA [21 U.S.C. § 352(bb)], a compounded drug is misbranded if its advertising or promotion is false or misleading in any particular.\nThe following claims concerning compounded semaglutide and sildenafil products appear on your website:\n• “Semaglutide GLP-1 is a once-a-week injection that contains the same active ingredient as Ozempic and Wegovy….”\n• “Sildenafil 2%: the active ingredient in Viagra. Clinically proven to improve outcomes in women with sexual arousal disorder by increasing blood flow to the genitals.”\nCompounded drug products are not FDA-approved. Your claims imply that your products are the same as an FDA-approved product when they are not. As a result, these claims are false or misleading and your products are therefore misbranded under sections 502(a) and 502(bb) of the FDCA [21 U.S.C. §§ 352(a) and (bb)].\nThe introduction or delivery for introduction into interstate commerce of these misbranded products is a prohibited act under section 301(a) of the FDCA [21 U.S.C. § 331(a)]. The claims identified in this letter put you on notice of our concerns but do not represent an exhaustive list of misbranding violations.2\nFor the reasons discussed above, your compounded semaglutide and sildenafil products are misbranded drugs under sections 502(a) and 502(bb) of the FDCA [21 U.S.C. §§ 352(a) and 352(bb)], introduced or delivered for introduction into interstate commerce in violation of section 301(a) of the FDCA [21 U.S.C. § 331(a)]. Please be advised, the receipt in interstate commerce of misbranded drugs, and the delivery or proffered delivery thereof, is also a violation of section 301(c) of the FDCA [21 U.S.C. § 331(c)].\nAs previously stated, the violations cited in this letter are not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your operations comply with all requirements of federal law, including FDA regulations.\nYou should take immediate action to address any violations (including, for example, ceasing and desisting from using the language cited above that misbrands the product). Failure to adequately address any violations may result in legal action without further notice, including, without limitation, seizure and injunction.\nWithin fifteen (15) working days of receipt of this letter, please provide a written response to the Office of Compounding Quality and Compliance (OCQC) within the Center for Drug Evaluation and Research (CDER)’s Office of Compliance describing the specific steps you have taken to address any violations. Please include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. This letter notifies you of our concerns and provides you an opportunity to address them. If you believe your products are not in violation of the FDCA, include your reasoning and any supporting information for our consideration. If you cannot completely address this matter within fifteen (15) working days, state the reason for the delay and the time within which you will do so.\nIf you are not located in the U.S., please note that products that appear to be misbranded may be detained or refused admission. We may advise the appropriate regulatory officials in the country from which you operate that your products referenced above appear to be misbranded drugs that cannot be legally sold to consumers in the U.S.\nAll correspondence should include a subject line that clearly identifies the submission as a Response to Warning Letter. If you have questions regarding the contents of this letter, please contact compoundinginspections@fda.hhs.gov.\n\nSincerely,\n\u002FS\u002F\nGeorge Tidmarsh, M.D., Ph.D.\nDirector\nCenter for Drug Evaluation and Research\nU.S. Food and Drug Administration\n\n1The semaglutide and sildenafil products offered on your website are drugs within the meaning of section 201(g) of the FDCA [21 U.S.C. § 321(g)] because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of diseases and\u002For because they are intended to affect the structure or any function of the body. Further, they are “new drugs” within the meaning of section 201(p) of the FDCA [21 U.S.C. § 321(p)] because they are not generally recognized as safe and effective for their labeled uses.\n\n2Overstatements of efficacy or minimization of risk are of particular concern and may constitute misbranding.","Las Villas Health Care LLC dba Villas Health","las-villas-health-care-llc-dba-villas-health-716504-09092025","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Flas-villas-health-care-llc-dba-villas-health-716504-09092025","2026-10-26T08:09:12.523015+00:00","716504","2026-08-19T16:23:04.859+00:00",{"id":246,"raw":247,"subject":252,"body_html":254,"body_text":255,"firm_name":256,"letter_id":257,"created_at":258,"fei_number":19,"letter_url":259,"updated_at":260,"action_type":22,"case_status":261,"posted_date":262,"marcs_cms_no":263,"product_type":26,"closeout_date":264,"issuing_office":251,"recipient_name":265,"body_fetched_at":266,"delivery_method":267,"recipient_title":19,"reference_number":19,"action_taken_date":268,"medical_device_id":19,"response_letter_date":19},2978,[248,249,250,251,252,13,253,13],"\u003Ctime datetime=\"2021-12-14T14:20:00Z\">12\u002F14\u002F2021\u003C\u002Ftime>\n","\u003Ctime datetime=\"2021-11-23T05:00:00Z\">11\u002F23\u002F2021\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fdevilbiss-healthcare-llc-619182-11232021\">DeVilbiss Healthcare LLC\u003C\u002Fa>","Office of Medical Device and Radiological Health Operations (Division 1)","Medical Device Reporting\u002FMisbranded","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fdrive-devilbiss-healthcare-llc-619182-10232024\">\u003Ctime datetime=\"2024-10-30T04:00:00Z\">10\u002F30\u002F2024\u003C\u002Ftime>\n\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>UNITED PARCEL SERVICE OVERNIGHT DELIVERY and EMAIL\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Derek Lampert\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Chief Executive Officer\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>DeVilbiss Healthcare LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>99 Seaview Blvd, Suite 210\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Port Washington\u003C\u002Fspan>, \u003Cspan>NY\u003C\u002Fspan> \u003Cspan>11050\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Office of Medical Device and Radiological Health Operations (Division 1)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>Dear Mr. Lampert:\u003C\u002Fp>\n\n\u003Cp>The United States Food and Drug Administration (FDA) conducted an inspection of your firm’s medical device operations at 100 DeVilbiss Dr, Somerset, PA, from 7\u002F28\u002F21 – 8\u002F25\u002F21. &nbsp;During the inspection, an FDA investigator determined that your firm is a manufacturer of oxygen concentrators, nebulizers, suction units, non-continuous ventilators and related accessories. &nbsp;Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\u003C\u002Fp>\n\n\u003Cp>This inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820. We received responses on September 16, 2021 and November 12, 2021 from Tony Sapp, Director, Regulatory Affairs and Audits, concerning our investigator’s observations noted on the Form FDA 483, List of Inspectional Observations (FDA-483) that was issued on August 25, 2021. &nbsp;We address the responses below, in relation to each of the noted violations. &nbsp;These violations include, but are not limited to, the following:\u003C\u002Fp>\n\n\u003Cp>1.&nbsp;&nbsp; &nbsp;Failure to confirm that design outputs meet design input requirements during design verification testing, as required by 21 CFR 820.30(f). &nbsp;Specifically,\u003C\u002Fp>\n\n\u003Cp>The model 525 oxygen concentrator is designed using the ZW280D2 compressor, which is specified by the manufacturer for an operating ambient temperature range of 40°F-\u003Cstrong>(b)(4)\u003C\u002Fstrong>°F (5°C-\u003Cstrong>(b)(4)\u003C\u002Fstrong>°C). &nbsp;Design verification test report for IEC 60601-01, Medical Electrical Equipment, report no. 31691761.005, 2018, Table 11-1-1, page 149, states that thermocouple measurements taken in the interior of the finished device showed an interior temperature above the temperature specifications of the compressor in \u003Cstrong>(b)(4)\u003C\u002Fstrong> of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> measurement sites at an environmental temperature of 22.9°C. At 40˚C, the interior temperature was above the temperature specifications of the compressor at all ten measurement sites. &nbsp;\u003C\u002Fp>\n\n\u003Cp>We reviewed your responses for this matter and conclude that they are not adequate. &nbsp;In your initial response you provided test reports that showed device interior temperatures ambient to the compressor to be frequently above the stated specification of \u003Cstrong>(b)(4)\u003C\u002Fstrong>°C. &nbsp;You based your response on a statement in the manufacturer’s specification, “It is the responsibility of the user to determine the suitability of the product for their intended use.” &nbsp;Your response maintains that this statement allows you to use a compressor for a use above its specified temperature range as long as you perform testing that shows the compressor is able to function above its recommended range. &nbsp;This testing does not address all aspects of the product’s intended use, including the long-term effects on a compressor that operates for many hours above its specified range, including overheating, worn cup seals, fan failures, and shortened life span.\u003C\u002Fp>\n\n\u003Cp>Included in your initial response is your “GSE Compressor Life Test Report,” which you maintain, demonstrates that the compressor is capable of operating for a normal lifetime at \u003Cstrong>(b)(4)\u003C\u002Fstrong>°C. This document, however, is of a study done to establish the expected lifespan of the compressor through accelerated aging. &nbsp;The \u003Cstrong>(b)(4)\u003C\u002Fstrong>°C ambient temperature is one of the stress factors used in the study. &nbsp;This would demonstrate not that \u003Cstrong>(b)(4)\u003C\u002Fstrong>°C is acceptable for long term operation, but instead shows that it is a high temperature that stresses the compressor for purposes of accelerated aging.&nbsp;\u003C\u002Fp>\n\n\u003Cp>In your response of 11\u002F12\u002F21 you provided two test reports, “Compressor Temperature Test Protocol and Report,” and “\u003Cstrong>(b)(4)\u003C\u002Fstrong> Test Protocol and Report.” &nbsp;The test of compressor temperatures ran for a duration of \u003Cstrong>(b)(4)\u003C\u002Fstrong> and used visual acceptance criteria of “no damage or deformation.” Ambient temperatures were recorded within the \u003Cstrong>(b)(4)\u003C\u002Fstrong> period that were higher than the manufacturer’s specified temperature for the compressors. &nbsp;The 525 Oxygen Concentrator is typically run for much longer periods of time than only \u003Cstrong>(b)(4)\u003C\u002Fstrong>, resulting in possible temperature \u003Cstrong>(b)(4)\u003C\u002Fstrong> that could result in much higher ambient temperatures over time. &nbsp;The test of \u003Cstrong>(b)(4)\u003C\u002Fstrong> did not include any definition of a time element in the test method or results. &nbsp;It cannot be determined the duration of the test, or how often data readings were taken.&nbsp;\u003C\u002Fp>\n\n\u003Cp>Please provide documentation that describes how you will address the fact that you are commercially marketing a device that is designed and built with a major component that has been shown by testing to be operating in ambient temperatures above its specified temperature range. &nbsp;\u003C\u002Fp>\n\n\u003Cp>2.&nbsp;&nbsp; &nbsp;Failure to maintain complaint files and establish and maintain procedures for receiving, reviewing, and evaluating complaints by a formally designated unit, as required by 21 CFR 820.198(a). &nbsp;Specifically,&nbsp;\u003C\u002Fp>\n\n\u003Cp>Your Complaint Handling Procedure, DVHC-SOP-0020, rev. 2, states in section 6.0 that Regulatory Affairs will ensure that complaints are reviewed and evaluated “in a timely and uniform fashion.” &nbsp;The procedure further provides in section 7.3, that a determination is made whether serious injury or death was reported and whether medical intervention was required. You are not following your procedure in that complaints are not documented in a timely manner and you are not documenting the determination of whether or not the complaint is reportable under 21 CFR Part 803 – Medical Device Reporting. &nbsp;Examples include, but are not limited to:\u003C\u002Fp>\n\n\u003Cp>•&nbsp;&nbsp; &nbsp;Complaint RO_0320803 was reported to an employee in customer service on 01\u002F19\u002F2021 and described a patient who was in distress from receiving low oxygen; however, the complaint was documented on 04\u002F02\u002F2021, 73 days later, simply as “defective alarm.”&nbsp;\u003C\u002Fp>\n\n\u003Cp>•&nbsp;&nbsp; &nbsp;Complaints were not reviewed for MDR reportability as prescribed in DVHC-SOP-0020, Complaint Handling Procedure, section 7.4, that requires each complaint to be evaluated for reportability according to Adverse Event Reporting procedure DVHC-SOP-0021, including documentation on the applicable form, Adverse Event Determination Form (DVHC-FORM-0105), which requires providing all information necessary to make a reportability determination. &nbsp;Examples include:&nbsp;\u003C\u002Fp>\n\n\u003Cp>&nbsp;RO_0264829, received on 04\u002F02\u002F2020\u003Cbr>\n­ RO_0252308, received on 1\u002F28\u002F2020\u003Cbr>\n­ RO_0208546, received on 04\u002F05\u002F2019\u003Cbr>\n­ RO_0180765, received on 08\u002F23\u002F2018\u003C\u002Fp>\n\n\u003Cp>•&nbsp;&nbsp; &nbsp;Complaint #RO_0208546, recorded on 04\u002F05\u002F2019, alleges a possible malfunction with a DeVilbiss 525DS Oxygen Concentrator, serial number \u003Cstrong>(b)(4)\u003C\u002Fstrong>, in which the complaint documented “extremely hot in the patient’s home to the point where they were smoking and too hot to touch. The one that happened today happened during a set up and the machine was only running for about 20 minutes while my tech was doing his instruction. The wife commented that she smelled something burning and the tech noticed the concentrator smoking and unplugged it. The machine never alarmed or turned off. The machine stayed hot to the touch for about 40 minutes. When it got back to the warehouse, I noticed that it had just been serviced by DeVilbiss on 3\u002F21\u002F19.” &nbsp;No information regarding the patient was included in the complaint report; there was no record of attempt to obtain patient information; and no record of follow-up with complainant to gather information relevant to determination of reportability.\u003C\u002Fp>\n\n\u003Cp>•&nbsp;&nbsp; &nbsp;Complaint #RO_0252308, recorded on 1\u002F28\u002F2020, alleges a possible malfunction with a DeVilbiss 525DS Oxygen Concentrator, serial number \u003Cstrong>(b)(4)\u003C\u002Fstrong>, in which the complaint documented the unit had clearly overheated as the case interior was melting and deforming as well as a portion of the back cover, and gross particle filter housing. The outlet air tubing from the compressor was so hot that it began melting the foam insulation of the back cover. The cooling fan below the compressor was not running at all. The complaint further documented it was self-evident that was a failure of the thermal cutoff for this unit as it should have shut down well before it ever got hot enough to begin to melt itself. &nbsp;No documentation of complainant or record of attempt to contact complainant to gather information relevant to reportability.\u003C\u002Fp>\n\n\u003Cp>We have reviewed your responses dated 9\u002F16\u002F21 and 11\u002F12\u002F21 and concluded that the adequacy of your responses cannot be determined at this time. Your responses state that you are revising complaint handling procedures to create more guidance with complaint detail record keeping. Your response also describes an ongoing effort to review complaints received between March 26, 2018 and July 27, 2021.&nbsp;\u003C\u002Fp>\n\n\u003Cp>Please provide documentation demonstrating that you have established the applicable procedures for receiving, reviewing and evaluating complaints by a formally designated unit, ensuring that all complaints are processed in a uniform and timely manner, oral complaints are documented on receipt; and complaints are evaluated to determine whether the complaint represents a reportable event. &nbsp;\u003C\u002Fp>\n\n\u003Cp>\u003Cbr>\n3.&nbsp;&nbsp; &nbsp;Failure to adequately establish procedures for corrective and preventive action, as required by 21 CFR 820.100(a). &nbsp;Specifically,&nbsp;\u003C\u002Fp>\n\n\u003Cp>Your CAPA procedure, DVHC-SOP-0029, Rev 03, section 7.2.5, states that a CAPA will be created when “a review of quality data suggests that \u003Cstrong>(b)(4)\u003C\u002Fstrong> is trending in a direction that could lead to a potential undesirable event.” &nbsp;No provision in your CAPA procedure requires opening a CAPA for a quality issue that presents a high risk to patients, and not necessarily based only on a \u003Cstrong>(b)(4)\u003C\u002Fstrong> “trending in a direction that could lead to a potential undesirable event.”\u003C\u002Fp>\n\n\u003Cp>We have reviewed your responses dated 9\u002F16\u002F21 and 11\u002F12\u002F21 and concluded that the adequacy of your responses cannot be determined at this time. &nbsp;Your initial response maintains that the rate of occurrence should not be calculated based on total complaints but based on total devices in the field. &nbsp;Your response does not address defining “trending in a direction that could lead to a potential undesirable event,” or what types of quality data are to be considered more significant indicators of possible quality issues than others. &nbsp;It does not address opening CAPAs commensurate with the significance and risk of the nonconformity. &nbsp;Your response of 11\u002F12\u002F21 describes your efforts to review complaints and establish a new risk-based alert limit for complaint reporting, and a timely and recurring complaint risk review.&nbsp;\u003C\u002Fp>\n\n\u003Cp>Please provide examples of how you are documenting and analyzing these quality data, and how your procedure assures that your investigations of events are commensurate with the significance and risk of nonconformities and events.\u003C\u002Fp>\n\n\u003Cp>4.&nbsp;&nbsp; &nbsp;Failure to evaluate and investigate any complaint involving the possible failure of a device, labeling, or packaging to meet any of its specifications, unless such investigation has already been performed for a similar complaint and another investigation is not necessary, as required by 21 CFR 820.198(c). &nbsp;Specifically,&nbsp;\u003C\u002Fp>\n\n\u003Cp>Your Complaint Handling Procedure, DVHC-SOP-0020, rev. 2, states in section 7.1.4 that any complaint involving the possible failure of a device, labeling, or packaging to meet any of its specifications shall be reviewed, evaluated and investigated unless an investigation has already been performed for a similar complaint and another investigation is not necessary. &nbsp;The following is an example of a complaint record that included documentation that parts were replaced or serviced, but did not document failure investigations:\u003C\u002Fp>\n\n\u003Cp>•&nbsp;&nbsp; &nbsp;Complaint #RO_0331417. The firm documented “FAIL” as the only information with the complaint and in the additional notes, documented “Na Nean” referring to a slang term “Na Mean”. The record notes state that the sieve beds were replaced due to low O2, and the compressor was replaced due to low pressure. The investigation does not document why the compressor, which was under warranty, failed.\u003C\u002Fp>\n\n\u003Cp>We have reviewed your responses dated 9\u002F16\u002F21 and 11\u002F12\u002F21 and concluded that the adequacy of your responses cannot be determined at this time. Your responses state that you are revising complaint handling procedures to create more guidance with complaint detail record keeping. Additionally, you are currently reviewing complaints received between March 26, 2018 and July 27, 2021. &nbsp;\u003C\u002Fp>\n\n\u003Cp>Please provide documentation demonstrating that you have established the applicable procedures to evaluate and investigate any complaint involving the possible failure of a device, labeling, or packaging to meet any of its specifications and the outcome of your retrospective review.\u003C\u002Fp>\n\n\u003Cp>5.&nbsp;&nbsp; &nbsp;Failure to establish procedures for rework of nonconforming products, including retesting and reevaluation of the nonconforming product after rework, to ensure that the product meets its current approved specifications; as well as documentation of the rework and reevaluation activities in the DHR, including a determination of any adverse effect from the rework upon the product, as required by 21 CFR 820.90(b)(2). &nbsp;Specifically, you do not have a written procedure that governs rework for in-process products. &nbsp;\u003C\u002Fp>\n\n\u003Cp>We have reviewed your responses dated 9\u002F16\u002F21 and 11\u002F12\u002F21 and concluded that they are inadequate. &nbsp;Your response of 11\u002F12\u002F21 provided your new in-process rework procedure, which does not require that a record of testing after rework must be included in that unit’s device history record (DHR). &nbsp;\u003C\u002Fp>\n\n\u003Cp>Please provide documentation that demonstrates you have established and implemented your procedure governing rework of in-process products, and that all rework activities and testing are recorded in the device history record (DHR).\u003C\u002Fp>\n\n\u003Cp>Our inspection also revealed that these devices are misbranded within the meaning of Section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information regarding the device that is required by or under Section 519 of the Act, 21 U.S.C. § 360i, and 21 CFR Part 803 – Medical Device Reporting. Violation includes, but is not limited to:\u003C\u002Fp>\n\n\u003Cp>6.&nbsp;&nbsp; &nbsp;Failure to establish an internal system which provides for timely and effective identification, communication and evaluation of events that may be subject to medical device reporting requirements, as required by 21 CFR 803.17(a)(1). &nbsp;Specifically, Complaints were not reviewed and recorded as unreportable for over 200 days after receipt of the complaint. &nbsp;Examples include but are not limited to, complaint numbers RO_0174581, RO_0171904, RO_0188624, and RO_0198227. &nbsp;\u003C\u002Fp>\n\n\u003Cp>We have reviewed your responses dated 9\u002F16\u002F21 and 11\u002F12\u002F21 and concluded that the adequacy of your responses cannot be determined at this time. &nbsp;Your responses state that you are reviewing and updating your procedures and processes for complaint handling and MDR reporting regarding intake, review, evaluation, and reporting of complaints. &nbsp;\u003C\u002Fp>\n\n\u003Cp>Please provide documentation that demonstrates you have established and implemented a procedure which provides for timely and effective identification, communication and evaluation of events that may be subject to medical device reporting requirements. &nbsp;\u003C\u002Fp>\n\n\u003Cp>7.&nbsp;&nbsp; &nbsp;Failure to submit an MDR report within 30 days of receiving or otherwise becoming aware of information that reasonably suggests that a marketed device may have malfunctioned or caused or contributed to a death or serious injury, as required by 21 CFR 803.50(a)(1). &nbsp;Specifically,&nbsp;\u003C\u002Fp>\n\n\u003Cp>On 01\u002F19\u002F2021, you were contacted regarding an injury event in which the patient suffered dyspnea, anxiety, low oxygen saturation and shaking\u002Ftremors, alleging a malfunction with a DeVilbiss 525DS Oxygen Concentrator, serial number \u003Cstrong>(b)(4)\u003C\u002Fstrong>. &nbsp;An MDR was not submitted to FDA until 04\u002F06\u002F2021. You did not report an adverse event within 30 days.\u003C\u002Fp>\n\n\u003Cp>We have reviewed your responses dated 9\u002F16\u002F21 and 11\u002F12\u002F21 and concluded that the adequacy of your responses cannot be determined at this time. &nbsp;Your responses state that you are revising the applicable procedures and conducting training to ensure clarification on the specific information that should be collected as part of the complaint intake process, including robust incident details to ensure prompt and compliant escalation to Regulatory Affairs for evaluation in regard to MDR filing. &nbsp;\u003C\u002Fp>\n\n\u003Cp>You also state that, based on your review of complaints thus far, you have identified several events where MDRs should have been reported, and are in the process of identifying additional events for reporting. &nbsp;These corrective actions are ongoing at this time.\u003C\u002Fp>\n\n\u003Cp>Please provide documentation that demonstrates that you have submitted MDRs for all applicable complaints that reasonably suggest that a marketed device may have caused or contributed to a death or serious injury, and that reportable events received since the time of the inspection have been reported within the required 30-day timeframe.\u003C\u002Fp>\n\n\u003Cp>Your firm should take prompt action to correct the violations addressed in this letter. &nbsp;Failure to promptly correct these violations may result in regulatory action being initiated by the FDA without further notice. &nbsp;These actions include, but are not limited to, seizure, injunction, and civil money penalties. &nbsp;Also, federal agencies may be advised of the issuance of Warning Letters about devices so that they may take this information into account when considering the award of contracts. &nbsp;\u003C\u002Fp>\n\n\u003Cp>Additionally, should FDA determine that you have Quality System Regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been corrected. &nbsp;Also, should FDA determine that your devices do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted. If you believe that your products are not in violation of the Act, please respond to FDA with your reasoning and any supporting information for our consideration. &nbsp;\u003C\u002Fp>\n\n\u003Cp>Please notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to correct the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. &nbsp;Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. &nbsp;If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. &nbsp;If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. &nbsp;Your firm’s response should be comprehensive and address all violations included in this Warning Letter.&nbsp;\u003C\u002Fp>\n\n\u003Cp>If you have questions regarding any issues in this letter, please contact Compliance Officer Richard Cherry at (215) 717-3075 or at richard.cherry@fda.hhs.gov. &nbsp;Please send your reply electronically to Gina Brackett, Director of Compliance Branch, at gina.brackett@fda.hhs.gov.&nbsp;\u003C\u002Fp>\n\n\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. &nbsp;It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. &nbsp;The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. &nbsp;Your firm should investigate and determine the causes of the violations and take prompt actions to correct the violations and bring the products into compliance.&nbsp;\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002Fs\u002F\u003Cbr>\nJoseph Matrisciano, Jr.\u003Cbr>\nProgram Division Director\u003Cbr>\nOffice of Medical Device and Radiological Health\u003Cbr>\nDivision 1\u003C\u002Fp>\n\n\u003Cp>cc: &nbsp;&nbsp; &nbsp;Joseph Lewarski, Senior Vice President, Clinical Affairs\u003Cbr>\n&nbsp;&nbsp; &nbsp;Tony Sapp, Director, Regulatory Affairs and Audits\u003Cbr>\n&nbsp;\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nUNITED PARCEL SERVICE OVERNIGHT DELIVERY and EMAIL\n\nProduct:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nDerek Lampert\n\nRecipient Title\n\nChief Executive Officer\n\nDeVilbiss Healthcare LLC\n\n99 Seaview Blvd, Suite 210\n\nPort Washington, NY 11050\n\nUnited States\n\nIssuing Office:\n\nOffice of Medical Device and Radiological Health Operations (Division 1)\n\nUnited States\n\nDear Mr. Lampert:\n\nThe United States Food and Drug Administration (FDA) conducted an inspection of your firm’s medical device operations at 100 DeVilbiss Dr, Somerset, PA, from 7\u002F28\u002F21 – 8\u002F25\u002F21. During the inspection, an FDA investigator determined that your firm is a manufacturer of oxygen concentrators, nebulizers, suction units, non-continuous ventilators and related accessories. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\n\nThis inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820. We received responses on September 16, 2021 and November 12, 2021 from Tony Sapp, Director, Regulatory Affairs and Audits, concerning our investigator’s observations noted on the Form FDA 483, List of Inspectional Observations (FDA-483) that was issued on August 25, 2021. We address the responses below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\n\n1. Failure to confirm that design outputs meet design input requirements during design verification testing, as required by 21 CFR 820.30(f). Specifically,\n\nThe model 525 oxygen concentrator is designed using the ZW280D2 compressor, which is specified by the manufacturer for an operating ambient temperature range of 40°F-(b)(4)°F (5°C-(b)(4)°C). Design verification test report for IEC 60601-01, Medical Electrical Equipment, report no. 31691761.005, 2018, Table 11-1-1, page 149, states that thermocouple measurements taken in the interior of the finished device showed an interior temperature above the temperature specifications of the compressor in (b)(4) of the (b)(4) measurement sites at an environmental temperature of 22.9°C. At 40˚C, the interior temperature was above the temperature specifications of the compressor at all ten measurement sites.\n\nWe reviewed your responses for this matter and conclude that they are not adequate. In your initial response you provided test reports that showed device interior temperatures ambient to the compressor to be frequently above the stated specification of (b)(4)°C. You based your response on a statement in the manufacturer’s specification, “It is the responsibility of the user to determine the suitability of the product for their intended use.” Your response maintains that this statement allows you to use a compressor for a use above its specified temperature range as long as you perform testing that shows the compressor is able to function above its recommended range. This testing does not address all aspects of the product’s intended use, including the long-term effects on a compressor that operates for many hours above its specified range, including overheating, worn cup seals, fan failures, and shortened life span.\n\nIncluded in your initial response is your “GSE Compressor Life Test Report,” which you maintain, demonstrates that the compressor is capable of operating for a normal lifetime at (b)(4)°C. This document, however, is of a study done to establish the expected lifespan of the compressor through accelerated aging. The (b)(4)°C ambient temperature is one of the stress factors used in the study. This would demonstrate not that (b)(4)°C is acceptable for long term operation, but instead shows that it is a high temperature that stresses the compressor for purposes of accelerated aging.\n\nIn your response of 11\u002F12\u002F21 you provided two test reports, “Compressor Temperature Test Protocol and Report,” and “(b)(4) Test Protocol and Report.” The test of compressor temperatures ran for a duration of (b)(4) and used visual acceptance criteria of “no damage or deformation.” Ambient temperatures were recorded within the (b)(4) period that were higher than the manufacturer’s specified temperature for the compressors. The 525 Oxygen Concentrator is typically run for much longer periods of time than only (b)(4), resulting in possible temperature (b)(4) that could result in much higher ambient temperatures over time. The test of (b)(4) did not include any definition of a time element in the test method or results. It cannot be determined the duration of the test, or how often data readings were taken.\n\nPlease provide documentation that describes how you will address the fact that you are commercially marketing a device that is designed and built with a major component that has been shown by testing to be operating in ambient temperatures above its specified temperature range.\n\n2. Failure to maintain complaint files and establish and maintain procedures for receiving, reviewing, and evaluating complaints by a formally designated unit, as required by 21 CFR 820.198(a). Specifically,\n\nYour Complaint Handling Procedure, DVHC-SOP-0020, rev. 2, states in section 6.0 that Regulatory Affairs will ensure that complaints are reviewed and evaluated “in a timely and uniform fashion.” The procedure further provides in section 7.3, that a determination is made whether serious injury or death was reported and whether medical intervention was required. You are not following your procedure in that complaints are not documented in a timely manner and you are not documenting the determination of whether or not the complaint is reportable under 21 CFR Part 803 – Medical Device Reporting. Examples include, but are not limited to:\n\n• Complaint RO_0320803 was reported to an employee in customer service on 01\u002F19\u002F2021 and described a patient who was in distress from receiving low oxygen; however, the complaint was documented on 04\u002F02\u002F2021, 73 days later, simply as “defective alarm.”\n\n• Complaints were not reviewed for MDR reportability as prescribed in DVHC-SOP-0020, Complaint Handling Procedure, section 7.4, that requires each complaint to be evaluated for reportability according to Adverse Event Reporting procedure DVHC-SOP-0021, including documentation on the applicable form, Adverse Event Determination Form (DVHC-FORM-0105), which requires providing all information necessary to make a reportability determination. Examples include:\n\nRO_0264829, received on 04\u002F02\u002F2020\n\n­ RO_0252308, received on 1\u002F28\u002F2020\n\n­ RO_0208546, received on 04\u002F05\u002F2019\n\n­ RO_0180765, received on 08\u002F23\u002F2018\n\n• Complaint #RO_0208546, recorded on 04\u002F05\u002F2019, alleges a possible malfunction with a DeVilbiss 525DS Oxygen Concentrator, serial number (b)(4), in which the complaint documented “extremely hot in the patient’s home to the point where they were smoking and too hot to touch. The one that happened today happened during a set up and the machine was only running for about 20 minutes while my tech was doing his instruction. The wife commented that she smelled something burning and the tech noticed the concentrator smoking and unplugged it. The machine never alarmed or turned off. The machine stayed hot to the touch for about 40 minutes. When it got back to the warehouse, I noticed that it had just been serviced by DeVilbiss on 3\u002F21\u002F19.” No information regarding the patient was included in the complaint report; there was no record of attempt to obtain patient information; and no record of follow-up with complainant to gather information relevant to determination of reportability.\n\n• Complaint #RO_0252308, recorded on 1\u002F28\u002F2020, alleges a possible malfunction with a DeVilbiss 525DS Oxygen Concentrator, serial number (b)(4), in which the complaint documented the unit had clearly overheated as the case interior was melting and deforming as well as a portion of the back cover, and gross particle filter housing. The outlet air tubing from the compressor was so hot that it began melting the foam insulation of the back cover. The cooling fan below the compressor was not running at all. The complaint further documented it was self-evident that was a failure of the thermal cutoff for this unit as it should have shut down well before it ever got hot enough to begin to melt itself. No documentation of complainant or record of attempt to contact complainant to gather information relevant to reportability.\n\nWe have reviewed your responses dated 9\u002F16\u002F21 and 11\u002F12\u002F21 and concluded that the adequacy of your responses cannot be determined at this time. Your responses state that you are revising complaint handling procedures to create more guidance with complaint detail record keeping. Your response also describes an ongoing effort to review complaints received between March 26, 2018 and July 27, 2021.\n\nPlease provide documentation demonstrating that you have established the applicable procedures for receiving, reviewing and evaluating complaints by a formally designated unit, ensuring that all complaints are processed in a uniform and timely manner, oral complaints are documented on receipt; and complaints are evaluated to determine whether the complaint represents a reportable event.\n\n3. Failure to adequately establish procedures for corrective and preventive action, as required by 21 CFR 820.100(a). Specifically,\n\nYour CAPA procedure, DVHC-SOP-0029, Rev 03, section 7.2.5, states that a CAPA will be created when “a review of quality data suggests that (b)(4) is trending in a direction that could lead to a potential undesirable event.” No provision in your CAPA procedure requires opening a CAPA for a quality issue that presents a high risk to patients, and not necessarily based only on a (b)(4) “trending in a direction that could lead to a potential undesirable event.”\n\nWe have reviewed your responses dated 9\u002F16\u002F21 and 11\u002F12\u002F21 and concluded that the adequacy of your responses cannot be determined at this time. Your initial response maintains that the rate of occurrence should not be calculated based on total complaints but based on total devices in the field. Your response does not address defining “trending in a direction that could lead to a potential undesirable event,” or what types of quality data are to be considered more significant indicators of possible quality issues than others. It does not address opening CAPAs commensurate with the significance and risk of the nonconformity. Your response of 11\u002F12\u002F21 describes your efforts to review complaints and establish a new risk-based alert limit for complaint reporting, and a timely and recurring complaint risk review.\n\nPlease provide examples of how you are documenting and analyzing these quality data, and how your procedure assures that your investigations of events are commensurate with the significance and risk of nonconformities and events.\n\n4. Failure to evaluate and investigate any complaint involving the possible failure of a device, labeling, or packaging to meet any of its specifications, unless such investigation has already been performed for a similar complaint and another investigation is not necessary, as required by 21 CFR 820.198(c). Specifically,\n\nYour Complaint Handling Procedure, DVHC-SOP-0020, rev. 2, states in section 7.1.4 that any complaint involving the possible failure of a device, labeling, or packaging to meet any of its specifications shall be reviewed, evaluated and investigated unless an investigation has already been performed for a similar complaint and another investigation is not necessary. The following is an example of a complaint record that included documentation that parts were replaced or serviced, but did not document failure investigations:\n\n• Complaint #RO_0331417. The firm documented “FAIL” as the only information with the complaint and in the additional notes, documented “Na Nean” referring to a slang term “Na Mean”. The record notes state that the sieve beds were replaced due to low O2, and the compressor was replaced due to low pressure. The investigation does not document why the compressor, which was under warranty, failed.\n\nWe have reviewed your responses dated 9\u002F16\u002F21 and 11\u002F12\u002F21 and concluded that the adequacy of your responses cannot be determined at this time. Your responses state that you are revising complaint handling procedures to create more guidance with complaint detail record keeping. Additionally, you are currently reviewing complaints received between March 26, 2018 and July 27, 2021.\n\nPlease provide documentation demonstrating that you have established the applicable procedures to evaluate and investigate any complaint involving the possible failure of a device, labeling, or packaging to meet any of its specifications and the outcome of your retrospective review.\n\n5. Failure to establish procedures for rework of nonconforming products, including retesting and reevaluation of the nonconforming product after rework, to ensure that the product meets its current approved specifications; as well as documentation of the rework and reevaluation activities in the DHR, including a determination of any adverse effect from the rework upon the product, as required by 21 CFR 820.90(b)(2). Specifically, you do not have a written procedure that governs rework for in-process products.\n\nWe have reviewed your responses dated 9\u002F16\u002F21 and 11\u002F12\u002F21 and concluded that they are inadequate. Your response of 11\u002F12\u002F21 provided your new in-process rework procedure, which does not require that a record of testing after rework must be included in that unit’s device history record (DHR).\n\nPlease provide documentation that demonstrates you have established and implemented your procedure governing rework of in-process products, and that all rework activities and testing are recorded in the device history record (DHR).\n\nOur inspection also revealed that these devices are misbranded within the meaning of Section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), in that your firm failed or refused to furnish material or information regarding the device that is required by or under Section 519 of the Act, 21 U.S.C. § 360i, and 21 CFR Part 803 – Medical Device Reporting. Violation includes, but is not limited to:\n\n6. Failure to establish an internal system which provides for timely and effective identification, communication and evaluation of events that may be subject to medical device reporting requirements, as required by 21 CFR 803.17(a)(1). Specifically, Complaints were not reviewed and recorded as unreportable for over 200 days after receipt of the complaint. Examples include but are not limited to, complaint numbers RO_0174581, RO_0171904, RO_0188624, and RO_0198227.\n\nWe have reviewed your responses dated 9\u002F16\u002F21 and 11\u002F12\u002F21 and concluded that the adequacy of your responses cannot be determined at this time. Your responses state that you are reviewing and updating your procedures and processes for complaint handling and MDR reporting regarding intake, review, evaluation, and reporting of complaints.\n\nPlease provide documentation that demonstrates you have established and implemented a procedure which provides for timely and effective identification, communication and evaluation of events that may be subject to medical device reporting requirements.\n\n7. Failure to submit an MDR report within 30 days of receiving or otherwise becoming aware of information that reasonably suggests that a marketed device may have malfunctioned or caused or contributed to a death or serious injury, as required by 21 CFR 803.50(a)(1). Specifically,\n\nOn 01\u002F19\u002F2021, you were contacted regarding an injury event in which the patient suffered dyspnea, anxiety, low oxygen saturation and shaking\u002Ftremors, alleging a malfunction with a DeVilbiss 525DS Oxygen Concentrator, serial number (b)(4). An MDR was not submitted to FDA until 04\u002F06\u002F2021. You did not report an adverse event within 30 days.\n\nWe have reviewed your responses dated 9\u002F16\u002F21 and 11\u002F12\u002F21 and concluded that the adequacy of your responses cannot be determined at this time. Your responses state that you are revising the applicable procedures and conducting training to ensure clarification on the specific information that should be collected as part of the complaint intake process, including robust incident details to ensure prompt and compliant escalation to Regulatory Affairs for evaluation in regard to MDR filing.\n\nYou also state that, based on your review of complaints thus far, you have identified several events where MDRs should have been reported, and are in the process of identifying additional events for reporting. These corrective actions are ongoing at this time.\n\nPlease provide documentation that demonstrates that you have submitted MDRs for all applicable complaints that reasonably suggest that a marketed device may have caused or contributed to a death or serious injury, and that reportable events received since the time of the inspection have been reported within the required 30-day timeframe.\n\nYour firm should take prompt action to correct the violations addressed in this letter. Failure to promptly correct these violations may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties. Also, federal agencies may be advised of the issuance of Warning Letters about devices so that they may take this information into account when considering the award of contracts.\n\nAdditionally, should FDA determine that you have Quality System Regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been corrected. Also, should FDA determine that your devices do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted. If you believe that your products are not in violation of the Act, please respond to FDA with your reasoning and any supporting information for our consideration.\n\nPlease notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to correct the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address all violations included in this Warning Letter.\n\nIf you have questions regarding any issues in this letter, please contact Compliance Officer Richard Cherry at (215) 717-3075 or at richard.cherry@fda.hhs.gov. Please send your reply electronically to Gina Brackett, Director of Compliance Branch, at gina.brackett@fda.hhs.gov.\n\nFinally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of the violations and take prompt actions to correct the violations and bring the products into compliance.\n\nSincerely,\n\n\u002Fs\u002F\n\nJoseph Matrisciano, Jr.\n\nProgram Division Director\n\nOffice of Medical Device and Radiological Health\n\nDivision 1\n\ncc: Joseph Lewarski, Senior Vice President, Clinical Affairs\n\nTony Sapp, Director, Regulatory Affairs and Audits","DeVilbiss Healthcare LLC","devilbiss-healthcare-llc-619182-11232021","2026-08-18T06:42:29.262718+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fdevilbiss-healthcare-llc-619182-11232021","2026-10-26T08:08:23.773628+00:00","Closed Out","2021-12-14","619182","2024-10-30","Derek Lampert","2026-08-20T02:20:42.968+00:00","UNITED PARCEL SERVICE OVERNIGHT DELIVERY and EMAIL","2021-11-23",14,{"510k":271,"classification":272,"enforcement":273,"event":274,"event_backfill":275,"pma":276,"warning_letter":277},"2026-11-16T02:00:55.89+00:00","2026-11-16T02:00:41.999+00:00","2026-11-16T02:00:49.415+00:00","2026-11-17T04:00:34.414+00:00","2026-09-07T05:17:28.839+00:00","2026-11-16T02:01:03.155+00:00","2026-11-17T01:02:55.859+00:00"]